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Parkinson’s disease (PD) is a progressive debilitating neurodegenerative disorder characterized 
by resting tremor, rigidity, bradykinesia and postural instability. As the disease progresses there 
is a loss of dopamine (DA) neurons in the substantia nigra projecting to the various forebrain and 
sub-cortical regions. Current treatments for PD are unable to prevent or curtail the 
neurodegenerative process; so rescuing remaining dopamine in the mid-brain has been the recent 
focus of research examining the effectiveness of neurotrophic factors (NTFs) in the treatment of 
PD. In this dissertation, the ability of three novel, recently discovered NTFs to restore DA 
neurons and motor function in a nonhuman primate model of PD was examined. The NTFs were 
Cerebral Dopamine Neurotrophic Factor (CDNF) and two variants of Neurturin (NRTN), N2 and 
N4, that have mutations that prevent binding to heparin sulfate binding sites in the brain.  These 
studies used the unilateral low dose (0.15 ± 0.001 mg/kg) monkey 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) model of PD to cause loss of DA neurons.  Six groups of monkeys 
were studied: vehicle-treated (negative control), Glial Cell-line Derived Neurotropic Factor 
(GDNF, positive control), two groups of CDNF-treated monkeys (450 µg and 150 µg), and N2 
and N4-treated groups. After MPTP, monkeys developed moderate symptoms of PD (PD rating 
scale score=7.9±0.5 on a scale of 0-22, p<0.001), motor dysfunction and increased daytime 
sleepiness. After three months of infusions, all three NTFs (150 µg CDNF, N2 and N4) 
significantly increased the number of DA neurons in the substantia nigra, p=0.03, and improved 
parkinsonian symptoms measured by rating scale, p<0.001. Most motor functions were 
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significantly correlated with the number of DA neurons in the substantia nigra. N4 significantly 
improved daytime sleep duration, bouts and wake-latency (p=0.02, p=0.06 and p=0.02, 
respectively). In summary, CDNF, N2 and N4 trophic factors are neurorestorative to DA 
neurons, motor function is tightly correlated with DA neuronal number, and N4 improved the 
non-motor symptom of increased daytime sleepiness in this monkey PD model. These factors 
hold promise for clinical therapy for PD patients. 
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1.0  GENERAL INTRODUCTION 
1.1 PARKINSON’S DISEASE (PD): OVERVIEW 
1.1.1 Clinical Characteristics of PD 
James Parkinson in 1817 wrote “An essay on the shaking palsy” and was the first person to 
describe in detail the clinical symptoms of this disease that later went on to bear his name 
[Parkinson, 1817]. Jean-Martin Charcot, a famous neurologist at la Salpêtrière hospital in Paris 
who contributed significantly to our understanding of this disease through his lectures sixty years 
later, referred to as Charcot’s lectures, distinguished this disease from other tremor-related 
neurological disorders and gave further details about the manifestation and time course of the 
progression of the disease as it was understood in the late 19th century (called ‘paralysis agitans’) 
[Charcot, 1877].  Charcot gave credit to Parkinson for his pioneering descriptions by referring to 
this disease as “maladie de Parkinson” or Parkinson’s disease (PD), as it is now called [Charcot, 
1877]. However, PD existed long before James Parkinson described six such cases in detail in 
1817. Galen of Pergamon observed a similar disease and wrote an Egyptian papyrus (1350-1200 
BC) that described it, suggesting that parkinsonism was occurring at that time [Forno, 1996]. 
Similarly, characteristics of the disease were also described in Charaka Samhita (400 – 600 BC) 
[Prasad et al., 2004; Nishteswar, 2011], one of the two foundational textbooks of Ayurveda. A 
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detailed description of PD was given in the ayurvedic textbook Basavarajiyam (1400 AD), and 
disease was called “kampa vata” [Nishteswar, 2011]. Leonard da Vinci also described many 
characteristics of the disease between 1489 and 1506 AD [Forno, 1996]. 
The cardinal features of PD are the movement problems of rigidity, resting tremor, and 
bradykinesia (i.e., abnormal slowness of movement). In later stages of the disease, loss of 
postural reflexes leads to postural instability and postural deformities associated with rigidity, 
such as flexed posture of the neck, trunk, elbows and knees are present [Hughes et al., 1992, 
1993; Jankovic, 2008].  Patients with PD also exhibit a variety of secondary motor symptoms 
that affect their functioning such as freezing of gait, blank facial expression and speech disorders 
[Lang et al., 1998].  
Non-motor features of the disease are common and are often considered the most 
debilitating limitations to normal daily functioning of patients [McDowell et al., 2012; 
Videnovic et al., 2012]. Roughly 90% of patients have substantial impact on their quality of life 
because of these non-motor symptoms, yet they are under-recognized because they are not 
considered part of the cardinal clinical features required for diagnosis of this disease [Chaudhuri 
et al., 2010].  These non-motor symptoms include sleep disturbances, anosmia, autonomic 
dysfunction, decreased motivation, depression, anxiety and cognitive dysfunction [Chaudhuri et 
al., 2010]. Interestingly, James Parkinson described the presence of sleep disturbances and other 
non-motor symptoms in his original essay [Parkinson, 1817].  
PD is a progressive neurodegenerative disease of the nervous system [Lang et al., 1998; 
Jankovic, 2008]. There are no biomarkers that are currently recognized for the early ante-mortem 
diagnosis of PD. The motor system manifestations of the disease are only evident after the 
pathology of the disease has reached an advanced stage, with typically over 60-80% of the 
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neurotransmitter dopamine (DA) lost in the striatum of patients before the first motor symptoms 
appear  [Bernheimer et al., 1973; Hornykiewicz, 1998; Jankovic, 2008]. At this time, the 
diagnosis of the disease still relies upon the presence, severity, progression of clinical motor 
symptoms of the disease and confirmation of diagnosis depends on post-mortem neuropathology 
[Hughes et al., 1992, 1993; Litvan et al., 2003; Braak et al., 2003, 2004; Jankovic, 2008]. It is 
currently recognized that development of specific biomarkers for PD, allowing for earlier 
suspicion of the disease, would be useful to identify groups at risk of developing PD and would 
provide patients with an opportunity to start a neurorestorative therapy early in the disease 
[Airavaara et al., 2011; Aron et al., 2011]. 
1.1.2 Etiology of PD 
Several genetic and environmental factors are now considered to play important roles in the 
etiology of the disease. The role of genetic factors in the etiology of PD was first described by 
Gowers [Gowers, 1896], who made the observation that there was an increase in PD occurrence 
among the relatives of PD patients. A minority of the cases, approximately 5-10% of PD 
patients, have a clear familial form of PD with an autosomal-dominant Mendelian form of 
inheritance [Olanow et al., 1999; Schapira, 2006]. Mutations in ∝-synuclein, parkin, UCHL1, 
DJ1, PINK1, and LRRK2 are known to cause genetic forms of PD [reviewed in Moore et al., 
2005]. Some of them, like DJ1 and PINK1, encode for mitochondrial proteins and over-
expression of others, like ∝-synuclein and parkin, induce mitochondrial deficits [Schapira, 
2006].  In most cases, the proteins they encode are involved in cellular responses to oxidative 
stress, mitochondrial function, or affect normal functioning of protein degradation pathways in 
midbrain DA neurons [Schapira, 2006]. The lack of proper elimination of toxic free radicals, by-
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products of oxidation reactions, and accumulation of ∝-synuclein can lead to acceleration of 
neuronal cell death [reviewed in Moore et al., 2005; Schapira, 2006].  
The concept that exposure to exogenous factors might also lead to the development of PD 
began to be recognized in late 1970’s  after drug addicts injecting a synthetic meperidine 
derivative resembling heroin developed remarkably similar anatomical and clinical features of 
PD [Davis et al., 1979]. The compound, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, came to 
be referred to by the abbreviation, MPTP, and was an unintended by-product in the synthetic 
process (see Section 1.4.2 for further details). Since then, a number of epidemiological studies 
have examined the contribution of many environmental factors that increase the risk of 
developing PD. These include rural residency [Rajput et al., 1986; Barbeau et al., 1987], 
drinking well water  [Tanner et al., 1996], exposure to pesticides [Fleming et al., 1994], 
industrial chemicals [Seidler et al., 1996], and farming [Tanner et al., 1996]. We now know that 
exposure to a number of exogenous toxins are associated with an increased risk of developing 
PD due to increased exposure of midbrain DA neurons to environmental toxins. These include 
trace metals, cyanide, organic solvents, carbon monoxide, carbon disulfide, rotenone, paraquat, 
and manganese [Olanow et al., 1999; Schapira, 2006]. These chemicals lead to increased 
oxidative stress in the vulnerable midbrain DA neurons, that are affected in PD (See Section 
1.4.3 for discussion of detailed biochemical changes). 
Post-mortem brain pathology is used to definitively diagnose PD, distinguishing it from 
other similar disorders. The presence of two characteristic changes in brain tissue is required for 
this diagnosis: the presence of evidence to conclusively determine loss of midbrain DA neurons 
that project to basal ganglia and the presence of Lewy pathology [Fahn, 2003; Litvan et al., 
2003]. Lewy pathology is defined as the presence of intra-neuronal inclusions of aggregates of 
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misfolded proteins containing ∝-synuclein [Hawkes et al., 2010].  These inclusions are detected 
using ∝-synuclein immunohistochemistry. Neurons containing these inclusions are typically 
referred to as ‘Lewy bodies’, that are round eosinophilic inclusions in a neuronal cell body or 
pleomorphic inclusions in cell processes that are dot-like, thread-shaped or spindle-shaped within 
axons and dendrites called as ‘Lewy neurites’.  It is now beginning to be accepted that there is a 
long dormant period of time before classic motor signs of PD begin to appear. Braak proposed a 
new staging system with six stages of progression of the disease from the brainstem to the 
neocortex based on neuro-pathological studies of post-mortem brain tissue of PD patients with 
varying degrees of Lewy pathology and severity of the disease [Braak et al., 2003, 2006, 2008]. 
According to the Braak hypothesis, the progression of pathology appears to begin with Stage I, 
in the gut gastric myenteric plexus, followed by pathology in the olfactory bulb and dorsal motor 
nuclear complex of cranial nerves IX and X (DMNC). In Stage II, the Lewy pathology spreads to 
the pons, locus coeruleus, lower raphe and magnocellular parts of reticular formation. Only in 
Stage III is there involvement of the substantia nigra, and other basal mid-brain and forebrain 
regions including the amygdala, tegmental pedunculopontine nucleus, and tuberomamillary 
nucleus. The first two stages, before the spread of the pathology to midbrain and substantia nigra, 
are referred to as the prodromal phase of the disease, before the appearance of clinically-defined 
PD motor symptoms. Henceforth, these stages are referred to in this document as pre-clinical or 
pre-diagnostic stages of PD. In Stage IV, pathology progresses from the allocortex to the 
neocortex and there is presence of Lewy pathology in the thalamic intra-laminar nuclei, 
interstitial nucleus of stria terminalis, temporal mesocortex, and second sector of Ammon’s horn, 
such that the pathology becomes widespread in the brain.  In Stage V, there is intensification of 
the damage in areas already affected from stages I-IV, followed by progression to insular, 
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subgenual mesocortex and anterior cingulate cortex. In the final stage of progression (i.e., Stage 
VI) there is widespread damage affecting the entire topography of the brain including secondary 
sensorimotor areas like sensory association areas and pre-motor areas. In very advanced cases 
primary areas of the neocortex including primary auditory areas, primary motor and sensory 
areas (M1 and S1) are also affected. A dual-hit theory has been proposed by Hawkes, Tredici and 
Braak [Hawkes et al., 2009] as a cause for this disease, where a pathogen enters the body via 
both the nasal and gut route (dual-hit) and spreads to the olfactory cortex and gut neurons (Stage 
I) and spreads eventually up the central nervous system to affect the entire brain.  
1.2 THE BASAL GANGLIA 
1.2.1 Anatomy of basal ganglia circuits 
1.2.1.1 Anatomical connections within basal ganglia structures 
The basal ganglia are comprised of a number of sub-cortical structures that form a complex 
network of connections with several nuclei in the forebrain, midbrain and thalamus (Figure 1). 
The basal ganglia were traditionally thought to be involved in motor control and execution 
[Alexander et al., 1990]. However, with the advancement of our understanding of the different 
nuclei, the basal ganglia are now considered to be important in the processes that underlie the 
learning of both new complex motor behaviors (i.e., movement, goal-directed behaviors), as well 
as a number of non-motor behaviors (i.e., habits, emotions, motivation, sleep and cognitive 
function) [Yin et al., 2006; Graybiel et al., 2008; Haber et al., 2009].  In this section, the 
different component nuclei of the basal ganglia, their anatomical location and how they are 
 7 
connected to the other nuclei, as well as the nature of their output projections (excitatory or 
inhibitory) and the targets of their innervation are described [Alexander et al., 1990; DeLong et 
al., 2007; Haber et al., 2009].   
 The components of the basal ganglia include (see Figure 1):  
A. The striatum, comprised of the caudate nucleus, and the putamen,  
B. The subthalamic nucleus (STN),  
C. The globus pallidus, comprised of the internal segment (GPi), the external segment 
(GPe) and the ventral pallidum,  
D. The substantia nigra, comprised of the pars compacta (SNpc) and the pars reticulata 
(SNpr)   
The major input pathways to the basal ganglia come through the striatum and STN.  All 
inputs are excitatory. The major output pathways of basal ganglia go through GPi and SNpr. All 
outputs from the basal ganglia are inhibitory. 
A. The striatum, 
Inputs: The striatum receives inputs from many distinct functional regions from across 
the entire cerebral cortex (for details, see Section 1.2.1.2). This is the pathway for the 
main input into the basal ganglia. All inputs to the striatum are glutamatergic and 
excitatory in nature.  
Outputs: The main output from the striatum is through the globus pallidus, both GPi and 
GPe. All outputs from striatal neurons are GABAergic and inhibitory.  
B.  The subthalamic nucleus (STN),  
Inputs: The STN receives both glutamatergic excitatory inputs from the cerebral cortex 
and inhibitory GABAergic inputs from the GPe. 
Outputs: The Globus Pallidus is the main output nucleus receiving excitatory outputs 
from the STN. The STN sends excitatory glutamatergic outputs to both GPe and GPi. 
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C. The globus pallidus, comprised of the 
Globus pallidus, internal segment (GPi), 
Inputs: The GPi receives inhibitory GABAergic inputs from both the striatum and the 
GPe, as well as excitatory glutamatergic inputs from the STN. 
Outputs: GPi neurons send inhibitory GABA outputs to the thalamus and brainstem. 
Globus pallidus, external segment (GPe)   
Inputs: The GPe receives inhibitory GABAergic inputs from the striatum and excitatory 
glutamatergic inputs from the STN.  
Outputs: GPe neurons send inhibitory GABAergic outputs back to the striatum, STN and 
the GPi. 
D. The substantia nigra, comprised of  
Substantia Nigra, pars compacta (SNpc)  
Inputs: The SNpc receives inhibitory GABA inputs from the striatum.  
Outputs: SNpc sends its output to the striatum using the neurotransmitter dopamine, DA. 
DA has excitatory effects on D1 receptors contained in striatal neurons that project 
through the direct pathway to the GPi. DA has inhibitory effects on D2 receptors 
contained in striatal neurons that project through the indirect pathway to the GPi via 
connections through the GPe-STN circuit. Thus, the SNpc dopaminergic nigrostriatal 
projection plays an important modulatory role in mediating basal ganglia function 
through both these pathways. 
Substantia Nigra, pars reticulata (SNpr)   
Inputs: The SNpr receives inhibitory GABAergic inputs from the striatum and the GPe, 
as well as excitatory glutamatergic input from STN.  
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Outputs: The outputs from SNpr are inhibitory GABAergic outputs to the thalamus and 
brainstem. These SNpr outputs specifically connect to thalamus that project to cortical 
and to brainstem regions that control eye movements. 
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Figure 1.  Basic circuit diagram of the different interconnected nuclei in basal 
ganglia. The three main neurotransmitter systems are indicated by three different 
arrowheads: glutamate, GABA and DA.  Substantia Nigra, pars compacta (SNpc); 
Substantia Nigra, pars reticulata (SNpr); Globus pallidus, external segment (GPe); 
Globus pallidus, internal segment (GPi); subthalamic nucleus (STN); Supplementary 
motor area (SMA); [based on Figure 31.2, Fundamental Neuroscience, 2002] 
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1.2.1.2 Distinct parallel sub-circuits within and outside the basal ganglia 
The striatum receives input to the basal ganglia from almost the entire cerebral cortex. Cortical 
input is glutamatergic. Projections from the cortex are made on to the dendrites of GABAergic 
medium spiny neurons (MSN), the major type of neuron present in the striatum. The topography 
of projections from the cerebral cortex are somewhat preserved within the basal ganglia through 
distinct ‘parallel loops’ that forms sub-circuits within each sub-cortical basal ganglia structure 
[Alexander et al., 1986, 1990; Middleton et al., 2000]. An example of this sub-circuit is the 
somatomotor circuit that is affected in PD. The neurons from the somatosensory and motor 
cortices project to the putamen. In PD, the putamen is generally first affected before the disease 
spreads to other sub-circuits [Graybiel et al., 2000, 2008]. Not surprisingly then, the putamen is 
the target of our neurotrophic factor infusions after MPTP administration in monkeys (see 
Section 2.2.3). In the later stages of PD, the disease progresses the other sub-circuits including 
the limbic and cognitive circuits. The spread of the disease within the basal ganglia follows a 
dorsolateral to ventromedial path that corresponds roughly to the spread of the dysfunction from 
anterior putamen involved in motor functions to the posterior tail of the caudate nucleus involved 
in higher order functions like cognition [Graybiel et al., 2000, 2008]. There are also basal 
ganglia circuits that are specifically oculomotor, cognitive and limbic in nature. [Middleton et 
al., 2000]. 
 The ventral portion of the striatum is generally not included as part of the traditional 
basal ganglia circuitry. However, the ventral striatum, consisting of the nucleus accumbens and 
the olfactory tubercle, has connections that follow a similar pattern as the traditional basal 
ganglia [Cardinal et al., 2002; Nicola, 2007]. The DA neurons from the mid-brain ventral 
tegmental area (VTA) send projections to the nucleus accumbens. However, unlike the 
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traditional basal ganglia structures that receive glutamatergic input from neocortex, nucleus 
accumbens receives direct input from the amygdala, which is part of the limbic system. The 
limbic system is involved in the control a variety of behaviors including mood, memory, 
motivation and olfaction [Mogenson et al., 1980; Salamone, 1992; Ikemoto et al., 1999; Cardinal 
et al., 2002; Nicola, 2007; Haluk et al., 2009]. Thus, changes to motivation and mood that are 
seen in later stages of PD could be linked to changes in the function of the ventral striatum. Thus, 
increasing the activity of accumbens circuits could lead to improvement of motivation leading to 
better performance in motor tasks (see Section 6.4.2). 
1.2.2 Physiology of the basal ganglia  
The study of the physiology of basal ganglia has been mostly focused on the relationship of its 
component nuclei to behaviors associated with movement. Much of what we know about the 
functions of the different structures within the basal ganglia comes from lesion studies in 
animals, followed by subsequent examination of the firing patterns of the constituent neurons in 
each structure in relation to various forms of movement [Alexander et al., 1990; Hamada et al., 
1992; Chesselet et al., 1996; Middleton et al., 1996; Wichmann et al., 1996; Fundamental 
Neuroscience, 2002; Yin et al., 2004; Clarke et al., 2008; Inokawa et al., 2010; Bostan et al., 
2010].  
A. The striatum,  
In the striatum, 80-90% of neurons are inhibitory GABA-containing medium spiny 
neurons (MSN) that project outside the striatum and fire at 0.1-1 Hz. About 10-15% of 
the neurons in striatum are tonically active, firing at 2-10 Hz, and hence are called 
Tonically Active Neurons (TAN’s). These neurons are differentiated from the MSN’s 
 13 
based on their firing frequency, and they appear to be cholinergic interneurons [Inokawa 
et al., 2010]. An even smaller subset of the neurons within the striatum are parvalbumin-
positive fast-spiking inhibitory local GABAergic interneurons [Inokawa et al., 2010].  
Different regions of the striatum have been linked to different behaviors. In rodents, there 
is just one contiguous structure, and lesions of the dorsolateral portions of this rodent 
striatum disrupt the formation of habits [Yin et al., 2004]. In primates, lesions of the 
medial portions of the striatum, mainly the anterior portion of the head of the caudate 
along with very small lesions in the anterior and medial portions of putamen, lead to 
enhanced preservative behavior [Clarke et al., 2008].  
B. The subthalamic nucleus (STN),  
The neurons in the STN contain the excitatory neurotransmitter glutamate and fire at a 
rate of about 20 Hz. About 90% of these neurons increase their firing rate prior to the 
onset of eye or limb movement. The region is somatotopically organized into different 
functional circuits. Thus, there are different projections from the cortex to distinct parts of 
the STN, that in turn project to other distinct basal ganglia nuclei [Alexander et al., 1990; 
Bostan et al., 2010]. Lesions of STN in normal monkeys induce dyskinesias in the 
contralateral limbs [Hamada et al., 1992].  
C. The globus pallidus, comprised of  
Globus pallidus, internal segment (GPi), 
The neurons in GPi are inhibitory and contain the neurotransmitter GABA, They 
are tonically active and fire at very high rates of 60-80 Hz. The neurons in this region 
are again somatotopically organized with leg and arm regions present in the GPi. 
Approximately 70% of GPi neurons increase their activity and 30% decrease their 
activity during arm movement.  However, lesions of the GPi lead to no discernible 
physical changes to movement in either humans or experimental animals. Most of the 
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findings from lesions of the GPi result in subtle temporary changes in fine motor 
movement, at most [Wichmann et al., 1996], so their particular role in normal behavior 
is still an open question. 
Globus pallidus, external segment (GPe)   
The neurons present in GPe also contain the inhibitory neurotransmitter GABA 
and can be classified into two types based on their firing rates. A majority of these 
neurons fire at a relatively high frequency of around 70 Hz, with their firing interrupted 
by long pauses. A small minority of GPe neurons fire around 10 Hz and have frequent 
spontaneous bursts of activity. Both types of neurons increase their activity during 
movement. Injections of biccuculine to inhibit neuronal activity in GPe, or lesions of 
GPe, induce rigidity or cataplexy [Wichmann et al., 1996]. GPe is also implicated in 
Huntington’s disease, as it is one of the main sites of neuronal degeneration. Chorea, 
which  is comprised of dance-like movements that spread from one muscle to another, 
belongs to a group of neurological disorders called dyskinesias. Chorea is also common 
in Huntington’s disease and abnormal functioning of the GPe is thought to mediate the 
generation of this dyskinetic movement [Chesselet et al., 1996].  
D. The substantia nigra, comprised of  
Substantia Nigra, pars compacta (SNpc)  
The DA neurons in SNpc fire at a constant rate of around 2 Hz and are not organized 
somatotopically. Unlike the rest of the basal ganglia, the neurons in SNpc do not fire with 
relation to movement. However, these DA neurons fire in response to environmentally 
relevant cues such as reward, motivation or salient instructions. Thus, the firing activity 
of these neurons has been suggested to modify striatal neuron outputs based on cortical 
inputs that occur related to a specific environmental context. For instance whenever a 
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tone is paired with the reward of juice after pressing a lever, the dopamine cells initially 
respond to the lever press and eventually the cells increase their firing just upon 
presentation of the rewarding tone.  These DA neurons project to the striatum within 
basal ganglia ‘parallel loops’ that are part of sensorimotor, associative and limbic circuits 
(see Section 1.2.1.2). However, we do not yet fully understand all the specific roles that 
are played by the DA system through its projections to these basal ganglia sub-circuits.  
Substantia Nigra, pars reticulata (SNpr)   
SNpr has GABAergic inhibitory neurons that are tonically active and they provide the 
output for face and eye movement-related activity from the basal ganglia. The neurons 
here are again somatotopically organized. However, unlike GPi neurons the SNpr 
neurons decrease their firing rate during saccadic eye movements. Lesions in the medial 
regions of SNpr produce a characteristic visual hallucination syndrome called 
“peduncular hallucinosis”. In peduncular hallucinosis, patients experience vivid realistic 
images of people and environments familiar to them. It is this characteristic that makes it 
hard for patients to distinguish these images from reality. Most patients experiencing 
“peduncular hallucinosis” also experience abnormal sleep patterns characterized by 
insomnia and excessive daytime sleep, both symptoms present in many PD patients 
also (see Section 1.3.2, Chapters 3 and 4). Similar visual hallucinations are reported in 
patients with other lesions of SNpr or in brainstem compression [Middleton et al., 1996].   
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1.3 SYMPTOMS IN PD 
1.3.1 Motor symptoms in PD 
There are three classical motor symptoms that have been well characterized in PD: bradykinesia, 
rigidity and tremor [Gelb et al., 1999; Fahn, 2003; Jankovic, 2008]. However, at this time there 
is no definitive diagnostic pre-clinical test or biomarker to predict PD before the first appearance 
of any of the motor signs of PD, and the motor symptoms manifest only after there has been a 
significant loss of striatal DA content. The pathological confirmation of nigrostriatal 
degeneration and presence of Lewy bodies on post-mortem analysis represent the gold standard 
for the definitive diagnosis of PD [Hughes et al., 1992, 1993; Olanow et al., 1999; Stern et al., 
2012; Berg et al., 2013]. Currently, the presence of a combination of motor features of the 
disease, asymmetry, and the patient’s response to levodopa, are the main clinical criteria used for 
diagnosing PD.   
‘Bradykinesia’ is derived from combining the Greek word “brady”, meaning slow, and 
“kinesia”, meaning motion. Bradykinesia in patients with PD varies in degree of slowness in all 
aspects of automatic, habitual, voluntary and involuntary movements from mildly slowed to a 
complete absence of movement (“akinesia”) in a minority of patients. Some examples of 
automatic and habitual movements that can be affected include decreased swinging of arms 
during walking, decreased eye blinking, less frequent swallowing of saliva leading to an 
increased probability of drooling [Jahanshahi et al., 1993; Bagheri et al., 1999; Berardelli et al., 
2001; Turner et al., 2003; Tumilasci et al., 2006]. Bradykinesia also affects tasks that require 
fine motor skills such as buttoning cloths and using cutlery. It is one of the most common 
symptoms of the disease affecting almost all PD patients. In fact, the United Kingdom 
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Parkinson’s disease clinical criteria lists bradykinesia as a necessary condition required for the 
diagnosis of PD [Gelb et al., 1999]. The slowness in movement can be either during the 
execution phase of the movement or during the initial preparatory phase before movement. In 
early stages of the disease, bradykinesia usually occurs in the execution phase of movement, with 
a decrease in electromyography signal (EMG) needed to accelerate limb movements [Hallett et 
al., 1980]. However, in later stages of PD the preparatory phase of movement is also affected; 
this is especially evident when patients are asked to self-initiate movements as opposed to 
responding to external cues [Jahanshahi et al., 1993,1995].  
Rigidity is the property of being stiff and resisting the flexion, extension or rotation of a 
joint during passive limb movement [Berardelli et al., 1983; Cantello et al., 1995; Gelb et al., 
1999; Broussole et al., 2007; Jankovic, 2008]. Although rigidity is classified as a cardinal feature 
of PD it does not impair the quality of life as much as the other symptoms, except on occasions 
when it is associated along with pain during joint movement. Normally, when muscles stretch 
there is a naturally-occurring suppression of antagonistic muscles. However, in PD patients there 
is actually an activation of the antagonist muscles during a passive movement that is thought to 
cause rigidity [Berardelli et al., 1983; Cantello et al., 1995]. The lack of suppression of 
antagonistic muscles is believed to result from abnormal inhibitory output of basal ganglia 
circuits in PD [Xia et al., 2004]. In later stages of the disease the constant antagonistic muscle 
activation leads to postural changes such as the flexed elbows, flexed knees, flexion of the trunk 
and neck that leads to the classic parkinsonian posture and gait in PD (i.e., stooped posture with 
small steps) [Parkinson, 1817; Gelb et al., 1999].  
Tremor is the most prominent and noticeable motor symptom in PD. It was this symptom 
that led James Parkinson to initially call this disease ‘Paralysis agitans’, which means shaking 
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palsy in English [Parkinson, 1817].   The most common tremor in PD is the ‘rest tremor’ 
[Jankovic et al., 1999; Shahed et al., 2007; Jankovic, 2008; Hallett et al., 2012]. This tremor has 
a characteristic frequency between 3-7 Hz. When patients perform voluntary movements or 
stretch their limbs the tremor is absent and hence does not affect the performance of daily 
activities. The pure rest tremor frequently occurs in the distal appendages (i.e., the arms and legs) 
and less frequently in the neck, body and head. However, most patients exhibit a range of 
tremors with different characteristics [Deuschl et al., 1998]. Type I tremor is the classic rest 
tremor condition that is described above. Type II tremors are a mixture of both distal rest tremors 
and postural tremors. This type the postural tremor has a higher frequency (>1.5 Hz) than the 
distal rest tremor condition. Type III tremors refer to conditions when there is only the presence 
of pure postural body tremors, with no rest tremors in the distal extremities. The parkinsonian 
tremor arises due to pronation and supination because of an alternate activation of the agonist 
and antagonist muscles, and is thus characteristically different from other essential tremors that 
are caused by co-contraction of agonist and antagonist muscles. Oscillations in the diseased basal 
ganglia circuits are thought to be the primary mechanism underlying tremor development in PD 
[Olanow et al., 1999; Jankovic, 2008; Hallett et al., 2012]. 
There are other changes to the motor system that also occur in later stages of PD. 
Freezing, a variant of akinesia, is another unique characteristic of PD, although it does not occur 
universally in all patients [Giladi et al., 1997, 2001; Schaafsma et al., 2003; Bloem et al., 2004; 
Macht et al., 2007]. It is defined as the sudden and transient inability to move due to complete 
loss of movement, a form of akinesia. This includes freezing of the legs during walking, and 
inability to move arms or eyelids. Freezing of the gait, followed by loss of postural reflexes, is 
one of the most common reasons for patient falls in PD, that leads to other complications such as 
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fractures. This is compounded by problems that normally occur with the aging process, including 
balance problems and a decreased ability to integrate multimodal sensory cues including speech, 
visual, vestibular and proprioceptive cues, [Critchley et al., 1981; Rascol et al., 1989; Hood et 
al., 2007; Jankovic, 2008; Ferrer et al., 2012]. Decreased facial expression (“hypomimia”), 
decreased amplitude of voice and a decrease in size of handwriting from normal to minute 
(“micrographia”) are other common symptoms reported in PD.  
1.3.2 Non-motor symptoms in PD 
It is now well accepted that PD is a disease that affects multiple neuronal systems and has both 
motor and non-motor complications [Braak et al., 2003, 2004; Pfeiffer, 2007; Berg et al., 2013]. 
The non-motor symptoms can be broadly divided into four categories: neuropsychiatric, 
autonomic, sensory and sleep. Among these, some symptoms including a decline in olfactory 
function (anosmia), sleep disorders (e.g., rapid-eye movement (REM) sleep behavioral disorder, 
excessive daytime sleepiness), and constipation can occur years to decades before the appearance 
of clinically diagnosed PD [Abbott et al., 2005; Braak et al., 2006, 2008; Hawkes et al., 2010; 
Gao et al., 2011].  
Neuropsychiatric symptoms can be mild to severe in nature and include anhedonia, 
apathy or decreased motivation (discussed in detail in Section 6.4.2.1), panic attacks, social 
phobias, depression, problems with controlling emotions, visual hallucinations, delusion, 
paranoia, mania, fatigue, mood disorders, cognitive dysfunction, loss of motivation and affect 
[Bayulkem et al., 2010; Grinberg et al., 2010; Korczyn et al., 2010; Pourcher et al., 2010; 
Jellinger et al., 2011; Ferrer et al., 2012]. Many of these behavioral and neuropsychiatric 
symptoms are known to occur with increased severity as the disease progresses. There has been 
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some correlation shown between these symptoms and the different stages of development of PD 
as classified by Braak. (for details see Section 1.1.2) 
Autonomic nervous system failure is also called dysautonomia. It is experienced by about 
75% of PD patients [Claassen et al., 2010]. It is present as a constellation of symptoms that 
affect the autonomic system including: cardiovascular, gastrointestinal, urological, 
thermoregulatory, and respiratory disturbances. Orthostatic hypotension is known to occur in PD 
patients where there is a sudden massive drop in blood pressure when the patient gets up from a 
seated position. It could be due to the degeneration of early stage cardiac sympathetic neurons. 
There are reports which support this based on data that show reduced uptake of I-MIBG- (I-
metaiodobezylguanidine) which measures cardiac sympathetic nervous function peripherally 
[Doorn et al., 2012; Zeimssen et al., 2010].  Additionally, some post-mortem studies have 
reported the presence of alpha-synuclein, beginning in the axons of the cardiac sympathetic 
nervous system before affecting the cell bodies and other sympathetic ganglia [Zeimssen et al., 
2010; Ferrer et al., 2012]. A multiplicity of gastrointestinal (GI) problems including dysphagia 
(difficulty in swallowing), drooling, dry mouth, belching, nausea, abdominal bloating, 
constipation and anismus are also common [Claassen et al., 2010; Jost, 2010]. Some theories 
suggest the GI tract as the origin of degeneration of neurons in PD [Braak et al., 2006; Hawkes et 
al., 2009]. Alpha-synuclein is present in Meissner’s and Auerbach’s plexuses that project axons 
into the gastrointestinal mucosa [Braak et al., 2006; Jost, 2010]. Some of the highest densities of 
alpha-synuclein deposits are found in lower esophagus and submandibular gland [Wakabayashi 
et al., 1988,1990; Braak et al., 2006; Beach et al., 2010; Ferrer et al., 2012]. Urinary tract 
problems, such as increased urgency and frequency to empty, nycturia (excessive urination at 
night) are also present in a majority of PD patients. The disinhibition of the detrusor muscle that 
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contracts before the bladder is full is thought as the reason for this. A bradykinesia that affects 
the spinchter characterized by a delayed relaxing of the muscle also adds to the problem. Apart 
from the symptoms described above, tachycardia (increase in heart rate), papillary dilation and 
other vascular and respiratory disturbances are also reported [Ferrer et al., 2012].   
There are different sensory abnormalities that are present in PD. They include 
disturbances in olfaction, vision and pain [Pfeiffer, 2007; Bayulkem et al., 2010; Korczyn et al., 
2010; Ferrer et al., 2012]. Olfactory disturbances have been reported in the early stages of PD 
[Hawkes et al., 1997]. Anosmia has been reported as an indicator of future risk to develop PD in 
epidemiological studies [Ferrer et al., 2012].  This also correlates well with the proposed 
development of alpha-synuclein aggregates in the anterior olfactory nucleus in the first stage of 
PD (for details see Section 1.1.2). There are dopamine neurons present in the olfactory bulb, 
however whether these are the first to develop these inclusions or are responsible for the 
condition of inability to smell is not clear. Blurred vision is present in many patients [Archibald 
et al., 2009]. Sometimes the loss of DA neurons in the retina also leads to impaired color vision 
[Archibald et al., 2009]. A large number of patients have also consistently reported problems 
with visual acuity (i.e., visual contrast sensitivity) [Pfeiffer, 2007; Archibald et al., 2009]. Some 
patients also experience visual hallucinations (see Section 1.2.2). Various types of pain are 
commonly experienced by PD patients: mucoskeletal pain, dystonia-associated pain, radicular 
pain, akathitic pain, and central pain [Korczyn et al., 2010]. The underlying causes of pain are 
complex and may not be directly related to the cause of the disease. The stooped and altered 
posture can lead to mucoskeletal and radicular pain. The dystonic pain is often associated with 
the non-medicated periods of the day. The central pain is thought to be of thalamic origin and has 
a burning characteristic. 
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Sleep disturbances constitute the most commonly reported non-motor problems occurring 
in PD [Lees et al 1988; Tandberg et al 1999; Arnulf et al 2000; Ondo et al 2001; Hobson et al 
2002; Brodsky et al 2003; Arnulf 2005; Chaudhuri et al., 2010; Knie et al 2011; Schulte et al 
2011; Videnovic et al 2012]. Sleep disturbances have an adverse effect on the quality of life in 
both the patients and their caregivers. A number of problems with sleep, ranging from a change 
in pattern of nighttime sleep to excessive daytime sleepiness, are observed in patients [Knie et al 
2011; Schulte et al 2011; Videnovic et al 2012]. Obstructive sleep apnea can also be present in 
PD patients and continuous positive air pressure (CPAP) devices have been used for treatment. 
Rest tremor occurring during sleep can also awaken the patient. Many prospective studies have 
shown that excessive daytime sleepiness and REM sleep problems can occur several years before 
the first motor symptoms of PD and hence is an important risk factor for the disease [Abbott et 
al., 2005; Gao et al., 2011; Iranzo et al., 2006; Martinez-Martin, 2011; McDowell et al., 2012]. 
REM sleep behavioral disorder, where the patients begin to act out their dreams, is known to 
cause injuries to both the bedmate and the patient [Iranzo et al., 2006, Knie et al., 2011]. 
Nighttime insomnia is also observed in PD patients [Schulte et al., 2011]. Possible causes of 
insomnia include increased sleeping during the day, inability to move in the bed at night, 
nycturia, anxiety and depression. The presence of excessive daytime sleepiness has also been 
reported many years ahead of the development of clinically recognized signs of PD (See Chapter 
3 for more details on daytime sleep). Many neural systems that affect sleep in the brain stem and 
other lower regions in the brain (for detailed discussion see Section 3.4) are affected first 
according to the Braak model of PD progression (see Section 1.1.2). This may well be the reason 
for the appearance of these non-motor symptoms well ahead of the clinical diagnosis of the 
motor problems in PD.     
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1.4 ANIMAL MODELS OF PD 
The use of animal models to investigate the pathophysiology of PD has provided valuable 
insights both of how PD affects the basic physiology of basal ganglia circuits, and identification 
of treatments that may be most efficacious for treating the motor symptoms of PD. The 
development of PD animal models began with the accidental discovery of the role of dopamine 
in reserpine-treated rats. Reserpine administration leads to akinesia and central loss of 
monoamines in rats [Carlsson 1957]. However, only L-dopa, the precursor to dopamine, was 
able to resuscitate motor function in these rats; 5-hyroxytryptophan, the precursor to serotonin, 
was not able to recover motor function. This discovery of the ability of L-dopa to reverse motor 
deficits in the reserpine-treated model paved the way for the hypothesis that dopamine deficiency 
played a key role in PD [Carlsson 1959]. This hypothesis was confirmed shortly thereafter by the 
discovery that there is indeed a loss of striatal dopamine in patients with PD [Carlsson 1959; 
Ehringer et al., 1960], which led to the search for chemical agents that could selectively 
incapacitate dopamine neurons and the first such discovery was of 6-hydroxydopamine (6-
OHDA) to lesion DA neurons in the rat [Porter 1963; Ungerstedt 1968].  
1.4.1 The 6-OHDA model of PD 
It has been five decades since the development of the rat 6-OHDA model of PD and it still 
continues to be the model for PD that is most routinely utilized in Parkinson’s disease research. 
In 1968, Ungerstedt injected 6-OHDA in the SNpc and was able to demonstrate loss of 
nigrostriatal dopamine neurons [Ungerstedt 1968].  
 
A. Mechanism of action of 6-OHDA 
 24 
The molecular structure of 6-OHDA is very similar to the molecular structure of DA, and 
hence the dopamine transporter has a very high affinity for the neurotoxin and transports 
it into the DA cell [reviewed in Blum et al., 2001]. 6-OHDA accumulates within the DA 
neuron and two main mechanisms have been proposed for its action leading to 
neurotoxicity: oxidative stress and mitochondrial deficits. 
Oxidative stress has been observed after 6-OHDA administration in vivo [Permual 
et al., 1989, 1992; Kumar et al., 1995 ] and in vitro [Tiffany-Castiglioni et al.,  1982; 
Decker et al., 1993; Abad et al., 1995]. An increase in oxidative stress is due to the 
generation of hydrogen peroxide, due to either rapid auto-oxidation of 6-OHDA 
[Heikkila et al., 1972; Seitz et al., 2000; Soto- Otero et al., 2000] or deamination of 6-
OHDA by the enzyme monoamine oxidase (MAO) [Breese et al., 1971; Karoum et al., 
1993]. Hydrogen peroxide, in the presence of iron (present in SNpc giving it the 
charcteristic black appearance in post-mortem tissue), leads to increased formation of 
reactive oxygen species by the Fenton reaction [Ben Shachar et al., 1991; Borisenko et 
al., 2000]. Moreover, increased levels of iron in the striatum and SNpc accumulate after 
administration of 6-OHDA  [Hall et al., 1992; He et al., 1996; Oestreicher et al., 1994]. 
This mechanism of action of 6-OHDA was confirmed through experiments co-
administering 6-OHDA and iron chelating agents resulting in a reduced neurotoxic insult 
of the 6-OHDA [Ben Shachar et al., 1991; Borisenko et al., 2000].  
6-OHDA also inhibits the respiratory chain mechanism in complex I of isolated 
brain mitochondria in vitro [Glinka et al., 1995, 1996, 1998]. In vivo, 6-OHDA leads to 
pathological changes in the mitochondrial membrane potential after an increase in 
intracellular levels of reactive oxygen species [Lotharius et al., 1999]. This can lead an 
increase in intracellular concentration of DA, and DA is toxic to cells when it is not 
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present inside vesicles [Hastings et al., 1996; Zigmond et al., 2002]. Both these changes 
can also lead to cell death [Lotharius et al., 1999; Hastings et al., 1996; Zigmond et al., 
2002].  
 
B. Methods of delivery of 6-OHDA 
There are several 6-OHDA models that have been developed (for review see Deumens et 
al., 2002; Blandini et al., 2008). 6-OHDA does not cross the blood brain barrier. 6-
OHDA injected directly into the two brain hemispheres leads to a non-selective loss of 
neurons in all monoaminergic pathways namely, dopamine, noradrenalin and serotonin 
leading to a complex pathology with some similarities to PD [Deumens et al., 2002; 
Blandini et al., 2008]. However, bilaterally injected animals exhibit severe motor 
dysfunction and require special animal care, such as tube-feeding to overcome aphagia 
(deficit in swallowing) and adipsia (deficit in drinking) [Deumens et al., 2002; Blandini 
et al., 2008]. To develop a more refined PD model, 6-OHDA has been administered after 
pre-treatment with either desipramine (i.e., a blocker of 6-OHDA uptake by 
noradrenergic neurons) or citalopram (i.e., a blocker of 6-OHDA uptake by serotonin 
neurons). A more recently developed method of 6-OHDA delivery is a unilateral 6-
OHDA injection to prevent the high mobidity and mortality caused by bilateral 6-OHDA 
administration. Unilateral injections have been given in the SNpc, the medial forebrain 
bundle (MFB) and the striatum. 
Injection of 6-OHDA in the SNpc leads to a massive and almost complete loss of 
dopamine neurons in the midbrain [Ungerstedt 1968]. The problem with this method is 
the lack of specificity to target the nigrostriatal dopamine neurons, as some loss in the 
other midbrain dopamine structures, such as the VTA, also occurs because it is difficult 
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to only inject in the very small structure of SNpc. SNpc injection leads to an animal 
model that resembles advanced stages of PD, with close to a 90% loss of TH-positive 
neurons. The timecourse of dopaminergic neuronal degeneration is very rapid, with loss 
of SNpc neurons beginning in the first twelve hours after 6-OHDA administration and the 
loss of striatal dopamine terminals being detectable within two to three days after 6-
OHDA administration.  
Injection of 6-OHDA in the MFB also leads to a nearly complete loss of DA 
neurons (> 95% loss of TH-positive cells) in the SNpc, with very few neurons surviving 
the insult [Deumens et al., 2002]. The major drawback of using this method of injection 
is that both VTA and SNpc send axons through this bundle and hence there is a near 
complete loss of midbrain TH-positive neurons. This generates a condition that has more 
severe loss of midbrain DA neurons than observed in PD and hence this model is used to 
quickly generate a severe PD-like animal useful to study the mechanisms present in the 
disease. 
Injection of 6-OHDA in the striatum is the most commonly used model of PD, as 
it produces immediate loss of striatal TH-positive DA terminals and initiates a process 
which leads to the loss of axon terminals first with a delayed, progressive, loss of SNpc 
TH-positive neurons [Zigmond et al., 1990; Deumens et al., 2002; Blandini et al., 2008]. 
Injections of 6-OHDA into the striatum leads to less extensive damage in both SNpc 
neurons (roughly 50-70% loss) and striatal TH-positive terminals (roughly a 60-80% 
loss). Partial lesions of the dopamine system using the striatum as the injection site and a 
moderate concentration of 6-OHDA produces a good model of the early to middle stages 
of PD. This rat model has evolved as the model of choice for testing the mechanisms of 
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action of new treatment paradigms in PD. The time course of 6-OHDA actions in this 
model is described below. The injection of a single dose of 6-OHDA (20 μg/3 μL) leads 
to a one-third loss of TH-positive terminals in the striatum within a day [Deumens et al., 
2002; Blandini et al., 2008]. This is followed by a slow linear progression with a loss of 
about two-thirds of the DA neurons within striatum by the three weeks after the lesion 
[Blandini et al., 2008]. In the SNpc loss of DA neurons is not evident for about a week 
after 6-OHDA injection and DA neuronal loss slowly increases to around 20% two weeks 
post-6-OHDA and then peaks and stabilizes with about a 40-50% loss of DA neurons by 
week four after 6-OHDA injection.  There is inflammation in the striatum associated with 
a 6-OHDA injection that progressively reduces in severity over the first four weeks after 
injection. Similarly, there is a weaker inflammation process in the SNpc also reduces in 
severity four weeks after injection.  
 
C. Functional changes after 6-OHDA 
There are three main phases of response that occur after 6-OHDA administrations [Agid 
et al., 1973; Hefti et al., 1980; Altar et al., 1987; Hudson et al., 1995; Zigmond et al., 
1981,1990, 1997, 2002]. The first phase constitutes acute changes in the striatal 
dopaminergic neurotransmission as a result of the neurotoxin insult. In the second phase, 
there are compensatory changes to accommodate the loss of DA neurotransmission. The 
final third phase encompasses progressive changes to the basal ganglia circuits that occur 
in parallel to the degenerative changes to the SNpc neurons in the midbrain following 6-
OHDA administrations.  
The changes that happen in Phase II and Phase III after this insult are described 
below. After a large initial 6-OHDA insult to striatal DA neurotransmission there are 
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compensatory changes in the function of the remaining neurons to try to maintain the 
same level of dopaminergic influence on striatal function. First, there is an increase in the 
amount of DA that is released from remaining DA terminals after each depolarization to 
maintain the level of DA available to striatal neurons. Second, there is a decrease in the 
high affinity DA reuptake sites resulting in prolonged DA stimulation to the post-synaptic 
DA receptors. These compensatory changes sometimes continue over a long period of 
time leading to a behavioral adaptation to the 6-OHDA insults, so that there appears to be 
a spontaneous recovery of function. This recovery of function can also be partially 
mediated by sprouting from the remaining TH-positive fibers in the striatum. There can 
also be an increase in the production of DA in the remaining terminals. (A detailed 
review of all the biochemical changes is in Section 1.4.3) 
1.4.2 MPTP model of PD 
In the mid-1970’s a new meperidine analog termed ‘synthetic heroin’ that was supposed to 
contain 1-methyl-4-phenyl-4-propionoxy-piperidine (MPPP) was developed in northern 
California. However, the synthesis had gone awry and when the meperidine analog was used 
intravenously by habitual drug addicts they began to develop severe PD-like symptoms [Davis et 
al., 1979].  It was later discovered that this contaminated batch originated from a home-based 
laboratory set up by a 23-year graduate student who had missed one crucial step in the 
biosynthesis of MPPP, and instead had produced 1-methyl-4-phenyl-1,2,5,6-tetrahydro-pyridine 
(MPTP) as a by product of this reaction [Langston et al., 1983]. MPTP was identified as the 
toxin that led to the production of PD-like symptoms in relatively healthy young adults 
[Langston et al., 1983]. Further analysis revealed 1-methyl-4-phenyl-pyridinium ion (MPP+) as 
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the metabolite of MPTP that was selectively toxic to SNpc dopaminergic neurons [Langston et 
al., 1984].  These findings led to the development of the first monkey model of PD, in which 
injection of MPTP in squirrel monkeys caused degeneration of nigral dopaminergic neurons and 
development of symptoms similar to PD [Langston et al., 1984].  
The monkey MPTP model has been utilized since this time to study symptoms of PD that 
are related to dopaminergic neuronal degeneration [Langston et al., 1984; Bankiewicz et al., 
1986; Bergman et al., 1990; Smith et al., 1993; Benazzouz et al., 1993; Ovadia et al., 1995; 
Gash et al., 1996; Bezard et al., 2001; Emborg, 2007; Bove et al., 2012]. PD-like motor 
symptoms in the monkey MPTP model are responsive to levodopa. Like Parkinson’s patients 
treated for an extended time with levodopa, MPTP-treated monkeys receiving L-dopa for 
prolonged periods develop levodopa-induced dyskinesias [Przedborski et al., 2001; Emborg, 
2007].  
 
A. Mechanism of action of MPTP  
MPTP is a highly lipophilic drug that easily crosses the blood-brain-barrier. Within the 
brain, MPTP is converted into its active metabolite MPP+, primarily by glial cells 
[Przedborski et al., 2003]. The enzyme monoamine oxidase B (MAO-B) is responsible 
for its biotransformation, as demonstrated by the protective ability of MAO-B inhibitors 
to prevent this neurotoxicity [Chiba et al., 1984].  MAO-B oxidizes MPTP to form 1-
methyl-4-phenyl-2,3-dihydropyridinium (MPDP+), but MPDP+ is unstable and 
immediately forms the active neurotoxin metabolite MPP+ [Chiba et al., 1985].  After the 
release of MPP+ into the extracellular space it is actively transported into DA neurons 
through the dopamine transporter (DAT), that has high affinity for MPP+ [Javitch et al., 
1985; Bezard et al., 1999]. Inhibition of DAT [Javitch et al., 1985], or its genetic ablation 
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[Bezard et al., 1999], prevents MPTP toxicity in these animals.  MPP+ accumulates in 
cells and can form a complex with neuromelanin or be trapped within synaptic vesicles 
by being taken up through the vesicular monoamine transporters (VMAT) on the surface 
of the vesicles [d’Amato et al., 1987; Takahashi et al., 1997; Staal et al., 2000]. MPP+ 
produces toxic effects through multiple mechanisms. Free MPP+ enters the mitochondria 
and inhibits mitochondrial respiration through NADH-ubiquinone oxireductase of the 
mitochondrial electron chain (mitochondrial complex I) activity, leading to decreased 
production of ATP and ultimately the death of DA neurons [Nicklas et al., 1985]. 
Evidence of cellular protection from MPTP in transgenic animals with an overexpression 
of superoxide dismutase [Przedborski et al., 1992] suggests that MPTP also has toxic 
effects by increasing the intracellular concentration of reactive oxygen species (ROS) that 
are toxic to cells. This is supported by the finding of increased cell loss in mice that lack 
superoxide dismutase or glutathione peroxidase and are treated with MPTP [Klivenyi et 
al., 2000; Zhang et al., 2000]. MPTP can also lead to increased levels of iron in the 
SNpc, accelerating formation of free radicals through the Fenton reaction [Temlett et al., 
1994]. Iron-regulatory element-binding proteins (IRPs) are intracellular RNA-binding 
proteins that respond to changes in cytosolic iron levels to regulate transcription of 
transferring receptor (TfR) and ferritin. MPTP leads to nitration of IRP’s causing it 
degradation through ubiquitin-proteasome pathway that ultimately results in an increase 
in iron levels [Mandel et al., 2004]. MPDP+ also is known to self-oxidize and increase 
formation of other superoxide radicals that are toxic to the DA neurons [Chiba et al., 
1985; Bove et al., 2012]. Nitric oxide synthase has also been implicated in the 
mechanism of MPTP action, as demonstrated by neuroprotection in mice lacking the 
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nitric oxide synthase gene that are given MPTP [Przedborski et al., 1996]. Thus, both 
mitochondrial deficits and oxidative stress contribute to MPTP-induced DA neuronal 
toxicity. Similar to patients with PD where there is progression of the disease over many 
years, some aspects of the toxicity seen in MPTP-treated monkeys has been shown to 
take a long time. For example, the inflammatory reactions in basal ganglia of monkeys 
receiving MPTP can continue for years suggesting that the pathological process follows a 
long time-course of progression even after a single MPTP administration [McGeer et al., 
2003]. 
 
B. Methods of delivery of MPTP   
MPTP has now been used to cause PD-like symptoms in various animal models, 
including monkeys, mice, cats, rats, guinea pigs, dogs, sheep, frog and goldfish [reviewed 
in Blum et al., 2001; Bove et al., 2012]. MPTP can be given either systemically or 
unilaterally, in one or multiple doses and in varying concentrations. The models that 
result from these administration modes are all different. The administration of MPTP 
based on the method of delivery leads to either unilateral or bilateral symptoms of either 
early stage or late stages of the disease. Although the effects of MPTP show considerable 
individual variability it is possible to develop predictable, stable models of the disease. 
The symptoms produced depend on the careful consideration of dosing of MPTP, 
treatment regimen, age, weight and animal species to induce the desired PD symptoms 
without causing adverse health problems [reviewed in Blum et al., 2001; Bove et al., 
2012].  As monkeys will be used in this dissertation, this section will focus on the effects 
of MPTP in monkeys. 
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Short-term systemic administration of MPTP via several dosing regimens produces 
bilateral signs of PD [for review see Emborg, 2007; Bove et al., 2012]. Generally, short-
term systemic dosing involves daily injections of 0.2 mg/kg – 2.0 mg/kg, with lower 
dosages used for intramuscular (IM) and intravenous (IV) administration and higher 
dosages used for subcutaneous (SC) administration to monkeys over a period of four days 
to three weeks. Short-term systemic administration of MPTP has been useful for studying 
the effects of MPTP on neuroinflammation in the basal ganglia and for examining the 
time course of cell death and strategies to prevent cell death. However, the drawback of 
short-term systemic administration is that behavioral recovery has often been observed 
over a period of time, starting from around three to five weeks after MPTP administration 
[Mounayar et al., 2007]. 
A regimen of chronic systemic administration of MPTP was developed to overcome 
these limitations. Again, 0.2 mg/kg – 2.0 mg/kg of MPTP (IM, IV or SC) per injection is 
given, however this is administered once or twice a week every one to two weeks for 
several weeks or months until the desired level of PD symptoms are present [for review 
see Przedborski et al., 2001; Blum et al., 2001; Jenner, 2003; Smeyne et al., 2005; 
Emborg, 2007; Bove et al., 2012]. There are several advantages to using this method 
where a slow chronic progression of symptoms that more closely reflects the progressive 
nature of PD is achieved.  Chronic systemic administration also provides sufficient time 
for the animal to recover general health between each dose, and animals are dosed until a 
specific severity of symptoms is reached which decreases individual variability in the 
final model used for studies. Animals have also been studied during the early time 
periods of chronic systemic MPTP dosing to examine neural changes that would reflect 
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the pre-diagnostic stages of PD in humans including cognitive impairments [Brownell et 
al., 1998] and sleep disturbances [Barraud et al., 2009]. This chronic systemic MPTP 
model is relevant for many scientific inquiries as it replicates some of the non-motor 
features of the disease including cognitive deficits, loss of motivation and change in sleep 
patterns [Emborg, 2007].  Interestingly, in these primate MPTP models it was recently 
observed that the non-motor symptoms like sleep problems develop earlier than motor 
symptoms as seen in human PD [Barraud et al., 2009]. Use of this model also allows 
investigation of compensatory changes that take place during early stages of the disease. 
The age of the animal plays a crucial role in the response to MPTP susceptibility, with 
older animals more significantly affected by MPTP compared to younger animals 
[Ovadia et al., 1995]. In many late stage bilateral models monkeys are so severely 
affected that they cannot care for themselves and need additional attention for housing 
and feeding [Smith et al., 1993]. Also, in some MPTP injection paradigms using this 
method there is no active process of degeneration after cessation of MPTP administration 
once the loss of nigral DA neurons plateaus and hence is not an exact replication of the 
progressive cell loss seen in PD [Garrido-Gil et al., 2009]. 
A third method of MPTP administration is the unilateral, intracarotid administration 
of MPTP [Bankiewicz et al., 1986; Ovadia et al., 1995; Gash et al., 1996; Zhang et al., 
1997; Grondin et al., 2002; Gash et al., 2005; Emborg, 2007; Bove et al., 2012]. There 
are several advantages to using this model including the ability of monkeys to care for 
themselves after a unilateral lesion. The calculation for dosing intracarotid MPTP is 
based on age, weight and species of monkeys to produce a very high rate of success in 
inducing either early or late stage symptoms of PD that are stable for many years 
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[Emborg, 2007; Bove et al., 2012]. In this method, surgical isolation of the internal 
carotid artery is made and MPTP is injected [Bankiewicz et al., 1986; Bergman et al., 
1990; Ovadia et al., 1995; Gash et al., 1996; Bezard et al., 2001; Emborg, 2007; Bove et 
al., 2012].  The production of symptomatology within days makes this model useful for 
studying neuroprotective and neurorestorative strategies, as well as for studying the 
pathophysiology within basal ganglia circuits that occurs secondary to loss of 
dopaminergic input. For example, the unilateral intracarotid MPTP monkey model was 
used for testing the effectiveness of deep brain stimulation for alleviating Parkinson 
symptoms [Benazzouz et al., 1993], which was successfully transferred from pre-clinical 
research to testing and use in patients very rapidly [Limousin et al., 1998]. One of the 
concerns using this low dose unilateral model could be that it may not affect non-motor 
symptoms and is a mild form of lesion compared to the chronic treatment. However, in 
later chapters in this dissertation I have found significant changes to non-motor 
symptoms using this model on sleep and motivational parameters in monkeys. (see 
Chapter 4) 
1.4.3 Biochemical changes in PD 
A. Changes to the DA neurotransmitter systems 
The role of DA in PD, ever since its first description in 1960 by Ehringer and 
Hornykiewicz in post mortem brain, has had a profound impact on our understanding of 
the disease process. The research into the dopamine deficit aspect of PD was a tipping 
point which led to a series of investigations into the biochemical aspects of the disease, 
the pathophysiology of dopamine deficit and this deficit in dopamine became the 
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rationale for treating PD patients with levodopa the synthetic precursor to dopamine. This 
successful transformation of a basic science biochemical finding into clinical practice 
helped establish a new branch of investigation into biochemical processes detectable of 
post-mortem brain tissue to learn more about the neuroscience of brain diseases.  
 The entire nigrostriatal dopamine neuron is affected in the severely affected PD 
patient [Olanow et al., 1999; Dauer et al., 2003]. The changes in the DA system in PD 
are distinct from the patterns of cell loss observed in normal aging [Fearnley et al., 1991; 
Dauer et al., 2003]. In PD, the ventrolateral and caudal portions of the SNpc are first 
affected, whereas in normal aging the dorsomedial aspects of the SNpc are first affected. 
The changes to the nigrostriatal DA system begin with reduced DA content in the 
striatum and this reduction is always higher than that observed in the midbrain DA 
neurons [Bernheimer et al., 1973]. This implies that the degenerative process in this 
disease begins in the striatum and proceeds later to the midbrain region. This process is 
sometimes referred to as the ‘dying back’ process of nigrostriatal DA system. There is 
also a strong correlation between the progressive worsening of the motor problems in the 
disease with reduced dopamine function in striatum and midbrain.  This is also supported 
by research in experimental models of PD that closely follow the changes observed in 
clinical PD, where in MPTP-treated primates there is first a reduction of TH-positive 
terminals in the striatum before a loss is evident in the midbrain DA neurons [Przedborski 
et al., 1996, 2001; Schmidt et al., 2001].  
The presence of different concentrations of DAT, the main transporter of DA, 
from the terminals in striatum differ across the SNpc population in midbrain region is 
proposed as the reason for the differential vulnerability of DA neurons in the midbrain 
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[Olanow et al., 1999; Przedborski et al., 1996, 2001]. There is some evidence that the 
decrease in mRNA concentration of DAT closely parallels the decrease in striatal DA 
content [Bernheimer et al., 1973; Uhl et al., 1994].  
 There is around a 60-80% loss of striatal DA content before the first motor signs 
of PD appear [Hornykiewicz, 1998; Zigmond et al., 2002; Dauer et al., 2003]. This 
implies that there is a long period of time when the disease slowly progresses in the brain 
before the appearance of external symptoms.  It has been proposed that during this 
dormant period of progression there is internal compensation in the nigrostriatal DA 
system that takes place [Bernheimer et al., 1973; Zigmond et al., 1990,1992, 1997, 2002; 
Bezard et al., 2003; Obeso et al., 2004]. The ability of the diseased nigrostriatal DA 
pathway to internally compensate for the increasing loss of DA from the striatum until 
there is around 60-80% loss shows a dynamic compensatory process. This compensation 
may be mediated directly by changes in the nigrostriatal DA neuron, the pathways it 
influences and/or other circuits that are extrinsic and do not directly influence the DA 
pathway. 
 The changes to the nigrostriatal DA pathway could primarily result from the 
following mechanisms [Agid et al., 1973; Hefti et al., 1980; Altar et al., 1987; 
Stachowiak et al., 1987; Snyder et al., 1990; Hudson et al., 1995; Sherman et al., 1995; 
Harsing et al., 1996, 1997, 1998; Garris et al., 1997; Zigmond et al., 1981,1990, 1997, 
2002]. After a loss of TH-positive fibers in the striatum there is a concurrent loss DAT. 
This results in an increased concentration of DA in the synaptic cleft that compensates for 
the loss of DA terminals. There is also a proposed increase in the synthesis of DA by the 
remaining DA neurons that could maintain the influence of nigrostriatal DA on its 
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targets. This compensatory mechanism was proposed based on the changes to the ratio of 
DA and its metabolite, homovanillic acid (HVA) [Zigmond et al., 1990]. Similar 
increases in dihydroxyphenylacetic acid (DOPAC) to DA ratio provide another indicator 
of increased DA turnover in the diseased striatum [Zigmond, 1997]. There is also 
evidence of an increase in postsynaptic receptors for DA during the pre-clinical phase of 
PD, to also help compensate for the decrease in secreted DA [Zigmond et al., 1990, 
1997]. Different amounts of DA loss could lead to different levels of compensations with 
moderate lesions not having much of a functional change, a large lesion leading to 
increased DA synthesis and release, and an extensive lesion leading to rapid 
compensatory processes [Zigmond et al., 1990,1997].  
Apart from the compensatory changes described above, electrophysiological 
changes to the activity of the different basal ganglia nuclei can internally compensate for 
the changes in activity resulting from nigrostriatal DA deficit [Grace, 1991]. It has been 
shown that there is an increase in activity of the STN and GPi, by way of an increase in 
firing of these neurons before the appearance of motor symptoms during the preclinical 
phase in the disease [Greenamyre, 1993; Albin et al., 1995]. It is proposed that the 
increase in firing of STN maintains the GPe physiological function and compensates for 
the abnormal processing of DA within the striatum in the initial stages of the disease. 
These changes in electrophysiological firing are found to occur after the changes to the 
DA receptor compositions in neurons [Zigmond et al., 1990, 1997]. There is a correlation 
between increasing loss of DA and an increase in activity of the structures described 
above [Greenamyre, 1993]. These electrophysiological abnormal outputs from the basal 
ganglia are propagated through the output circuits to thalamus and cortex. Further 
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research is needed to determine if there is plasticity in these external circuits that do not 
directly influence the DA pathway, to maintain the homeostasis of normal function 
during the long pre-symptomatic period in PD, although there is a clear abnormal output 
from basal ganglia. 
 
B. Lewy bodies in PD 
PD, which was earlier more or less thought of as just an isolated disorder of the 
dopaminergic system, is becoming more complex as we learn more about the pathology 
of the disease [Braak et al., 2000, 2003 and 2004].  It now beginning to be widely 
accepted that the loss of neurons in PD follows a non-random pattern and the changes 
involve a widespread degeneration affecting the human central, peripheral and enteric 
nervous systems. 
 
Lewy bodies are composed of abnormal intra-neuronal protein aggregates that are present 
in cells as cytoplasmic inclusions. Lewy first described these abnormal protein aggregates 
in detail, within the substantia inominata and dorsal vagal nucleus in PD [Lewy, 1912]. 
Tretiakoff was the first to observe these inclusions in substantia nigra [Tretiakoff, 1919]. 
He gave these inclusions the name ‘Lewy bodies’. Since then, Lewy bodies have been 
consistently found in post-mortem brain tissues of PD patients. These inclusions are 
found in a number of regions [Braak et al., 2000]. It is proposed that all the neurons that 
are susceptible to have Lewy body inclusions share two common properties [Braak et al., 
2004]. First, all the affected neurons are projection neurons that have very long and thin 
axons in comparison to their cell body size. Second, neurons with Lewy bodies have 
long, thin axons that are unmyelinated or poorly myelinated. In PD, during the long 
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preclinical duration of the disease, the pathological process is thought to begin in the 
brainstem within the dorsal motor nucleus of IX/X and progresses upward reaching the 
neo-cortex in the final advanced stages of the disease.  Lewy bodies have been found not 
only within the central nervous sytem but also within the enteric nervous system [Braak 
et al., 2006]. These changes are thought to account for the autonomic symptoms that are 
frequently seen in PD patients.  
 
C. Changes to other non-DA neurotransmitter systems 
There are changes to other neurotransmitter systems besides the dopaminergic system 
with PD. The most prominent among these are noradrenalin, serotonin, GABA and 
glutamate [Ohama et al., 1976; Greenamyre et al., 1993; Blandini et al., 1996; 
Hornykiewicz, 1998]. However, in contrast to the consistent presence of nigrostriatal DA 
loss in the post-mortem brain tissue of PD patients, changes to other neurotransmitter 
systems are variable and have not been studied as extensively. There have been reports of 
inclusion of Lewy bodies in dorsal raphe nucleus and locus coeruleus neurons, along with 
a concurrent reduction of both serotonin and noradrenalin levels in the post-mortem 
brains of PD patients [Bethlem et al., 1960; Ohama et al., 1976]. However, only recently 
have these changes in other non-dopaminergic regions in PD have gained recognition 
[Braak et al., 2000,2003,2006; Hawkes et al., 2010]. Changes to GABAergic MSN 
neurons in the striatum have been observed, that could be due to the secondary effects of 
nigrostriatal DA loss [Hornykiewicz, 1998]. There is a direct correlation between the 
losses of DA innervation of striatum which projects to its primary target of striatal 
GABAergic medium spiny neurons and increase in GABA levels in the striatum [Kish et 
al., 1986; Hornykiewicz, 1998].  Similarly, there is increased glutamatergic activity in the 
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striatum, which constitutes the main input to the basal ganglia, that occurs secondary to 
DAergic loss [Greenamyre, 1993]. An increase in the activity of STN, that contains 
glutamatergic connection to the basal ganglia output structures, is also observed together 
with changes to the glutamate receptors in these regions [Blandini et al., 1996]. It is also 
important to note that glutamate can act as a neurotoxin in the cases of impaired cellular 
functioning [Blandini et al., 1996; Hornykiewicz, 1998]. One of the proposed mechanism 
through which this might occur is that a loss of DA influence in the striatum that contains 
GABA inhibitory projection neurons after DA loss, that can lead to increased activity in 
excitatory glutamate-containing STN neurons. These changes in GABA and glutamate 
neurotransmission have also been observed in animal models of PD [Greenamyre, 1993; 
Blandini et al., 1996,2000; Hornykiewicz, 1998]. The non-motor symptoms that are seen 
in PD before the appearance of motor symptoms could be related to changes in many of 
the monoaminergic neurotransmitter systems that extensively innervate the CNS before 
degeneration of the DA system [Braak et al., 2000, 2006, 2008; Hawkes et al., 2008, 
2009, 2010]. 
1.5 NEUROTROPHIC FACTORS THAT SUPPORT DA NEURONS 
Neurotrophic factors are proteins that support the growth, survival and function of specific 
neuronal populations during the course of development [Thoenen, 1995; Barbacid, 1995; 
Ibanez,1995; Saarma et al., 1999, 2002, 2003]. There is interest in the use of these molecules as 
therapeutic agents in the treatment of a wide variety of neurological disease conditions. Stanley 
Cohen and Rita Levi-Montalcini discovered the first identified neurotrophic factor that affects 
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nerve cells [Cohen et al., 1954]. They called it Nerve Growth Factor (NGF), and received the 
Nobel Prize in 1986 for its discovery. Since that time a number of neurotrophic factors have been 
identified. Neurotrophic factors can be grouped into different families based on homology of the 
molecules, receptors they bind to, and common transduction pathways. NGF belongs to the 
Neurotrophin family. There are three main families of neurotrophic factors that have been 
discovered, the Neurotrophin family [Cohen et al., 1954], the Glial cell-line Derived 
Neurotrophic Factor (GDNF) family [Lin et al., 1993] and the Mesencephalic Astrocyte-derived 
Neurotrophic Factor (MANF) family [Petrova et al., 2003 and Lindholm et al., 2007]. The two 
families that are most directly relevant to supporting dopamine neurons that degenerate in 
Parkinson’s disease are the GDNF and MANF families [for review see Peterson et al., 2008; 
Lindholm et al., 2010; Aron et al., 2011]. Specifically, GDNF and Neurturin (NRTN), that 
belong to the GDNF family, and Cerebral Dopamine Neurotrophic Factor (CDNF), that belongs 
to the MANF family, show both neuroprotection and neurorestoration of DA neurons after toxic 
insults in animal models of PD [Lindholm et al., 2007,2008, 2010; Voutilainen et al., 2011; 
Airavaara et al., 2012]. 
1.5.1 Glial Cell-line Derived Neurotrophic Factor, GDNF 
Lin et al. discovered GDNF in 1993 in a rat glial cell-line (B49), as a soluble factor released by 
the cell culture. GDNF is a glycosylated, disulfide bonded homodimer whose molecular weight 
is approximately 33–45 kDa, while the monomer has a molecular weight of 16 kDa after 
deglycosylation [Lin et al., 1993,1994]. GDNF is synthesized as an inactive 211 amino acid pre-
pro-GDNF secretory protein that is cleaved into the mature GDNF protein of 134 amino acids. 
The regional distribution and cellular localization of GDNF was identified using PCR techniques 
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in the central nervous system of rats and humans [Lin et al., 1993; Schaar et al., 1993, 1994; 
Stromberg et al., 1993; Springer et al., 1994]. GDNF protein was found to be present in a 
number of brain regions in the rat central nervous system, including the striatum, hippocampus, 
cortex, cerebellum and spinal cord. In the human central nervous system, GDNF transcripts were 
identified in the striatum, caudate, hippocampus, cortex and spinal cord. More importantly, 
GDNF message was expressed in the substantia nigra and basal forebrain type I astrocytes 
[Schaar et al., 1993, 1994]. Addition of GDNF to cultured primary dopaminergic neurons in 
vitro increases DA cell number, neurite length, cell size, and dopamine uptake [Lin et al., 
1993,1994]. GDNF also reduces the rate of apoptosis and prolongs neuronal survival in cultured 
dopaminergic neurons [Clarkson et al., 1995, 1997]. 
In PD, there is selective loss of nigrostriatal dopaminergic neurons and there is evidence 
that GDNF can play a therapeutic role in rescuing DA neurons in animal models of PD [Gash et 
al., 1995; Hou et al., 1996; Martin et al., 1996; Opacka-Juffry et al., 1995; Schults et al., 1996]. 
In vivo animal models that mimic symptoms of PD are produced using selective dopaminergic 
neurotoxins, such as 6-hyroxy-dopamine (6-OHDA) and MPTP. GDNF has been shown to 
rescue injured dopaminergic neurons in these models [Hoffer et al., 1994; Tomac et al., 1995; 
Beck et al., 1995; Bowenkamp et al., 1995; Bjorklund et al., 1997]. After intranigral 
administration of GDNF in the 6-OHDA-treated rat model there is neurochemical and behavioral 
improvement of PD-like motor symptoms [Bjorklund et al., 1997]. In addition, intra-striatal 
injection of GDNF also prevents dopaminergic loss after 6-OHDA induced nigrostriatal lesions 
[Opacka-Juffry et al., 1995; Sauer et al., 1995; Schults et al., 1996]. GDNF has also been shown 
to rescue dopaminergic neurons in animal models receiving the DA toxin, MPTP [Tomac et al., 
1995; Hou et al., 1996; Gash et al., 1996]. GDNF when injected in the substantia nigra or 
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striatum of monkeys before administration of MPTP significantly protected the dopaminergic 
system, while GDNF when injected after MPTP administration significantly restored dopamine 
levels and dopamine fiber density [Gash et al., 1996; Zhang et al., 1997; Connor et al., 1998]. 
Recombinant Adeno-Associated-Viruses (AAV) that carry the gene encoding human GDNF, 
also have been shown to protect DA neurons from progressive neurodegeneration when injected 
near the substantia nigra or in the striatum of both mice and primates prior to MPTP 
administration [Choi-Lundberg et al., 1997; Bilang-Bleuel et al., 1997; Kordower et al., 2000; 
Eslamboli et al., 2005]. Thus AAV-GDNF gene therapy may also be a treatment option for PD. 
Thus, GDNF shows both neuroprotection and neurorestoration of DA neurons [Tomac et al., 
1995; Hou et al., 1996; Gash et al., 1996; Hoffer et al., 1994; Beck et al., 1995; Bowenkamp et 
al., 1995; Bjorklund et al., 1997].  
 There have been four clinical trials that have been conducted with GDNF [Nutt et al., 
2003; Gill et al., 2003; Patel et al., 2005; Slevin et al., 2005]. There was no significant 
improvement in motor symptoms when GDNF was injected into the cerebrospinal fluid (CSF) in 
the first clinical trial [Nutt et al., 2003]. The authors suggested that this may reflect poor 
penetration of GDNF into the brain from CSF [Nutt et al., 2003]. In order to achieve better brain 
penetration and targeting, GDNF was directly infused in the putamen using minipumps in the 
subsequent trials [Gill et al., 2003; Patel et al., 2005; Slevin et al., 2005]. The second and third 
open label trials led to significant clinical improvements in patients [Gill et al., 2003; Patel et al., 
2005; Slevin et al., 2005]. However, in the fourth double-blind placebo controlled trial there was 
no improvement seen [Lang et al., 2006]. Some patients in that clinical trial developed anti-sera 
against GDNF, although there were no adverse consequences detected. Around the same time as 
the fourth study, in a parallel study in monkeys, cerebellar lesions were detected in animals that 
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received three to four times the dose of GDNF used in human trials [Hovland et al., 2007]. The 
findings of no clinical improvement, coupled with development of antisera to GDNF and 
cerebellar lesions, led Amgen, the company that licensed the use of GDNF for the treatment of 
PD, to decide to stop all clinical testing of GDNF.  However, there has been a lot of discussion 
about this decision [Barker, 2006, 2009; Evans et al., 2008]. The reason for the failure in the 
fourth clinical trial could be due to the dose of GDNF that was used, properties of the catheter 
used to administer GDNF, the choice of patients included in the trials, the duration of study in 
the clinical trial or the inability of GDNF to reach the intended target regions in the brain [Barker 
, 2006, 2009; Evans et al., 2008; Deierborg et al., 2008]. A common failure in all the above 
experiments is inability to delivery bioactive GDNF that can diffuse to the entire target region in 
the brain [Deierborg et al., 2008; Bjorklund et al., 2009]. The reason for this main setback that is 
common to all four clinical trials could be due to the binding of GDNF to heparin-like binding 
sites in the brain for which GDNF has high affinity [Rider, 2006]. 
1.5.2 Neurturin, NRTN 
Neurturin (NRTN), the second member of the GDNF family of neurotrophic factors, was 
discovered three years later in Jeffrey Milbrandt’s lab [Kotzbauer et al., 1996]. Mature NRTN is 
100 amino acids long and shares 42% sequence homology with GDNF [Kotzbauer et al., 1996]. 
GDNF and NRTN share intracellular signaling pathways [Kotzbauer et al., 1996]. NRTN, like 
GDNF, promotes DA neuronal survival, and both factors have distinct functional roles in the 
developing and adult midbrain dopaminergic neurons [Akerud et al., 1999]. GDNF and NRTN 
are expressed sequentially as endogenous trophic factors to the developing DA neurons. During 
post-natal development NRTN plays a vital role in DA innervation of the striatum. The post-
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natal expression profile of NRTN is thought to sustain this dopaminergic innervation of striatum 
[Trupp et al., 1996; Akerud et al., 1999]. Thus, the selective DA neuron survival-promoting 
activity of NRTN is complementary to the earlier expression of GDNF that induces sprouting 
and increases cell-body size of dopaminergic neurons [Lin et al., 1993; Bowenkamp et al., 1995; 
Sauer et al., 1995]. The combined sequential expression of GDNF and NRTN, and their distinct 
functional roles suggest a complimentary coordinated activity during development [Trupp et al., 
1996; Akerud et al., 1999]. 
 NRTN, like GDNF, also prevents the degeneration of substantia nigra dopamine 
neurons by being neuroprotective in 6-OHDA injected rats [Horger et al., 1998; Akerud et al., 
1999; Rosenblad et al., 1999]. NRTN has also shown neuro-restorative effects in 6-OHDA 
injected rats [Oiwa et al., 2002]. One of the main problems, as for GDNF, is continuous delivery 
of NRTN to intracerebral targets in the brain over long periods of time. There have been 
advances made with use of safe viral vectors (recombinant Adeno-Associated Viruses rAAV and 
recombinant Lentivirus rLV) for transfection and delivery of neurotrophic factors in vivo 
[Bilang-Bleuel et al., 1997; Lapchak et al., 1997; Bensadoun et al., 2000; Rosenblad et al., 2000; 
Connor et al., 2001; Kordower et al., 2003]. Lentiviral delivery of NRTN to the striatum of 6-
OHDA lesioned rats resulted in protection of over 90% of nigral DA cells compared to vehicle 
treatment [Fjord-Larsen et al., 2005]. Ceregene Inc. developed an Adeno-associated virus type-2 
(AAV2) vector that encodes a modified form of human NRTN, called CERE-120. When injected 
into 6-OHDA lesioned rats CERE-120 prevented motor deficits and loss of nigral neurons that 
was equipotent to GDNF and significantly improved from vehicle-treated group which had close 
to 70% decrease in number of TH-positive DA neurons [Gasmi et al., 2007]. The above 
experiment was independently confirmed along with another series of experiments in 
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collaboration with the Kordower lab. CERE-120 was shown to provide protection to both 
structure and function of nigral DA neurons in both rat and monkey models of PD [Kordower et 
al., 2006; Gasmi et al., 2007; Herzog et al., 2007; Herzog et al., 2008; Herzog et al., 2009]. 
 There have been three clinical trials using CERE-120 [Marks et al., 2008; Marks 
et al., 2010, MJFF press release, 2013]. Intraputamenal administration of CERE-120 improved 
motor function in a Phase I clinical trial and was found to be safe at one-year post-administration 
[Marks et al., 2008]. In this open label trial, 12 patients with advanced PD were injected 
bilaterally with CERE-120 in the putamen. This resulted in significant improvement in the 
Unified Parkinson’s Disease Rating Scale (UPDRS) motor score when they were “off” 
medication [Marks et al., 2008]. Importantly, none of the patients experienced dyskinesias 
during the trial.  These initial positive results led to a Phase II double-blind randomized clinical 
trial with CERE-120 [Marks et al., 2008, 2010]. Like GDNF, the CERE-120 phase II testing in a 
larger cohort of 58 PD patients failed to show any significant improvements in motor function. 
Post-mortem data collected from two patients from this cohort who had died of other 
complications, indicated that NRTN showed poor diffusion into the brain parenchyma and no 
NRTN was found in cell bodies of nigral DA neurons [Marks et al., 2010; Vastag, 2010].  This 
data from post-mortem brain tissue led to refinement of the dosing of CERE-120 to both enhance 
and accelerate the effects of NRTN by injecting directly both into the substantia nigra and 
putamen at the same time. A Phase I open-label clinical trial with six PD patients was again 
successful [Ceregene press release 2013; MJFF press release, 2013]. This was followed by a 
Phase II clinical trial with fifty-one patients with PD, monitoring them for fifteen to twenty-four 
months to test the benefits and safety of using CERE-120 [Ceregene press release 2013; MJFF 
press release, 2013]. Ceregene Inc. recently announced the results from its second Phase II 
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clinical trial, where there was no significant improvement to the UPDRS motor scores in the 
absence of medication in CERE-120 administered patients compared to sham-control patients 
[MJFF press release, 2013]. However, CERE-120 showed improvement in other measures like 
the “diary-off score” (daily diaries that assess motor function throughout the day) that measures 
qualitative motor function throughout the day for these patients, and this trial also provided 
further evidence for the safety of CERE-120, the dosing and viral vector delivery methods used. 
The data from this trial is still being analyzed [MJFF press release, 2013]. NRTN that belongs to 
the same family of neurotrophic factor as GDNF is known to bind to heparin-like binding sites in 
the brain with high affinity. Hence, poor diffusion of NRTN within the brain could again be the 
reason for the statistically insignificant improvement in the above clinical trials [Marks et al., 
2010, Vastag, 2010; Ceregene press release 2013; MJFF press release, 2013].  
Mutations in the NRTN molecule at the sites that putatively bind to these extracellular 
matrix components were generated and tested in vitro [Runeberg, Saarma and Penn, unpublished 
data]. Four such NTRN variants were generated, two molecules out of them i.e., N2 and N4 were 
found to give better yields, were more stable and easy to handle. N2 and N4 also showed 
improved resistance to proteolytic cleavage in vitro. 
N2 and N4 were tested in vivo in a rat 6-OHDA model of the disease. N2 and N4 were treated 
groups improved significantly in motor function tests. In particular, N4 showed increased 
diffusion compared to N2 and GDNF. N4 was also significantly better than GDNF in rescuing 
both DA neurons and improving motor functions. This could be both due to the widespread 
diffusion of N4 and the increased proteolytic stability of the molecule. In a pilot study, N4 
diffused the maximum with almost twice the diffusion volume of GDNF although N4 was 
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infused in a 10% smaller volume [Runeberg, Saarma and Penn, unpublished data]. Thus N2 and 
N4 have the potential to restore DA neurons and motor functions in PD. 
1.5.3 Cerebral Dopamine Neurotrophic Factor, CDNF 
In 2007, Lindholm et al. discovered a novel trophic factor, CDNF, which belongs to the newly 
identified MANF family of neurotrophic factors [Lindholm et al. 2007].  CDNF contains eight 
conserved cysteine residues and is a secreted protein with a strong homology to MANF 
[Lindholm et al. 2007]. In mice and humans, CDNF is encoded as a 187 amino acid protein with 
no ‘pre’ or ‘pro’ sequence and has a molecular weight of 18 kDa. The presence of CDNF 
messenger RNA and protein in the adult mouse was detected using RT-PCR and western blotting 
techniques respectively, in the brain, heart muscle and testis. In the brain, the CDNF message is 
present in embryonic, post-natal and adult stages of development [Lindholm et al. 2007]. CDNF 
protein has been detected in neuronal cell somas in the adult layers two to six of the cortex, 
hippocampus layers CA1 to CA3, and in the thalamus, striatum and non-dopaminergic solitary 
cells in the substantia nigra midbrain region, purkinje cells in the cerebellum and in other brain 
stem regions.  CDNF and MANF are conserved through evolution with a 49% homology 
between the human peptides and those of the fruit fly (Drosophilia melanogaster) and 46% 
homology with worm (Caenorhabditis elegans) [Lindholm et al. 2007].  Unlike GDNF that 
supports motorneurons in the enteric, sensory, parasympathetic and sympathetic neurons in the 
peripheral nervous system, CDNF does not support the survival of these peripheral neurons 
[Lindholm et al. 2007]. Although CDNF is present endogenously in the adult brain it has not 
been found to promote neurite outgrowth or sprouting of axons in culture [Lindholm et al. 2007]. 
When CDNF is infused into normal mouse brain, no changes were observed in endogenous 
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levels of DA, DAT or TH, and no detectable changes in mouse behavior were present; there was 
only an increase DA metabolism in the striatum [Airavaara et al., 2012].  
 In animal models of PD with loss of nigrostriatal DA neurons, CDNF has been shown to 
be both neuroprotective and neurorestorative [Lindholm et al. 2007; Airavaara et al., 2012]. In a 
unilateral 6-OHDA rat model of PD, injection of CDNF prior to administration of the neurotoxin 
6-OHDA led to significant neuroprotection of the midbrain DA neurons [Lindholm et al. 2007; 
Airavaara et al., 2012]. This protection was comparable to that offered by GDNF, however the 
CDNF-treated animals continued to show significant behavioral recovery at four weeks after 
injection but GDNF did not have this effect [Lindholm et al. 2007]. To test if CDNF was also 
neurorestorative, rats were injected with 6-OHDA unilaterally and CDNF, GDNF or vehicle was 
infused four weeks later and the animals were tested for behavioral recovery and post-mortem 
measurements of recovery in nigrostriatal DA system [Lindholm et al. 2007; Airavaara et al., 
2012]. CDNF-treated animals showed a less than a 50% loss of DA neurons in the lesioned side 
of the brain and also significantly reduced the amphetamine-induced rotation behavior by about 
33% [Lindholm et al. 2007; Airavaara et al., 2012]. In a mouse model of PD, where MPTP was 
administered as a neurotoxin, CDNF again showed both neuroprotection and neurorestoration 
[Airavaara et al., 2012].  More recently, CDNF was successfully transfected into the rat brain 
using AAV vector-mediated delivery [Back et al., 2013]. The expression of CDNF using AAV-
mediated delivery into the striatum of rats provided significant recovery of behavior and 
nigrostriatal DA system both when measured in a short-term study of ten weeks duration where 
AAV-CDNF was tested as a neuroprotective agent [Back et al., 2013] and also in a 
neurorestorative study when AAV-CDNF offered protection fifty-four weeks after transfection in 
a 6-OHDA rodent model of PD [Ren et al., 2013]. In a comparative study of diffusion of trophic 
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factors, both CDNF and MANF were shown to diffuse over a greater volume than GDNF 
initially after administration of the neurotrophic factors [Lindholm et al., 2010; Voutilainen et 
al., 2011]. Thus, CDNF has been shown to be neuroprotective and neurorestorative in two 
different rodent models of PD using different method of delivery of the trophic factor into the 
brain. 
1.6 SPECIFIC AIMS 
The main setback that has thus far prevented the translation of neurotrophic factors (i.e., GDNF 
and NRTN) into the clinic for the treatment of PD has been the failure of NTFs (GDNF and 
NRTN) in large Phase II double blind clinical trials [Barker, 2006, 2009; Evans et al., 2008; 
Marks et al., 2010, Vastag, 2010]. This failure has been attributed to several possible reasons, 
however there is one major common underlying theme. It is the lack of ability for these trophic 
factors to diffuse to reach intended targets in the brain. In order to overcome this limitation two 
mutant forms of NRTN that have mutations in the sites of the molecule that putatively bind to 
these sites in the extra cellular matrix but still maintains bioactivity for its trophic capabilities 
were developed [discussed in detail in Section 1.5.4], N2 and N4. Along with these two mutants, 
another recently discovered trophic factor, CDNF [Lindholm et al., 2007], also diffuses widely 
in the brain. CDNF can spread easily in the brain as it belongs to a novel class of trophic factors 
with different structural properties. In this dissertation I address test whether these three NTFs, 
CDNF, N2 and N4, which readily diffuse in brain parenchyma, are effective in restoring 
dopaminergic function in the MPTP primate model of PD. 
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1.6.1 Specific Aim 1 
To determine if CDNF and NRTN mutants that do not bind to heparin-like binding sites in the 
brain stimulate restoration of motor function in the unilateral MPTP monkey model of PD.  
The motor aspects of PD including tremor, rigidity, bradykinesia and postural instability,  
were induced in rhesus monkeys unilaterally on the left side of the body by a single low-dose 
unilateral MPTP injection in the right carotid artery. Motor function was assessed and quantified 
using five separate measures of gross motor function and fine motor function, before and after 
MPTP administration, and in response to three neurotrophic factor/vehicle infusions into the 
putamen. 
1.6.2 Specific Aim 2 
To determine if CDNF and NRTN mutants that do not bind to heparin-like binding sites in the 
brain stimulate restoration of normal sleep patterns in monkeys receiving unilateral MPTP 
infusions. 
Non-motor problems are present in almost all PD patients, with a very high prevalence of 
sleep pattern disturbances. Increased daytime sleepiness is one of the chief complaints of PD 
patients. The Cameron laboratory has validated actigraphic methods to noninvasively measure 
sleep in nonhuman primates. Actigraphy was used to assess the changes in sleep patterns before 
and after MPTP and after neurotrophic factor infusions. The changes in sleep patterns after 
MPTP were analyzed and compared with the sleep patterns after three infusions of the three 
NTFs (i.e., N2, N4 or CDNF). Results were compared to animals who received vehicle infusions 
or GDNF infusions. 
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1.6.3 Specific Aim 3 
Identification of changes in the nigrostriatal dopamine system after monkeys with unilateral 
MPTP lesions receive intraputamenal infusions of, CDNF, N2, N4, GDNF or vehicle  
Post-mortem brain tissue from unilateral MPTP-treated monkeys was collected after three 
months of neurotrophic factor administration and analyzed for degenerative changes in midbrain 
dopamine neurons. The total numbers of DA neurons present after four monthly infusions of 
vehicle or neurotrophic factors were counted. Changes the tissue levels of DA and DA 
metabolites, homovanillic acid (HVA) and DOPAC, in the terminal fields of nigrostriatal DA 
neurons (i.e., the caudate, putamen, and nucleus accumbens) will be measured in upcoming 
analyses (however, these assessments have been delayed due to the need to get permission to 
send the brain tissue out of the country for analysis so this information is not part of this 
dissertation).  
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2.0  EFFECTS OF CDNF, N2 AND N4 ON RECOVERY OF MOTOR FUNCTION IN 
MPTP-TREATED MONKEYS 
2.1 INTRODUCTION 
Since the first reports that GDNF could rescue dopamine neurons after toxic insult [Lin et al., 
1992; Schaar et al., 1993, 1994; Stromberg et al., 1993; Springer et al., 1994; Tomac et al., 
1995; Hou et al., 1996; Gash et al., 1996] there has been considerable interest in the 
development of trophic factors as a treatment option for PD. GDNF has been found to be both 
neuroprotective [Choi-Lundberg et al., 1997; Bilang-Bleuel et al., 1997; Kordower et al., 2000; 
Eslamboli et al., 2005] and neurorestorative [Opacka-Juffry et al., 1995; Sauer et al., 1995; 
Schults et al., 1996] in toxin-induced rodent and primate models of PD.  GDNF when given 
either before or after toxin insult has been shown to lead to greater survival of DA neurons in the 
substantia nigra [Hoffer et al., 1994; Beck et al., 1995; Bowenkamp et al., 1995; Bjorklund et 
al., 1997], and better motor function [Tomac et al., 1995; Hou et al., 1996; Gash et al., 1996]. 
However, clinical trials of GDNF have been more mixed, with the most recent Phase II clinical 
trials not showing significant improvement of motor function in PD patients [Patel et al., 2005; 
Slevin et al., 2005; Lang et al., 2006]. One of the main reasons attributed to the failure in clinical 
trials is the poor diffusion of GDNF in brain tissue possibly due to its high affinity binding to 
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extracellular heparan sulphates [Rickard et al., 2003; Saarma et al., 2003; Rider, 2006; Barker, 
2006, 2008; Deierborg et al., 2008; Bjorklund et al., 2009; Pitonen et al., 2009]  
  Another member of the GDNF family of ligands, NRTN, has also shown potential as a 
therapeutic option for PD. Similar to GDNF, NRTN showed promising therapeutic efficacy in 
rodent and monkey models of PD [Horger et al., 1998; Akerud et al., 1999; Rosenblad et al., 
1999; Kordower et al., 2006; Gasmi et al., 2007; Herzog et al., 2007; Herzog et al., 2008; 
Herzog et al., 2009]. An AAV vector-containing the gene for NRTN (CERE-120) was 
successfully tested in a small Phase I clinical trial with PD patients [Marks et al., 2008; Marks et 
al., 2010]. A larger phase II trial was carried out recently to test the effectiveness and safety of 
viral vector-based delivery of NRTN (CERE-120) in the brain to treat PD [Marks et al., 2008; 
Marks et al., 2010, MJFF press release, 2013]. However, in a very recent press release CERE-
120 effectiveness in this Phase II clinical trial was reported to have little success [MJFF press 
release, 2013]. One of the main concerns that may account for the failure of the clinical trial was 
the inability of NRTN produced at the site of CERE-120 injection to diffuse to the various target 
locations that experience neurodegenerative changes in PD. GDNF and NRTN are both 
neurotrophic factors that belong to the GDNF family of ligands, and it is well known that both 
NTF’s have a strong affinity to bind to heparin-like binding sites in the brain [Rider, 2006]. As a 
result of this binding, both GDNF and NRTN when given in the striatum are known to diffuse to 
fewer target regions in the large human brain compared to the much smaller brains of 
experimental animals [Barker, 2006, 2009; Evans et al., 2008; Marks et al., 2010].  
The problem with diffusion of the GDNF family ligands led to the search for novel 
trophic factors. In 2007, CDNF was identified; a NTF that belongs to a new family of trophic 
factors, the MANF family [Lindholm et al., 2007]. MANF family trophic factors, unlike GDNF 
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family trophic factors, do not bind to heparin-like binding sites, thus they have a greater 
distribution in the brain compared to GDNF and NRTN [Lindholm et al., 2010; Voutilainen et 
al., 2011]. The effectiveness of CDNF was tested in rodent toxin models of PD. CDNF was 
shown to be both neuroprotective and neurorestorative [Lindholm et al., 2007; Airavaara et al., 
2012]. Moreover, CDNF was effective for a longer duration than GDNF in these animal models, 
with CDNF showing significantly improved behavioral recovery four weeks after injection, 
while GDNF-treated animals showed behavioral recovery for only two weeks [Lindholm et al., 
2007; Airavaara et al., 2012]. CDNF has not been tested in animals with larger brains and one 
goal of the current study was to determine if CDNF is neurorestorative in the larger brain of a 
nonhuman primate. 
Another strategy to obtain greater tissue distribution of trophic factors has been to make point 
mutations in NRTN in the region of the heparin-like binding site to decrease binding and thereby 
increase diffusion within the brain [Runeberg, Saarma and Penn, unpublished data]. Runeberg et 
al. made point mutations, based on the consensus sequence in a positively charged area 
containing arginine residues at the surface of NRTN molecule known to bind to the heparin-like 
binding sites. Four such mutant variants of NRTN (N1 to N4) were created [Runeberg, Saarma 
and Penn, unpublished data]. These four mutants were tested in vitro for bioactivity, ease of 
production, binding to heparin, and stability and effectiveness as a trophic factor to DA neurons 
[Runeberg, Saarma and Penn, unpublished data]. After extensive testing, two of these mutants 
(N2 and N4) that showed the best efficacy were tested in rodent models of PD. N2 and N4 were 
found to be more effective than GDNF in improving motor behaviors. In a preliminary test to 
check the distribution of N2 and N4 in the larger monkey brain, equimolar quantities of GDNF, 
N2 and N4 were injected in one monkey [Penn, unpublished data]. N4 showed the maximum 
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distribution followed by N2, even though the NRTN mutants were injected in smaller volumes 
than GDNF (N2: a 25% smaller volume, N4: a 10% smaller volume). A second goal of the 
current experiment was to test the effectiveness of N2 and N4 in restoring motor function and 
maintaining DA neurons in a primate model of PD. 
2.2 MATERIALS AND METHODS 
2.2.1 Animals 
Thirty female rhesus monkeys (Macaca mulatta) were used in this study. The animals were 
between the ages of 17 and 20 years, with a mean age of 18.2 ± 0.2 years. Average weight was 
8.3 ± 0.2 kg. All monkeys were housed in social living pens (1.6m x 2.3m x 3.5m) that had 
multiple perches, toys, and a thick layer of sawdust bedding with overhead skylights that 
provided natural lighting, as well as artificial lighting that turned on at 0700 h and off at 1900 h. 
This housing facility has 20 pens in a wing, and pens have wire mesh fencing fronts so that 
monkeys in each pen could see and hear other monkeys in a number of other pens. Monkeys 
were pair-housed. Monkeys were fed Purina Monkey Chow (#5038; Ralston Purina Co., St. 
Louis, MO) once daily and given fresh fruit, vegetables, nuts and seeds to encourage foraging, as 
well as ad libitum access to drinking water.  All monkeys were observed daily for health and 
menstrual status.  All procedures were performed in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals and were approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee. 
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2.2.2 MPTP Administration 
Prior to MPTP administration, baseline assessments of motor and non-motor functions (for an 
average of 3.2±0.2 weeks) were made for each monkey. All monkeys then underwent a surgery 
to expose the right carotid artery and each received a right internal intracarotid injection of 
MPTP-HCl (Sigma Chemical Co., St. Louis MO), at a concentration of 0.14-0.16 mg/kg 
(0.15±0.001 mg/kg), delivered at 1 mL/min, using previously published techniques [Ovadia et 
al., 1995; Gash et al., 1996; Grondin et al., 2002]. The dose was adjusted based on each animal’s 
age and weight, as these factors have been previously shown to affect response to MPTP in 
macaques [Ovadia et al., 1995; Ding et al., 2008]. After surgery, animals were allowed to 
recover in quarantine for 4 days to allow for excretion of MPTP.  
2.2.3 Experimental design 
Group Size: Monkeys were assigned to six experimental groups (n=4-6/group). In the 
first seven monkeys tested, NTF injections were given starting at twelve weeks post-MPTP. 
However, in these first seven monkeys PD-like symptoms were stable from six weeks to twelve 
weeks post-MPTP. Hence, in all subsequent cohorts of animals in this study, NTF injections 
were given starting at six weeks post-MPTP. In the first seven monkeys a standard dose of 0.15 
mg/kg MPTP was given. However, three monkeys receiving this dose had very little reaction to 
MPTP so they could not be used to test NTF’s; this led to the subsequent adjustment of MPTP 
dosage for individual monkeys based on age and weight (as noted above in section 2.2.2). One 
monkey died in surgery from a toxic reaction to the anesthesia (isoflurane). Experimental groups 
were treated with four monthly injections of vehicle (n=4), CDNF (450 µg; n=5), CDNF (150 
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µg; n=6), GDNF (450 µg; n=5), N2 (337.5  µg; n=6), or N4 (280 µg; n=5), all in a 225 µL 
volume (Vehicle, 450 µg CDNF, 150 µg CDNF, 450 µg GDNF) and 337.5 µL volume (337.5  
µg N2, 280 µg N4) of phosphate-buffered saline (CDNF, N2, N4) or citrate buffer (GDNF), pH 
7.4.   
Neurotrophic Factor Dosing: Many trophic factors and pharmacological agents have 
“inverted U” dose response curves, with lower efficacy at both lower and higher concentration 
levels [Gash et al., 1995, 1996; Zhang et al., 1997], and this was taken into consideration when 
choosing doses of NTFs to test in this study. The CDNF doses that were utilized for the current 
study were chosen based on previous work demonstrating that a 450 µg dose of GDNF, 
delivered intraputamenally, was effective in improving DA function in MPTP-treated monkeys 
[Ovadia et al., 1995; Gash et al., 1996; Grondin et al., 2002]. We chose to test this same dose of 
CDNF in monkeys in one experimental group. However, CDNF had been shown to be more 
effective than GDNF in a rodent model of PD [Lindholm et al., 2007], so there was concern that 
if the same was true for monkeys we may be on the diminishing slope in an “inverted U” dose 
response curve. Thus, a lower dose of CDNF was also tested (150 µg). A dose of N2 (337.5  µg) 
that was the molar equivalent of the 450 µg dose of GDNF, was tested. N4 was less soluble than 
N2 and hence a 280 µg dose, that could be dissolved in the same volume as the N2 solutions 
tested was used. 
Convection Enhanced Delivery (CED) Infusion: CDNF, GDNF, N2, N4 and vehicle were 
given as stereotactic needle injections (using a 26 g side-port needle) into the putamen a total of 
four times, at 6, 10, 14 and 18 weeks post-MPTP, in MRI-guided surgeries. CED involved a 
slow infusion rate of 2 µL/min, that has previously been shown to distribute trophic factors in a 
spherical fashion within the target tissue [Gash et al., 1996; Grondin et al., 2002]. Each monthly 
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injection was made in a different location within the putamen, such that by the end of the fourth 
injection the entire putamen was covered, and no injection tracks crossing paths [Grondin et al., 
1998; Gash et al., 2005]. Post-injection, the injection needle was left in place for twenty minutes, 
and then the needle was withdrawn from the brain at a slow rate of 1 mm/min. At the initial 
stages of the experiment, we used MRI to visualize the intraputamenal distribution of the 
infusate after each monthly injection by co-infusing Magnevist that could be detected by MRI 
immediately after the termination of the infusion (see Figure 2).   
Motor function assessments: Motor function assessments were carried out throughout the 
duration of the study (see Figure 3). Motor function was evaluated using five methods:  the 
monkey Parkinson’s rating scale [Ovadia et al., 1995]; measurement of minute-by-minute 
activity measured by omnidirectional accelerometers [Sullivan et al., 2006; Hunnel et al., 2006; 
Papailiou et al., 2008; Sullivan et al., 2010]; automated movement tracking using EthoVision 
software to assess changes in motor behaviors in a controlled environment [Grondin et al., 2002; 
Walton et al., 2006]; testing of fine motor function using the monkey Movement Assessment 
Panel (mMAP) [Gash et al., 1999; Maswood et al., 2002; Kastman et al., 2012]; and detailed 
analysis of naturally-occurring gross and fine motor function in videotapes of monkey homepen 
behavior [Papillaou et al., 2008]. For each measurement, raters who scored the behavior were 
blind to the treatment groups that monkeys were in. 
A. Monkey Parkinsonian Rating Scale: The monkey Parkinson’s rating scale was 
developed at the Kentucky Udall Center and was patterned after the human 
UPDRS [Ovadia et al., 1995].  In the current study, behavior was videotaped 
while monkeys were given the opportunity to forage after seeds and nuts were 
scattered in the sawdust bedding in the pen. Assessments were made once a 
week throughout the study. Motor functions were scored from 0 (normal) to 3 
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(severe disability) in the following categories: rigidity, bradykinesia, posture, 
balance, tremor, and hand dexterity. The left side and right side were scored 
separately for rigidity, bradykinesia and tremor. The maximum score possible 
was 22. Two independent raters scored each videotaped session and assigned 
ratings for each video session. If variability between the two independent raters 
was greater than 15%, a third rater scored the session. Overall, inter-rater 
reliability was 88.6 ± 2.9%. 
B. Activity Monitoring: Activity was measured in each animal using an 
omnidirectional Actical accelerometer (Respironics, Phoenix, AZ) mounted on a 
loose-fitting collar (Primate Products, Immokalee, FL), using previously published 
methods [Sullivan et al., 2006; Hunnel et al., 2006; Papailiou et al., 2008; 
Sullivan et al., 2010]. Monkeys adapted quickly to the collars, which did not 
interfere with activities such as feeding or sleeping. Activity monitors were set to 
collect activity counts on a per minute basis. Activity was measured for 13±0.6 
days pre-MPTP. Then, monkeys did not wear collars with activity monitors for the 
first two weeks after MPTP surgery to allow healing of the surgical incision in the 
carotid region that was made for the intracarotid MPTP injection. Subsequently, 
activity was measured continuously for the rest of the study. For activity 
calculations, the start of the daytime was determined as the time of sunrise or 
0700 h, depending on which occurred first; similarly the end of daytime was 
calculated as 1900 h or the time of sunset, depending on which occurred last.  
Monkeys were sedated with Ketamine HCl (0.1-0.2 mg/kg, i.m.) and activity 
monitors were downloaded every 2-3 weeks, calibrated and reset.  
C. Automated Movement Tracking System, Ethovision: Throughout the study, 
monkeys were moved once a week from their homepen to a cage in a novel 
room and videotaped for a one-hour period, while white noise played in the 
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background. The Ethovision program, developed by Noldus, Inc (Wageningen, 
NL) was then used to track the center of gravity of each monkey over the one 
hour time period. Distance travelled, speed of movement and time spent with the 
monkey’s center of gravity in the top or bottom of testing cage was quantified.  
D. Monkey Movement Analysis Panel (mMAP): This apparatus and testing protocol 
was developed by the Kentucky Udall Center [Gash et al., 1999]. Briefly, mMAP 
testing was performed from two to six weeks pre-MPTP (mean=3.0±0.2 weeks 
pre-MPTP), for 5 weeks post-MPTP (starting 10.7+0.7 days post-MPTP), and 
during the entire duration of the NTF infusions.  For each testing session, 
monkeys were transferred from their homepen to a testing room and placed in a 
testing cage with the mMAP apparatus attached to the front.  Monkeys had been 
acclimated to the testing cage for at least 1 week prior to the onset of testing.  
Each day of mMAP testing consisted of 12 trials total, 6 trials for each hand. This 
allowed us to compare motor function between the left hand (i.e., the side that 
would be affected by right intracarotid MPTP administration) and the right hand 
(i.e., the unaffected side).  During mMAP testing, monkeys were required to 
reach through an opening (one opening for the left hand and another opening for 
right hand) to retrieve a small food reward placed on a platform the animal could 
see [Gash et al., 1999].  The openings were each equipped with photodiodes to 
monitor arm/hand movements of the monkey, thereby recording with millisecond 
accuracy the latency to retrieve the food reward [Gash et al., 1999].  Monkeys 
were given one minute to retrieve each treat. For each trial, on the right or left 
side, monkeys were given a total of five chances to respond before the trial 
ended. For each trial, the latency to retrieve the treat was recorded. If the 
monkey did not retrieve a treat at the end of five chances the trial was scored as 
a balk. The trials alternated between the right and left hands. The testing was 
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stopped if a monkey balked for three consecutive trials. Before testing, all 
monkeys were trained to use the mMAP apparatus until they routinely retrieved 
food from the receptacle with each hand.  After the training period, baseline 
measurements were collected before MPTP administration. Monkeys were then 
tested twice a week after MPTP injection. Importantly, mMAP testing was carried 
out only twice per week so that monkeys did not become over-trained in this 
procedure as training, itself, leads to an improvement in motor function 
[Matsuzaka et al., 2007].  
E. Monkey Homepen Assessments: Once a week monkeys were videotaped for a 
seventy-five minute period in their normal homepen environment. The videotaped 
sessions were used to quantify the various naturally-occurring motor activities 
displayed by the monkeys using The Observer Program (Noldus, Inc) [Papillaou 
et al., 2008]. Behaviors scored included eating, grasping, grooming, circling, 
moving, jumping, and sleeping. 
Post-mortem collection of brain tissue: Eighteen weeks after unilateral MPTP injection, 
immediately following their fourth NTF infusion, monkeys were sacrificed and their brain tissue 
collected for post-mortem analysis (as indicated in Figure 3). Monkeys were deeply sedated with 
Ketamine HCl (20-25 mg/kg, SC) and sodium pentobarbital (30 mg/kg, i.v.) was administered. 
When the monkey completely lost reflexes, it was placed on its back and a midline incision made 
in the chest wall. The pericardium was opened, a cannula is inserted into the aorta through a 
small incision in the left ventricle, and the right auricle cut. The descending aorta was clamped to 
direct perfusate only to the head, and the vascular system was perfused with ice-cold 
physiological saline containing 5,000 IU sodium heparin and 2% sodium nitrite to remove blood 
from the brain. When the perfusate ran clear, the perfusion was stopped, the skull quickly opened 
using a bone saw, and the brain immediately removed. The brain was put in a brain mold 
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(immersed in ice-chilled DEPC saline), and the brain was cut every 4 mm rostral to caudal 
(placing the first blade just caudal to the optic chiasm), and slabs were removed and placed on 
glass slides. All sections containing putamen, caudate and globus pallidus were snap frozen on 
dry ice. Slabs containing the mid-brain dopamine regions were immediately fixed in 
paraformaldehyde. The fixed sections were used for post-mortem DA cell counts and the frozen 
sections were used for collecting tissue punches for later biochemical measurements. Each slab 
that had been frozen and had punches removed was wrapped in foil and all frozen slabs from 
each brain were placed into a single sealed plastic bag and stored at -80°C. Consistent use of 
these procedures provided a mean postmortem interval 48.7±2.4 min from the chest incision to 
collection of the last brain slab. 
Staining and Counting Substantia Nigra DA neurons: 4 mm slabs containing the mid-
brain dopamine regions were immersion-fixed in 4% paraformaldehyde solution at 4°C for three 
days. Following this, the brain slabs were transferred to a 15% sucrose solution and allowed to 
stay in it until the brain sunk to the bottom of the jar. The brain slabs were then transferred to 
30% sucrose and the same procedure was followed. Once the brain slabs sank in the 30% 
solution they were wrapped in foil, snap frozen and processed so that 40 μm thick coronal 
sections could be cut on a sliding knife microtome through the substantia nigra. As described 
elsewhere [Gash et al., 1996; Grondin et al., 2002], SN sections were processed for 
immunohistochemical staining for tyrosine hydroxylase, (TH monoclonal antibody, 1:1000; 
Chemicon International, Temecula, CA). The number of TH+ midbrain DA neurons was 
measured using an optical fractionator method for unbiased stereological cell counting [Gash et 
al., 1996; Grondin et al., 2002]. Briefly, the substantia nigra is defined as consisting of all 
midbrain TH+ neurons except those interspersed with the oculomotor nerve rootlets. Using an 
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optical fractionator method for unbiased stereological cell counting, the number of TH+ neurons 
in the substantia nigra was estimated. On each section, a 200 μm X 200 μm grid was randomly 
superimposed with a 150 μm X 150 μm counting chamber placed on each fifth intersection. A 20 
μm deep fraction of the counting chamber was determined by a stage encoder attached to the 
microscope to measure the z-axis. All neurons completely within the boundaries of the chamber 
or crossing the upper or right side of the chamber within the 20 μm depth were counted and their 
perimeter (minus neurites) measured. 
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Figure 2. MRI of monkey brain after administration of 150 µg CDNF + Magnevist into the 
putamen. 
 
 
 
Figure 3. Experimental design. Motor and non-motor assessments were made throughout 
the study starting with baseline measures before MPTP administration, followed by post-
MPTP, and after each infusion of NTF. The six experimental groups and sample sizes are 
also listed. 
 
 66 
2.2.4 Statistical Analysis 
For all analyses, normality and homogeneity of variance were first tested. If these criteria were 
met, parametric statistical tests were used. Comparisons across the five time points in the study 
(pre-MPTP, post-MPTP, post-infusion 1, post-infusion 2 and post-infusion 3) were made using 
repeated measures analysis of variance, while comparisons between two time points (pre-MPTP 
vs. post-MPTP, post-MPTP vs. post-infusion 3) were subsequently made using paired Student’s 
t-tests. If normality or homogeneity of variance criteria were not met, data was transformed to 
normalize the data prior to statistical analyses, if possible. Cell count data was normalized by a 
log transformation before being analyzed using Pearson’s correlations. A non-parametric 
statistical test, specifically the two sample Kolmogrov-Smirnov test, was used to compare the 
raw cell count data. Pearson’s correlation coefficients, or Spearman’s correlation coefficients if 
normality criteria were not met, were used to calculate the relationship between DA cell counts 
and all motor measurements made. Statistical analyses were performed using MATLAB (The 
MathWorks Inc., Natick, MA). Values are presented as means ± SEM. P < 0.05 was considered 
significant. 
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2.3 RESULTS 
2.3.1 Effect of MPTP Administration on Motor Movement 
 
Parkinson’s Rating Scale: Monkeys at baseline had a rating scale score of 0, as the monkeys did 
not exhibit any PD-like symptoms. After MPTP administration the monkey Parkinson’s rating 
scale score increased significantly to 7.9 ± 0.5, p<0.001 (data not shown).  
Activity: There was a 57.1% decrease in the average daily activity counts, with mean activity 
counts decreasing from 113,472±10,055 pre-MPTP to 48,682±6,995 post-MPTP (Figure 4). 
Correspondingly, the daytime activity reduced by 58.4% from 105,097±14,854 pre-MPTP to 
43,705±9,240 post-MPTP, p<0.001 and the nighttime activity reduced by 33.2% from 
5,980±1990 pre-MPTP to 3997±996 post-MPTP, p=0.03 (Figure 4). 
Ethovision: There was a significant decrease, p<0.005, from pre-MPTP to post-MPTP for all 
parameters measured using the Ethovision program [total distance moved, duration of time spent 
in top of cage, and distance moved in top of cage]. The total distance moved by the monkeys 
decreased significantly post-MPTP by 23.6% (p=0.004). The duration of time spent in top of 
cage significantly decreased from pre-MPTP to post-MPTP by 50.9% (p=0.0004). The 
corresponding decrease in the distance moved in the top of the cage was also significantly 
reduced by 48.6% (p=0.0001; Figure 5). 
mMAP: After right-side unilateral MPTP injection there was a significant increase in time taken 
to retrieve a treat with the left hand from 1.17 ± 0.08 sec pre-MPTP to 2.03 ± 0.26 sec post-
MPTP (p=0.002; n=13; data not shown). However, 57% of the monkeys completely stopped 
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using their left-hand after MPTP injection (n=17). There was no significant change in the time 
taken to retrieve a treat with the right hand and all of the monkeys continued to use their right 
hand in the task at least some of the time, 1.21 ± 0.04 sec pre-MPTP to 1.24 ± 0.09 sec post-
MPTP (p=0.32). Balking with the left hand increased from 2.1% of the trials pre-MPTP to 69.8% 
of the trials post-MPTP, p<0.001 (Figure 6). Balking with the right hand increased from 1.5% 
pre-MPTP to 11.7% post-MPTP, p=0.008, but this was a significantly smaller increase in balking 
than occurred on the left side, p<0.001 (Figure 6).  
Homepen movement: Monkeys displayed significant motor impairments naturally-
occurring movement in the homepen after MPTP administration. Spontaneous circling towards 
the side of the lesion (circling to the right) increased significantly after MPTP, p<0.001 (Figure 
7 A). There was a significant decrease in the total movement of monkeys after MPTP, p=0.003 
(Figure 7 B). There was a significant decrease in fine motor movement the time to use the left 
hand post-MPTP, p<0.001 (Figure 7 C).  
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Figure 4. Mean daily activity counts before (open bars) and after (closed bars) MPTP 
administration, measured by accelerometer (n=30). A. Total Activity (p<0.001 
compared to pre-MPTP), B. Daytime activity (p<0.001 compared to pre-MPTP), C. 
Nighttime activity (p=0.03 compared to pre-MPTP). Asterisks indicate a significant 
difference, p<0.05, from pre-MPTP values.  
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Figure 5. Movement measured by Ethovision. ). A. Total distance moved (p<0.005 
compared to pre-MPTP), B. Duration of time spent in top of cage (p<0.005 compared to 
pre-MPTP), C. Distance moved in top of cage (p<0.005 compared to pre-MPTP). 
Asterisks indicate a significant difference, p<0.005, from pre-MPTP period. 
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Figure 6. Balk rate during mMAP testing.  Asterisks indicate a significant difference, 
p<0.001, from the pre-MPTP period. 
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Figure 7. Changes in motor behavior by homepen assessments. Asterisks indicate a 
significant difference, p<0.005, from Pre-MPTP period. 
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2.3.2 Effect of GDNF, CDNF, N2 and N4 Infusions on Motor Movement 
 
Monkey Parkinsonian Rating Scale: Monkeys receiving intraputamenal infusions of GDNF, 150 
µg CDNF, N2 and N4 showed significant improvement in the monkey Parkinson’s rating scale 
scores after three monthly NTF infusions (Figure 8A). The rating scale scores for the 150 µg 
CDNF, N2 and N4 groups were significantly different than the rating scale scores for the 
vehicle-treated group at the end of the three-month infusion period (Figure 8B). The 150 µg 
CDNF group showed progressive improvement in the rating scale score after each infusion, 
while the N2 and N4-treated groups had a maximal improvement in rating scale score after the 
first infusion and then the rating scale score remained at the same until the end of the study 
(Figure 8B). 
Activity Monitoring: Monkeys activity did not recover significantly after three months of 
infusions in any of the six treatment groups back to the daily level of activity before MPTP 
administration. Similarly, both daytime and nighttime activity also did not recover back to 
baseline (data not shown). 
Automated Movement Tracking System, Ethovision: Monkeys did not change 
significantly after three monthly infusions of the NTFs or vehicle compared to post-MPTP 
values in the different parameters [total distance moved, duration of time spent in top of cage, 
and distance moved in top of cage] measured using Ethovision (data not shown).  
Monkey Movement Analysis Panel (mMAP):  
Vehicle - Pre-MPTP the mean time taken to retrieve a treat using the left hand was 1.34 ± 
0.37 sec (n=4). However, post-MPTP only one out of the four monkeys would use its left hand, 
i.e. 75% of the monkeys in the vehicle group did not work. The one monkey that did work was 
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43% slower using its left hand compared to pre-MPTP.  After three months of vehicle infusions, 
the monkey that worked post-MPTP stopped working completely, however, there was another 
monkey that would use its left hand during this period, and this monkey was 41.5% slower than 
its pre-MPTP values.  The use of the right hand was also similar from the post-MPTP period 
(1.46 ± 0.16 sec) to the period after the third infusion (1.00 ± 0.10 sec, p=0.14 compared to post-
MPTP). 
450 µg CDNF - Pre-MPTP, the mean time taken to retrieve a treat using the left hand was 
1.20 ± 0.26 sec (n=3). One monkey refused to work, even in the control pre-MPTP state. Post-
MPTP, two of the three monkeys continued to use their left hand, with one monkey balking. 
Post-MPTP, the 2 monkeys that used their left hands did so in 1.93 ± 1.03 sec (p=0.33 compared 
to pre-MPTP). However, after three months of 450 µg CDNF infusions only one out of the three 
monkeys would use its left hand with a speed of 1.22±0.28 sec that was not different from pre-
MPTP (p=0.99).  The use of the right hand was similar from the post-MPTP period (1.41 ± 0.39 
sec) to the period after the third infusion (1.54 ± 0.44 sec, p=0.83 compared to post-MPTP). 
150 µg CDNF - Pre-MPTP, the mean time taken to retrieve a treat using the left hand was 
1.18 ± 0.19 sec (n=6). Post-MPTP, two of the six monkeys worked using their left hand, with 
four monkeys balking during left hand testing. Post-MPTP, the average time taken by the two 
monkeys that used their left hands was 1.65 ± 0.09 sec (p=0.15 compared to their pre-MPTP 
speeds). After three months of CDNF infusions four of the six monkeys used their left hand in 
mMAP testing. However, the two monkeys that worked throughout the study had a non-
significant improvement in their total time taken with the left hand (13.5% increase in speed, 
p=0.35). However, the four monkeys using their left hands post-infusion no longer showed a 
significant decrease in speed from pre-MPTP levels, although they did show a trend toward 
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being slower (2.16 ± 0.54 sec, p =0.07 compared to pre-MPTP). The use of the right hand in this 
group was similar from the post-MPTP period (1.23 ± 0.24 sec) to the period after the third 
infusion (0.81 ± 0.04 sec, p=0.10). 
450 µg GDNF - Pre-MPTP, the mean time taken to retrieve a treat using the left hand 
was 0.81 ± 0.08 sec (n=4). Post-MPTP only one monkey used its left hand (1.11 ± 0.26 sec), 
with three monkeys balking. After three months of GDNF infusions three out of the four 
monkeys would use their left hand but continued to be slow (2.16 ± 0.54 sec, p=0.22, compared 
to post-MPTP). In contrast, the use of the right hand was similar from the post-MPTP period 
(0.92 ± 0.12 sec) to the period after the third infusion (1.17 ± 0.41 sec, p=0.38).  
N2 - Pre-MPTP, the mean time taken to retrieve a treat using the left hand was 1.24 ± 
0.11 sec (n=6). Post-MPTP, three of the six monkeys used their left hand and three monkeys 
balked. Post-MPTP, the three monkeys who used their left hands did so in 1.39 ± 0.08 sec, which 
was not a significant slowing from their pre-MPTP speed of 1.29 ± 0.17 sec  (p=0.39). However, 
after three months of N2 infusions the mean time for left hand use was significantly improved for 
the same three monkeys from the post-MPTP speed (1.01 ± 0.10 sec, p=0.04 compared to post-
MPTP). In contrast, the use of the right hand was similar from the post-MPTP period (1.38 ± 
0.28 sec) to the period after the third infusion (1.27 ± 0.21 sec, p=0.18 compared to post-MPTP).  
N4 - Pre-MPTP, the mean time taken to retrieve a treat using the left hand was 1.20 ± 
0.11 sec (n=5). Post-MPTP, four monkeys used their left hand, with one monkey balking. There 
was a significant slowing of left hand use in these four monkeys from 1.20 ± 0.11 sec pre-MPTP 
to 2.61 ± 0.35 sec post-MPTP for three monkeys (p=0.01). However, after three months of N4 
infusions the mean time for left hand use was significantly decreased to 1.60 ± 0.40 sec for the 
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three monkeys that continued to work (p=0.0003 compared to post-MPTP; p=0.18 compared to 
pre-MPTP). Similarly, the use of the right hand showed a trend towards decrease from the post-
MPTP period  (1.12 ± 0.12 sec) to the period after the third infusion (0.85 ± 0.04 sec, p=0.07 
compared to post-MPTP). 
Homepen Assessments:  After infusions, there were no significant change in circling, fine 
motor, and stationary in homepen sessions for any of the treatment groups. However, for total 
movement after post-infusions of NTFs the N2 treatment group showed a trend towards a 
significant improvement in total movement, p=0.06 (Figure 9). 
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Figure 8. A.  Changes in monkey Parkinson’s rating scale from Post-MPTP (black bars) to Post-
Infusions (grey bars) for each experimental group. Asterisks indicate a significant difference, 
p<0.05, from pre-MPTP B. Monkey Parkinson’s rating scale scores for each experimental group, 
normalized to the post-MPTP mean score for each group. Vehicle: black line, p>0.05 post-
infusion 1, 2 and 3; 450 µg CDNF: blue line, p>0.05 post-infusion 1, 2 and 3; 150 µg CDNF: red 
line, p=0.02 post-infusion 1, p=0.002 post-infusion 2, and p=0.0002 post-infusion 3; 450 µg 
GDNF: yellow line, p>0.05 post-infusion 1, 2 and p=0.06 post-infusion 3; 337.5 µg N2: brown 
line, p=0.01 post-infusion 1, 2, and 3; 280 µg N4: purple line, p=0.03 post-infusion 1, p=0.04 
post-infusion 2  and p=0 02 post-infusion 3  
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Figure 9. Changes to the total motion scored in homepen after three months of N2 
(337.5 µg) infusions, p=0.06. Plus sign indicates a trend. 
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2.3.3 Post-mortem cell count data and prediction of post-infusions motor measures based 
on cell counts measures 
 
 
 
 
 
 
 
 
 
 
There was a significant increase in the number of midbrain SNpc dopamine cells in monkeys 
receiving GDNF, 150 ug CDNF, N2, and N4 treatments compared to the vehicle group (Figure 
10). The number of dopamine neurons was significantly correlated with a number of measures of 
motor function. There was a significant correlation between the Parkinson’s Rating Scale score 
measured in the last month of the study and the number of DA neurons present at the end of the 
study (r= -0.72 p<0.001, Figure 11A). For fine motor function, the time taken to retrieve a treat 
with left hand in the last month of the study in mMAP testing was significantly correlated with 
the DA neuron cell counts (r=-0.53 p=0.002, Figure 11B). Another measures of gross motor 
activity, activity measured by accelerometer, showed a trend towards significance (Activity: 
r=0.30, p=0.059; Figure 12A). Total distance moved as measured by Ethovision analysis was 
significantly correlated to the DA neuron cell counts (r= 0.45 p=0.009, Figure 12B). Circling, a 
    
Figure 10. Number of dopamine neurons post-infusion 4. Asterisks indicate a 
significant difference from the vehicle-treated group, p<0.05.  
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gross motor function, at the end of the NTF infusions, was significantly correlated with the 
number of DA cell counts (r=-0.32 p=0.05, Figure 13A). And left fine motor values measured in 
the homepen assessments showed a trend towards significance (r=0.30 p=0.06, Figure 13B). 
 A median split of monkeys divided by the number of DA cells they had in the post-
mortem analysis (Figure 14A) showed significant differences in monkey Parkinson’s rating 
scale score (bottom half: 6.88 ± 0.58, top half: 3.14 ± 0.58, p<0.001, Figure 14B),  total distance 
moved in Ethovision assessments (bottom half: 80.62 ± 12.47, top half: 116.27 ± 16.24, p=0.05, 
Figure 14C), and time taken to retrieve a treat with the left hand in mMAP testing (bottom half: 
39.57 ± 7.60, top half: 22.22 ± 7.81, p=0.04, Figure 14D).  
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Figure 11. Correlation between DA cell counts and (A) Monkey Parkinson’s rating scale 
score, and  (B) left hand time to retrieve a treat in the mMAP. Vehicle (open diamond), 450 
µg GDNF (open square), 450 µg CDNF (open circle), 150 µg CDNF  (closed circle), 337.5 
µg N2 (closed square), 280 µg N4 (closed diamond) 
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Figure 12. Correlation between DA cell counts and A. Percent change in activity from post-
MPTP to post-Infusions of NTFs, B. Percent change in total distance moved measured by 
Ethovision. Vehicle (open diamond), 450 µg GDNF (open square), 450 µg CDNF (open circle), 
150 µg CDNF  (closed circle), 337.5 µg N2 (closed square), 280 µg N4 (closed diamond) 
 
 
 
Figure 13. Correlation between DA cell counts and A. Circling, and B. Left fine motor 
measured in the homepen. Vehicle (open diamond), 450 µg GDNF (open square), 450 µg 
CDNF (open circle), 150 µg CDNF  (closed circle), 337.5 µg N2 (closed square), 280 µg N4 
(closed diamond) 
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Figure 14. Comparison of A. Number of DA neurons, B. monkey Parkinson’s rating scale 
score, C. Total distance moved measured in ethovision, and D. Time taken to retrieve treat 
with left hand measured in mMAP, in animals that had DA cell counts in the bottom half 
(Blue bars) and top half (Red bars) of the population in post-mortem analysis (p<0.001, 
p<0.001, p=0.05, p=0.04 respectively). Asterisks indicate a significant difference, p<0.05 
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2.4 DISCUSSION 
2.4.1 Effects of unilateral low-dose MPTP on motor movement 
There were significant PD-like symptoms, that represented early to mid-stage severity of the 
disease, in monkeys that received a single unilateral low-dose MPTP intracarotid injections 
(0.15±0.001 mg/kg). This study used multiple strategies to carefully define the extent of 
impairments that developed in gross and fine motor function. Gross motor impairments were 
assessed using the monkey Parkinson’s rating scale, activity monitoring by accelerometer, an 
automated program to track movement (i.e., Ethovision), and homepen scoring of naturally-
occurring motor assessments. Fine motor movements were measured using the monkey 
movement assessment panel (mMAP) and by homepen scoring of fine motor behaviors. 
Monkeys had an average Parkinson’s rating scale score of 7.9 ± 0.5 out of a possible score of 0-
22. This level of impairment was similar to what was previously reported by Ding et al. [2008], 
using the same animal model.  Locomotion, measured by Ethovision scoring showed an 
approximate 50% reduction post-MPTP, comparable to the loss seen in previous studies using 
this monkey model [Ding et al., 2008; Grondin et al., 2008]. Locomotion was also measured for 
the first time in this monkey model using accelerometers, which similarly showed about a 50% 
reduction in gross motor activity. Fine motor performance, measured using mMAP, showed a 
significant increase in balking (~75% with the left hand) after MPTP. This was comparable to 
the decrease in naturally-occurring fine motor performance scored for the first time in this animal 
model in homepen assessments (~70%).  Overall, moderate impairments in both gross motor 
function and fine motor function were comprehensively characterized for the first time in this 
dissertation, showing that this nonhuman primate model of PD reliably shows approximately a 
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50% impairment in total gross motor function and 70% impairment in fine motor function on the 
affected side. 
Although the two quantitative measures of gross motor function made in this study, using 
accelerometers and Ethovision assessments, showed about a 50% reduction post-MPTP, this was 
not outside of the normal range of gross motor function seen in normal populations of rhesus 
monkeys. Previous studies in rhesus monkeys have shown that there can be an 8-10-fold 
variation in naturally-occurring activity level in monkeys in a variety of housing conditions 
ranging from single animal cages to large group living pens [Sullivan et al., 2006; Hunnel et al., 
2006; Papailiou et al., 2008; Sullivan et al., 2010]. After MPTP, activity levels for monkeys 
uniformly fell close at the low end of the naturally-occurring spectrum for this species. This is 
the first time behavior of MPTP-treated monkeys in their normal home environments has been 
comprehensibly assessed. Interestingly, this comprehensive analysis also showed that post-
MPTP there was a significant increase in spontaneous circling towards the side of the lesion (i.e. 
circling to the right side). This behavior has been characterized in detail in rodent models of PD 
and is regularly used to assess the effectiveness of treatment in these models [Hefti et al., 1980, 
Lindholm et al., 2007; Voutilainen et al., 2011]. However, very little is known about this 
characteristic in primates [reviewed in detail in Blum et al., 2001; Bove et al., 2012]. Similarly, 
the Ethovision assessments measured in this study during the pre-MPTP baseline period were in 
the normal range of locomotion activity in adult rhesus monkeys, as previously reported [Walton 
et al., 2006]. However, after MPTP administration the measures of locomotion in our 17-20 year 
old monkeys resembled that of older aged monkeys, 25-30 year old, that was significantly slower 
than locomotor activity in younger monkeys [Walton et al., 2006; Grondin et al., 2008]. Thus, 
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locomotor activity tracked by Ethovision also showed MPTP-treated animals lying close to the 
low-end of the naturally-occuring spectrum of locomotor activity [Walton et al., 2006].  
2.4.2 Effects of neurotrophic factors CDNF, N2 and N4 on motor movement 
After three months of infusions, the GDNF, 150 µg CDNF, N2 and N4-treated groups of 
monkeys showed significant improvement in the monkey Parkinson’s rating scale scores. 
Correspondingly, these same treatment groups showed significantly increased numbers of 
dopamine neurons in the substantia nigra in post-mortem analyses. Moreover, the number of 
dopamine neurons was significantly correlated with the rating scale score measured at the end of 
three monthly NTF infusions. There were also significant correlations in gross motor activity 
measured by accelerometer, Ethovision tracking, and in the homepen assessments of naturally-
occurring activity. The number of dopamine neurons was also significantly correlated with fine 
motor function measured by both mMAP testing and naturally-occurring use of the left hand in 
the homepen. A median split of the monkeys into those with lower numbers of dopamine 
neurons vs. higher numbers of dopamine showed significant differences in these groups in rating 
scale scores, and measures of both gross and fine motor function. Interestingly, 100% of the 
monkeys in the control and 450 µg CDNF groups fell into the bottom half of the post-mortem 
DA neuron cell group, whereas nearly 70% of the monkeys in the three effective treatment 
groups (150 µg CDNF, N2 and N4) fell into the top half of the post-mortem DA neuron cell 
group. The improvements in these three treatment groups were comparable to the effects of 
GDNF that was previously reported (~ 30 % improvement in rating scale) [Zhang et al., 1997; 
Grondin et al., 1998, 2002; Gash et al., 2005]. Together, these studies provide three lines of 
evidence that the low-dose CDNF treatment and the N2 and N4 treatments provide significant 
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therapeutic value in the monkey MPTP model of PD. First, all three NTFs significantly increased 
the number of surviving DA neurons in the substantia nigra. Second, all three NTFs significantly 
improved motor function measured using the monkey Parkinson’s rating scale. Third, the 
findings that DA neuron count significantly correlated with a number of measures of both gross 
and fine motor movement, and that GDNF, 150 µg CDNF, N2 and N4-treated groups had 
significantly higher DA neuron counts compared to vehicle-treated animals provides strong 
evidence for neurorestorative properties of these four neurotrophic factors. 
This study was initially designed as a pilot study undertaken to provide a first assessment 
of whether CDNF, N2 and N4 could provide neurorestoration in a primate model of PD. As a 
pilot study, the sample sizes for each treatment group were smaller than would be optimal to 
comprehensively assess the impact of these neurotrophic factors on motor function. Power 
analyses at the end of the experiment indicate that if there had been 8-10 animals/group it is 
likely that low dose CDNF would have shown significant improvements in both gross and fine 
motor function, whereas many more animals would have been needed to see significant results 
with N2 and N4 on gross and fine motor functions.  
We conclude that 150 µg CDNF, N2 and N4 treatments rescue DA neurons from cell 
death and recover gross and fine motor functions in monkeys treated with MPTP. These three 
trophic factors are potential candidates for future clinical trials of novel therapeutic strategies for 
treating PD. Further studies with larger sample sizes and sufficient power would help identify the 
best treatment option. Moreover, as discussed in Chapter 5, testing alternative treatment 
strategies with combinations of these NTFs, given together or sequentially, may provide even 
more effective treatment for the motor symptoms of PD. 
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3.0  EFFECTS OF UNIRLATEAL MPTP INJECTIONS ON SLEEP 
 89 
 
3.1 INTRODUCTION 
Excessive daytime sleep (EDS) is common in patients with Parkinson’s disease (PD) [Knie et al., 
2011; Schulte et al., 2011; Videnovic et al., 2012]. Although increased daytime sleepiness 
becomes more common with age [Pal et al., 2001; Arnulf 2005; Rye et al., 2006; Wolkove et al., 
2007], EDS is fifteen-fold more frequent in Parkinson’s patients than in age-matched controls 
[Knie et al., 2011; Tandberg et al., 1999]. The Epworth Sleepiness Scale (ESS) is the most 
widely used scale to assess the tendency to fall asleep in patients [Johns et al., 1991]. 
Epidemiological studies conducted in multiple centers have consistently found ESS scores that 
are about 50% higher in PD patients compared to age- and gender-matched controls [Ondo et al., 
2001; Hobson et al., 2002; Brodsky et al., 2003; Arnulf 2005].  
Increased daytime sleep has also been reported in animal models of PD created by 
administration of dopaminergic neurotoxins [Hartmann et al., 1971; Garcia et al., 2005; Yi et al., 
2007; Friedman et al., 2008; McDowell et al., 2010, 2012]. 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) is a dopamine neurotoxin which primarily affects the dopamine-
containing neurons of the SNpc (Substantia Nigra pars compacta) and has been used in mice and 
monkeys [Burns et al., 1983; Heikkila et al., 1984; McDowell et al., 2012]. In MPTP-treated 
mice that experience a 65% loss of dopamine in the striatum, sleep duration during the normal 
waking period has been reported to increase about 50% compared to saline-treated mice, and the 
mean duration of these sleep episodes was also significantly longer [Monaca et al., 2004; Laloux 
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et al., 2007, 2008]. In rats given the DA neurotoxin, rotenone, leading to a 75% decrease in 
number of DA neurons in SNpc, there was about a two-fold increase in percent time spent 
sleeping when rats are most active [Yi et al., 2007]. Daytime sleep problems have also been 
reported in monkeys that received multiple systemic injections of the neurotoxin MPTP [Barraud 
et al., 2009]. A five-fold increase in percent time spent in daytime sleep duration was observed 
in MPTP-treated monkeys with a greater than 95% loss of dopamine and dopamine metabolites 
[Barraud et al., 2009].  
Interestingly, recent clinical studies have reported increased daytime sleepiness occurring 
even before the motor symptoms of PD manifest [Gjerstad et al., 2006, Dhawan et al., 2006, 
Iranzo 2011]. This suggests that EDS may be able to serve as a diagnostic tool for detecting PD 
[Abbott et al., 2005]. However, it is unknown whether decreasing levels of dopamine are causing 
increased daytime sleepiness in the early stages of PD, or whether there are other neural systems 
whose functions are altered in early PD that could be influencing sleep. Studies examining the 
effects of mild decreases in dopamine, similar to those occurring in early PD, have not been 
reported in animal models. To address this question, the current study in which a single low-
dose, unilateral injection of MPTP was given to monkeys to mimic the early stages of loss of 
dopamine in PD  [Ovadia et al., 1995, Gash et al., 1996, Grondin et al., 2002], examined 
whether there were changes in daytime sleepiness. 
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3.2 MATERIALS AND METHODS 
3.2.1 Animals 
Twenty eight female rhesus macaques (Macaca mulatta), 16-20 years of age (mean age: 
18.3+0.2 years) were housed in social living pens (1.6m x 2.3m x 3.5m) that had multiple 
perches, toys, and a thick layer of sawdust bedding with overhead skylights that provided natural 
lighting. In addition to the natural lighting, artificial lighting turned on at 0700 h in the morning 
and lights turned off at 1900 h at night. For sleep calculations, the start of the daytime was 
determined as the time of sunrise or 0700 h, depending on which occurred first; similarly the end 
of daytime was calculated as 1900 h or the time of sunset, depending on which occurred last.  
This housing facility has 20 pens in a wing, and pens have wire mesh fencing fronts such that 
monkeys in each pen could see and hear other monkeys in a number of other pens. Monkeys 
were pair-housed. Monkeys were fed Purina Monkey Chow (#5038; Ralston Purina Co., St. 
Louis, MO) once daily and given fresh fruit, vegetables, nuts and seeds to encourage foraging, as 
well as ad libitum access to drinking water.  All monkeys were observed daily for health and 
menstrual status.  All procedures were performed in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals and were approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee. 
3.2.2 MPTP Administration 
Prior to MPTP administration, baseline assessments of motor function and sleep were made for 
approximately a two-week period (13.2+0.5 days) for each monkey. All monkeys then 
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underwent a surgery to expose the right carotid artery and each received a right intracarotid 
injection of MPTP-HCl (Sigma Chemical Co., St. Louis MO), at a concentration of 0.14-0.16 
mg/kg (average dose=0.15±0.001 mg/kg), delivered at 1 mL/min, using previously published 
techniques [Ovadia et al., 1995; Gash et al., 1996; Grondin et al., 2002]. After surgery, animals 
were allowed to recover in quarantine for 4 days to allow for excretion of MPTP. Monkeys did 
not wear collars with activity monitors for the first two weeks after surgery to allow healing of 
the surgical incision that was made for the intracarotid injection. Activity was measured from 3-6 
weeks post-MPTP administration. 
3.2.3 Experimental design 
Group Size: Monkeys were assigned into six experimental groups (n=4-6/group). At six 
weeks post-MPTP, when stable symptoms of PD were established, monkeys were assigned to an 
experimental group, taking care to make sure the distribution of PD-like symptoms was uniform 
across the six experimental groups. In the treatment groups, each monkey received four 
intraputamenal infusions of trophic factor or vehicle at monthly intervals (see Figure 2). 
Experimental groups were treated with four monthly injections of vehicle (n=4), GDNF (450 µg; 
n=5), CDNF (450µg; n=5), CDNF (150 µg; n=6), N2 (337.5  µg; n=6), or N4 (280 µg; n=5). 
Vehicle, GDNF and CDNF were given in a 225 µL volume and N2 and N4 were given in a 337.5 
µL volume of phosphate-buffered saline (vehicle, CDNF, N2, N4) or citrate buffer (GDNF), pH 
7.4.   
Activity Monitoring: Activity was measured in each animal using an omnidirectional 
Actical accelerometer (Respironics, Phoenix, AZ) mounted on a loose-fitting collar (Primate 
Products, Immokalee, FL), using previously published methods [Sullivan et al., 2006; Hunnel et 
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al., 2006; Papailiou et al., 2008; Sullivan et al., 2010]. Monkeys adapted quickly to the collars, 
which did not interfere with activities such as feeding or sleeping. Activity monitors were set to 
collect activity counts per minute. Activity was measured for approximately two-week periods in 
each monkey prior to MPTP (13.2+0.5 days), 3-4 weeks post-MPTP (10.6+0.7 days), and 5-6 
weeks post-MPTP administration (11.0+0.4 days).   
3.2.4 Sleep Assessments 
Sleep Measurement from Actigraphic Records: Analysis parameters for defining actigraphic 
sleep were developed in a previous study in which sleep was measured by EEG and actigraphy 
and validated by infra-red videography [Herringa et al., 2009]. Sleep was defined as twelve 
minutes of continuous zero activity counts. Various sleep parameters were calculated including: 
nighttime sleep latency (time from lights off to first sleep episode overlapping with or after lights 
off), number of nighttime awakenings, total night sleep duration, morning wake latency (time 
from lights on to beginning of first wake episode after or overlapping with lights on), total 
daytime sleep duration, and number of daytime sleep bouts. 
Validation of Sleep Measurement Post-MPTP by Videography: After MPTP 
administration monkeys had reduced mobility and in order to ensure that our algorithm for 
quantifying actigraphy-defined sleep (i.e., twelve minutes of zero activity counts) was still valid 
post-MPTP, monkeys were videotaped for a twenty-four hour period by infra-red videography. 
Videotapes were manually scored for sleep behavior (i.e., monkeys sitting in a hunched sleep 
position not moving) in thirteen monkeys for at least thirty minutes of daytime sleep (detected by 
actigraphy) both before and after MPTP administration. Videographically-defined sleep was 
compared to actigraphy-defined sleep.  
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3.2.5 Assessment of Motor Function 
To confirm previously reported findings that a single, low-dose intracarotid injection of MPTP 
results in stable mild motor dysfunction [Ovadia et al., 1995, Ding et al., 2008], we assessed 
monkeys on the primate version of the Unified Parkinson’s Disease Rating Scale [the monkey 
Parkinson’s rating scale; Smith et al., 1993, Ovadia et al., 1995] once a week for 4 weeks pre-
MPTP and 6 weeks post-MPTP. Motor functions were scored from 0 (normal) to 3 (severe 
disability) in the following categories: rigidity, bradykinesia, posture, balance, tremor, and hand 
dexterity. The left side and right side were scored separately for rigidity, bradykinesia and 
tremor. The maximum score possible was 22. Two independent raters scored each videotaped 
session and assigned ratings for each video session. If variability between the two independent 
raters was greater than 15%, a third rater scored the session. Overall, inter-rater reliability was 
88.6 ± 2.9%. 
3.2.6 Statistical Analysis  
For all analyses, normality and homogeneity of variance criteria were met, and a repeated 
measures analysis of variance (ANOVA) was used to identify significant changes in each sleep 
parameter across the pre-MPTP, 3-4 weeks post-MPTP and 5-6 weeks post-MPTP periods. Post-
hoc comparisons were made using paired Student’s t-tests. A repeated measures analysis of 
variance (ANOVA) was also used to identify significant changes in each sleep parameter across 
the four quartiles across the day and if it was significant post-hoc t-tests, with bonferroni 
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corrections, were used to identify specific significant pair wise comparisons. Pearson’s 
correlation coefficients were used to calculate the relationship between daytime sleep duration 
and daytime sleep bouts and the monkey Parkinson’s rating scale score. Statistical analyses were 
performed using MATLAB (The MathWorks Inc., Natick, MA). Values are presented as means 
± SEM. P < 0.05 was considered significant. 
3.3 RESULTS 
The specificity of actigraphy-defined sleep for the current MPTP study was plotted on the plot of 
the receiver-operating characteristic (ROC) analysis from our previous study in normal monkeys 
that defined twelve minutes of zero activity as sleep (Herringa et al., 2009; Figure 15). The 
specificity for post-MPTP daytime sleep was validated using videography to determine if the 
criteria for identifying sleep remained reliable post-MPTP. Using the same criteria to identify 
sleep that had been optimal in monkeys pre-MPTP (actigraphy-defined sleep=12 min of zero 
activity counts), the specificity of post-MPTP sleep fell directly on the pre-MPTP ROC curve 
(Figure 15). 
Pre-MPTP, the average sleep duration during the day was 91.03 ± 10.16 minutes and 
the mean number of daytime sleep bouts was 4.93 ± 0.44 bouts/day. Daytime sleep duration 
increased significantly by three to four weeks post-MPTP to 210.71 ± 21.49 minutes (p<0.001; 
Figure 16A). Daytime sleep duration remained stable at five to six weeks post-MPTP (200.50 ± 
17.89 minutes, p<0.001; Figure 16A). The number of sleep bouts during the day also 
significantly increased post-MPTP to 9.97 ± 0.82 bouts/day by three to four weeks post-MPTP, 
and remained elevated five to six weeks post-MPTP at 9.80 ± 0.68 bouts/day (p<0.001; Figure 
16B). Correspondingly, the average awake duration during the day significantly decreased from 
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628.97±10.16 minutes pre-MPTP to 509.29 ± 21.49 minutes (p<0.001) three to four weeks post-
MPTP administration, and to 519.50 ± 17.89 minutes (p<0.001) five to six weeks post-MPTP 
administration (data not shown). The mean latency to wake up in the morning pre-MPTP was 
4.74 ± 1.99 minutes after lights on. At three to four weeks after MPTP administration the latency 
to wake showed a trend toward increasing to 7.79 ± 2.55 minutes (p=0.08; Figure 16C). And 
there was a significant increase (8.44 ± 2.30 minutes; p=0.05; Figure 16C) at five to six weeks 
post-MPTP administration.   
The increase in daytime sleep was apparent throughout the day after MPTP 
administration. The average daytime sleep duration during the four quarters of a day pre-MPTP 
was: first quartile: 34.70 ± 3.92, second quartile: 10.84 ± 2.06, third quartile: 18.39 ± 3.51, fourth 
quartile: 25.51 ± 3.75. Daytime sleep was greatest in the first quartile of the day, and there was 
a significant difference in the daytime sleep across the quartiles for both daytime sleep duration 
and daytime sleep bouts between the first quartile and second quartile of the day (p<0.001). 
Daytime sleep duration increased during each quartile of the day in a uniform manner by three 
to four weeks post-MPTP and stayed significantly elevated at five to six weeks post-MPTP 
(p<0.001, for all quartiles): first quartile: 72.60 ± 6.72 (2.1-fold increase), second quartile: 38.58 
± 6.00 (3.2-fold increase), third quartile: 36.10 ± 5.26 (2-fold increase), fourth quartile: 50.12 ± 
5.93 (2-fold increase). Similarly, the daytime sleep bouts increased significantly for all four 
quartiles from pre-MPTP to five to six weeks post-MPTP (p<0.001, for all quartiles): first quartile: 
1.90 ± 0.19 to 3.52 ± 0.25 bouts, second quartile: 0.70 ± 0.13 to 2.05 ±0.29 bouts, third quartile: 
1.00 ± 0.15 to 1.89 ±0.24 bouts, fourth quartile: 1.02 ± 0.13 to 2.11 ± 0.18 bouts.  
Average nighttime sleep duration pre-MPTP was 521.16 ± 16.22 minutes and the mean 
sleep bouts during the night was 18.38 ± 0.53 bouts/night. There was no change in the nighttime 
sleep duration of monkeys after MPTP administration (548.38 ± 16.11 minutes, five to six weeks 
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post-MPTP; p>0.05). The number of sleep bouts during the night also did not change post-MPTP 
(18.11 ± 0.57 bouts/night, five to six weeks post-MPTP; p = 0.23). Similarly, there were no 
significant changes to the nighttime awake duration and the number of wake bouts during the 
night at any time after MPTP administration.  
The Monkey Parkinson’s rating scale was used to determine the severity of motor 
impairments after MPTP administration. There was a significant correlation between daytime 
sleep duration 5-6 weeks post-MPTP administration and the rating scale score (r=0.31, p=0.05; 
Figure 17).  
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Figure 15.  The receiver-operator characteristic (ROC) curves with varying duration 
thresholds for sleep criteria for nighttime sleep (open triangles) and daytime sleep 
(closed circles) as measured in a normal population of rhesus monkeys by 
actigraphy, EEG and validated by videography. The red circle indicates the 
specificity for identifying sleep from actigraphy data during the daytime in monkeys 
in this study post-MPTP. 
 
 
 99 
  
 
 
 
Figure 16. A. Mean daytime sleep duration, B. mean daytime sleep bouts, and C. mean latency to 
wake, pre-MPTP (open bar) and at 3-4 weeks and 5-6 weeks post-MPTP (closed bars). Asterisks 
indicate a significant difference from pre-MPTP values (p<0.001). Plus sign indicates a significant 
trend from pre-MPTP values (p=0.08)  
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Figure 17. Correlation between, monkey Parkinson’s rating scale score and 
daytime sleep duration post-MPTP. Vehicle (open diamond), 450 µg GDNF (open 
square), 450 µg CDNF (open circle), 150 µg CDNF  (closed circle), 337.5 µg N2 
(closed square), 280 µg N4 (closed diamond) 
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3.4 DISCUSSION 
 
Monkeys that received a single low-dose unilateral MPTP injection had a significant increase in 
daytime sleepiness measured by actigraphy at two weeks after the DA lesion, suggesting that this 
primate model will be useful for future studies aimed at understanding the role of DA in the 
development of this prevalent non-motor symptom that occurs in the early stages of PD. This 
increase in daytime sleepiness occurred throughout the day. Interestingly, there was no 
accompanying decrease in nighttime sleep in this model. Thus, the sleep changes apparent in this 
low dose, unilateral MPTP nonhuman primate model are similar to what is seen clinically in 
early stage PD where there is a decrease in daytime sleepiness prior to impairment of nighttime 
sleep [Schulte et al., 2011; Knie et al., 2011; Videnovic et al., 2012 ]. 
Actigraphy allows assessment of sleep in more natural conditions than are easily 
measured by EEG, such as in this study where monkeys were housed in group-living pens with a 
social partner. However, we were concerned that the increase in daytime sleepiness that was 
measured by actigraphy may be confounded by the motor problems that developed subsequent to 
MPTP. To address this concern, thirteen monkeys were videotaped for a twenty-four hour time 
period using a camera with an infrared light source (allowing visualization of monkeys during 
both the day and night) and the efficiency of actigraphically-defined sleep was compared to the 
human observer-rated sleep. Results of this analysis were also compared with the results from a 
previous study using EEG, actigraphy and infrared videography to define sleep in normal rhesus 
monkeys [Herringa et al., 2009]. Receiver-operator curve (ROC) analysis was used to determine 
the efficiency and specificity of actigraphy-defined sleep compared to EEG-defined sleep in the 
previous study, and the specificity of actigraphy-defined sleep for the current MPTP study fell 
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right within the range of the previous study in normal monkeys (see Figure 11), providing strong 
evidence that the 2.5-fold increase in daytime sleep occurring soon after MPTP was not the result 
of an increase in false positive sleep measured by actigraphy.  
There was a greater than two-fold increase in daytime sleep duration and number of 
daytime sleep bouts three to four weeks after MPTP. Similarly, the latency to wake up in the 
morning was also significantly increased by about two-fold at five to six weeks after MPTP. 
Daytime sleepiness was directly correlated with the severity of PD motor symptoms. This is 
strong evidence that only a moderate decrease in overall brain dopamine leads to increase in 
daytime sleepiness, corresponding to similar observations of increased daytime sleepiness 
preceding motor symptoms at PD onset [Abbott et al., 2005; Gao et al., 2011].  
There have been reports of increased daytime sleepiness reported in animal models of PD 
after large, bilateral experimental lesions of the nigrostriatal dopamine pathway [Hartmann et al., 
1971; Garcia et al., 2005; Yi et al., 2007; Friedman et al., 2008; McDowell et al., 2010, 2012]. 
However, in this study, we show that a unilateral relatively mild lesion to the DA pathway is 
sufficient to produce about a two-fold increase in daytime sleep duration, sleep bouts and latency 
to wake [Subramanian et al., 2012]. Not surprisingly, the increase in daytime sleepiness found in 
this study is lower than reported in a previous study in monkeys where a larger dose of MPTP 
(0.5 mg/kg MPTP intravenous injections until progressive and severe parkinsonism was 
established) [Barraud et al., 2009] led to a > 95% loss of dopamine and dopamine metabolites 
was associated with a five-fold increase in daytime sleep duration.  
DA plays a very complex role in the regulation of sleep that is not well characterized. 
Patients taking dopamine agonists have reported sudden onsets of sleepiness [Frucht et al., 
1999], but amphetamines that are known to increase the concentration of DA promote 
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wakefulness [Jankovic, 2002]. The effects of dopamine on the regulation of sleep appear to be 
dependent upon the type of DA drug used, the concentration of specific receptor subtypes for 
dopamine and the different regional distributions of these receptors. Many dopamine agonists, 
such as pramipexole and ropinirole, have been directly implicated in causing daytime sleepiness 
[Frucht et al.,1999; Ondo et al., 2001; Montastruc et al., 2001]. However, other drugs like 
selegiline and amantadine, that prolong the effect of dopamine, can lead to delayed sleep onset if 
they are taken in the latter part of the day [Videnovic et al., 2012].  This dichotomy of the effects 
of DA on sleep could be due to their separate actions on two subtypes of DA receptors: D1-like 
and D2-like dopamine receptors. Low doses of dopamine may lead to increased sleepiness by 
acting through D2-like receptors, while high concentrations of DA might be acting through D1-
like receptors to increase wakefulness [Jankovic, 2002; Monti et al., 2007].  Alternatively, 
increased daytime sleepiness might be a characteristic of the disease itself, due to degeneration 
of other sleep modulating circuits in the lower brain regions [Braak et al., 2002; Hawkes et al., 
2010; Knie et al., 2011; Schulte et al., 2011; Videnovic et al., 2012]. However, our data suggests 
that there is increased daytime sleepiness after low dopamine due to MPTP lesions. This implies 
either that dopamine, itself, is having effects on sleep or that there are very fast compensatory 
changes that take place in the sleep-regulating circuits as a consequence to low dopamine. MPTP 
is also known to cause depletion of other monoamines, like NA [Forno, 1996; Fornai et al., 
2007], and serotonin [Perez-Otano et al., 1991; Russ et al., 1991].  A combination of lower brain 
neuro-modulatory systems, including the NA system, are thought to act by a common pathway to 
excite serotonin neurons leading to arousal [Brown et al., 2002].  These changes could also 
partly explain the development of sleep problems that is seen in the MPTP-treated primate model 
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[Barraud et al., 2009; Verhave et al., 2011] and  MPTP-treated mouse models of PD [Monaca et 
al., 2004; Laloux et al., 2007, 2008; Mc Dowell et al., 2010, 2012]. 
PD is also associated with an increased incidence of nighttime sleep problems including 
insomnia, rapid eye movement (REM) sleep behavioral disorder (RBD) and sleep related 
breathing disorders (SRBD’s) [Lees et al., 1988; Arnulf et al., 2000; Schulte et al., 2011]. 
However, in our low-dose MPTP monkey model we did not observe any changes in nighttime 
sleep. Interestingly, clinical studies have reported no relationship between nighttime sleep and 
daytime sleep problems in PD [Rye et al., 1999; Arnulf et al., 2002; Arnulf et al., 2005].  And, 
although some studies suggest that excessive daytime sleep may precede the diagnosis of PD 
[Abbott et al., 2005; Gao et al., 2011], nighttime sleep problems tend to occur later in the disease 
process [Videnovic et al., 2012]. We are using an early stage model of PD, thus it may not be 
surprising that we see only see changes daytime sleep in this model. In monkey studies using 
more severe DA lesions nighttime sleep problems have been reported [Barraud et al., 2009].  
In this study we were not able to examine sleep during the first two weeks post-MPTP 
and how changes in daytime sleepiness developed relative to the development of motor 
impairments because monkeys could not wear collars with accelerometers during the period of 
time the surgical incision was healing post-MPTP. However, given that we found increased 
daytime sleep as soon as we were able to measure sleep post-MPTP, and the fact that previous 
clinical studies have reported that the incidence of longer daytime napping in a nonclinical 
population was associated with future risk of PD occurrence [Abbott et al., 2005; Gao et al., 
2011], we believe that the low dose unilateral MPTP monkey model of PD will be useful for 
studying whether it is the moderate loss of dopamine that leads to increased daytime sleepiness 
that precedes the development of motor impairments in PD. To address this issue, monkeys 
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could wear activity monitors sewn into a pocket in a jacket, rather than housed in a collar, 
allowing activity monitors to be put back on monkeys immediately after administration of 
MPTP.  
It is important to recognize that sleep was assessed in this study using an indirect 
measurement of changes in the pattern of motor behavior by actigraphy. Sleep assessment by 
actigraphy has become relatively common in clinical studies over the last 15 years [Sadeh et al., 
1995, 2011; Ancoli-Israel et al., 2003; Herringa et al., 2009]. Although there are drawbacks to 
measuring sleep by actigraphy rather than by continuous electroencephalography (EEG), such as 
an inability to discern specific sleep stages, there are also important benefits including that 
actigraphy is non-invasive and can easily be adapted to home environments [Ancoli-Israel et al., 
2003; Sadeh et al., 1995, 2002, 2011]. The same is true for nonhuman primates. Sleep has been 
studied by EEG in freely-moving monkeys [Almirall et al., 1999; Barraud et al., 2009], however 
this required surgery to implant electrodes. Actigraphy on the other hand, provides an indirect 
measure of sleep without any invasive procedure, and thus monitoring the natural state of sleep 
in monkeys without significant manipulations that may, in of themselves, influence to the sleep 
behavior [Sadeh et al., 1995, 2002, 2011].  
In summary, we show for the first time that a mild reduction in brain dopamine levels 
induced by a single unilateral MPTP injection is sufficient to cause changes in sleep pattern and 
lead to excessive daytime sleepiness in monkeys. The neural circuits that underlie excessive 
daytime sleepiness are currently unknown. Future studies with this animal model can be used to 
identify the specific neural circuits that underlie arousal and the role of dopamine in these 
circuits that could lead to this sleep dysfunction.  Further this animal model can also be used to 
test new therapies for daytime sleep disorders.    
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4.0  EFFECTS OF GDNF, CDNF, N2 AND N4 ON DAYTIME SLEEP IN MPTP-
TREATED MONKEYS 
 
4.1 INTRODUCTION 
 
Non-motor symptoms in PD are under-recognized and can be an important cause of reduced 
quality of life, even more than the motor impairments in PD [reviewed in Knie et al., 2011; 
Videnovic et al., 2012]. In a recent survey, it was found that in more than 50% of cases of PD 
there is under-reporting of non-motor symptoms associated with PD and daytime sleepiness was 
the most frequently undeclared non-motor symptom (52.4% of patients) [Chaudhuri et al., 2010]. 
An increased incidence of accidents due to increased daytime sleepiness in PD patients has also 
been reported [Ondo et al., 2001; Frucht et al., 1999]. Many PD patients show evidence of 
increased daytime sleepiness before the motor symptoms of PD develop [Gjerstad et al., 2006; 
Dhawan et al., 2006; Iranzo 2011]. And, increased daytime sleepiness has been reported to be 
predictive of future development of PD [Abbott et al., 2005; Gao et al., 2011].  
The treatment and management of increased daytime sleepiness is thus an important 
therapeutic goal that needs to be addressed by a comprehensive plan in order to improve the 
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quality of life of PD patients [Pal et al., 1999; Knie et al., 2011]. Coming up with effective 
treatments requires an understanding of the possible mechanisms underlying increased daytime 
sleepiness. The mechanisms that lead to hypersomnia during the day is of prime importance to 
both sleep medicine and basic research as industrial societies continue to look for ways to 
increase daytime productivity and reduce fatigue [Frucht et al., 1999; Brodsky 2003; Gjerstad et 
al., 2006; Schulte et al., 2011]. The presence of excessive daytime sleepiness in PD has triggered 
research to identify the role of DA in regulating sleep and to find effective treatments for it 
[Jankovic, 2002, see Section 3.4 for more detailed discussion on role of DA in sleep].  
There are many wakefulness-promoting drugs currently available for treating daytime 
sleepiness. These drugs are thought to modulate dopamine release but the exact mechanisms of 
action are not established. However, most of these drugs have a common feature of increasing 
extracellular dopamine concentration in structures associated with arousal, like nucleus 
accumbens [Boutrel et al., 2004; Murillo-Rodríguez et al., 2007; Zolkowska et al., 2009]. 
Modafinil, a wakefulness-promoting drug, has been shown to increase extracellular dopamine in 
the nucleus accumbens and increase wakefulness in rats [Murillo-Rodríguez et al., 2007; 
Zolkowska et al., 2009]. Modafinil was used successfully in the treatment of excessive daytime 
sleepiness for PD in two small clinical trials [Hogl et al., 2002; Adler et al., 2003; Korczyn, 
2006]. However, Modafinil failed in a larger double-blind study to improve daytime sleepiness 
[Ondo et al., 2005].  
A number of secreted proteins and signaling molecules during development (growth 
hormone releasing hormone (GHRH), nerve growth factor (NGF), brain-derived neurotrophic 
factor (BDNF), GDNF, and interleukin-1, (IL-1)) are thought to play a role in sleep regulation 
[Sassin et al., 1969; Obal et al., 1988; Kerkhofs et al., 1993; Kapas et al., 1996; Faraguna et al., 
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2008; Kreuger et al., 1999; Kushikata et al., 2000]. Injection of these (GHRH, NGF, BDNF, 
GDNF, IL-1) is known to cause an increase of either rapid eye movement sleep or non-rapid eye 
movement sleep, or both. Many sleep regulatory substances like interleukins are known to 
enhance GDNF release.  GDNF has been shown to regulate sleep in rats and rabbits [Kushikata 
et al., 2000].  We hypothesized that NTF’s may restore problems of sleep and arousal in PD and 
in animal models of PD. There have been many recent advances in the development and use of 
NTF’s as treatment options for PD [Lindholm et al., 2007; Bjorklund et al., 2009; Marks et al., 
2008; Marks et al., 2010; Vastag 2010; Aron et al., 2011]. However, the use of trophic factors to 
improve sleep problems in both patients and animal models of PD has not been investigated thus 
far. NRTN belongs to the GDNF family, which has been studied most extensively with regards 
to a potential therapeutic role in PD (see Chapter 1 for review), and CDNF is a newly discovered 
trophic factor that has been shown to be more effective than GDNF in rodent models of PD 
[Lindholm et al., 2007, 2010; Voutilainen et al., 2011]. The experiments described here were 
designed to test if two variants of NRTN (N2 and N4) and CDNF were effective in restoring 
normal daytime sleep in a primate model of PD. Reported here, for the first time, is evidence that 
mutant variants of NRTN, N2 and N4, are effective in restoring some aspects of sleep 
dysfunction in a monkey model of PD.  
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4.2 MATERIALS AND METHODS 
4.2.1 Animals 
Twenty eight female rhesus macaques (Macaca mulatta), 16-20 years of age (mean age: 
18.3+0.2 years) were housed in social living pens (1.6m x 2.3m x 3.5m) that had multiple 
perches, toys, and a thick layer of sawdust bedding with overhead skylights that provided natural 
lighting. In addition to the natural lighting, artificial lighting turned on at 0700 h in the morning 
and lights turned off at 1900 h at night. For sleep calculations, the start of the daytime was 
determined as the time of sunrise or 0700 h, depending on which occurred first; similarly the end 
of daytime was calculated as 1900 h or the time of sunset, depending on which occurred last.  
This housing facility has 20 pens in a wing, and pens have wire mesh fencing fronts such that 
monkeys in each pen could see and hear other monkeys in a number of other pens. Monkeys 
were pair-housed. Monkeys were fed Purina Monkey Chow (#5038; Ralston Purina Co., St. 
Louis, MO) once daily and given fresh fruit, vegetables, nuts and seeds to encourage foraging, as 
well as ad libitum access to drinking water.  All monkeys were observed daily for health and 
menstrual status.  All procedures were performed in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals and were approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee. 
4.2.2 MPTP Administration 
Prior to MPTP administration, baseline assessments of motor function and sleep were made for 
approximately a two-week period (13.2+0.5 days) for each monkey. All monkeys then 
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underwent a surgery to expose the right carotid artery and each received a right intracarotid 
injection of MPTP-HCl (Sigma Chemical Co., St. Louis MO), at a concentration of 0.14-0.16 
mg/kg (average dose=0.15±0.001 mg/kg), delivered at 1 mL/min, using previously published 
techniques [Ovadia et al., 1995; Gash et al., 1996; Grondin et al., 2002]. After surgery, animals 
were allowed to recover in quarantine for 4 days to allow for excretion of MPTP. Monkeys did 
not wear collars with activity monitors for the first two weeks after surgery to allow healing of 
the surgical incision that was made for the intracarotid injection. Activity was measured from 3-6 
weeks post-MPTP administration. 
4.2.3 Experimental design 
Group Size: Monkeys were assigned into six experimental groups (n=4-6/group). At six 
weeks post-MPTP, when stable symptoms of PD were established, monkeys were assigned to an 
experimental group, taking care to make sure the distribution of PD-like symptoms was uniform 
across the six experimental groups. In the treatment groups, each monkey received four 
intraputamenal infusions of trophic factor/vehicle at monthly intervals (see Figure 2). 
Experimental groups were treated with four monthly injections of vehicle (n=4), GDNF (450 µg; 
n=5), CDNF (450µg; n=5), CDNF (150 µg; n=6), N2 (337.5  µg; n=6), or N4 (280 µg; n=5). 
Vehicle, GDNF and CDNF were given in a 225 µL volume and N2 and N4 were given in a 337.5 
µL volume of phosphate-buffered saline (vehicle, CDNF, N2, N4) or citrate buffer (GDNF), pH 
7.4.   
Activity Monitoring: Activity was measured in each animal using an omnidirectional 
Actical accelerometer (Respironics, Phoenix, AZ) mounted on a loose-fitting collar (Primate 
Products, Immokalee, FL), using previously published methods [Sullivan et al., 2006; Hunnel et 
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al., 2006; Papailiou et al., 2008; Sullivan et al., 2010]. Monkeys adapted quickly to the collars, 
which did not interfere with activities such as feeding or sleeping. Activity monitors were set to 
collect activity counts per minute. Activity was measured for approximately two-week periods in 
each monkey prior to MPTP (13.2+0.5 days), 3-4 weeks post-MPTP (10.6+0.7 days), and 5-6 
weeks post-MPTP administration (11.0+0.4 days).   
 
NTF Administration: Many trophic factors and pharmacological agents have “inverted 
U” dose response curves, with lower efficacy at both lower and higher concentration levels 
[Gash et al., 1995, 1996; Zhang et al., 1997], and this was taken into consideration when 
choosing doses of NTFs to test in this study. The CDNF doses that were utilized for the current 
study were chosen based on previous work demonstrating that a 450 µg dose of GDNF, 
delivered intraputamenally, was effective in improving DA function in MPTP-treated monkeys 
[Ovadia et al., 1995; Gash et al., 1996; Grondin et al., 2002]. We chose to test this same dose of 
CDNF in monkeys in one experimental group. However, CDNF had been shown to be more 
effective than GDNF in a rodent model of PD [Lindholm et al., 2007], so there was concern that 
if the same was true for monkeys we may be on the diminishing slope in an “inverted U” dose 
response curve. Thus, a lower dose of CDNF was also tested (150 µg). A dose of N2 (337.5  µg) 
that was the molar equivalent of the 450 µg dose of GDNF, was tested. N4 was less soluble than 
N2 and hence a 280 µg dose, that could be dissolved in the same volume as the N2 solutions 
tested was used. Monkeys were sacrificed immediately following the fourth infusion to compare 
the actual distribution of trophic factors within the brain and also for post infusion biochemical 
analysis.    
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4.2.4 Sleep function assessments  
Analysis parameters for defining actigraphic sleep were developed in a previous study in which 
sleep was measured by EEG and actigraphy and validated by infra-red videography [Herringa et 
al., 2009]. Sleep was defined as twelve minutes of continuous zero activity counts. Various sleep 
parameters were calculated including: nighttime sleep latency (time from lights off to first sleep 
episode overlapping with or after lights off), number of nighttime awakenings, total night sleep 
duration, morning wake latency (time from lights on to beginning of first wake episode after or 
overlapping with lights on), total daytime sleep duration, and number of daytime sleep bouts. 
4.2.5 Assessment of Motor Function 
To confirm previously reported findings that a single, low-dose intracarotid injection of MPTP 
results in stable mild motor dysfunction [Ovadia et al., 1995, Ding et al., 2008], we assessed 
monkeys on the primate version of the Unified Parkinson’s Disease Rating Scale [the monkey 
Parkinson’s rating scale; Smith et al., 1993, Ovadia et al., 1995] once a week for 4 weeks pre-
MPTP and 6 weeks post-MPTP. Motor functions were scored from 0 (normal) to 3 (severe 
disability) in the following categories: rigidity, bradykinesia, posture, balance, tremor, and hand 
dexterity. The left side and right side were scored separately for rigidity, bradykinesia and 
tremor. The maximum score possible was 22. Two independent raters scored each videotaped 
session and assigned ratings for each video session. If variability between the two independent 
raters was greater than 15%, a third rater scored the session. Overall, inter-rater reliability was 
88.6 ± 2.9%. 
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4.2.6 Statistical Analysis  
For all analyses, normality and homogeneity of variance criteria were met, and a paired t-test 
was used to identify significant changes in each sleep parameter across the post-MPTP and post-
infusion three periods. Pearson’s correlation coefficients were used to calculate the relationship 
between latency to wake and the post-mortem DA cell counts. Statistical analyses were 
performed using MATLAB (The MathWorks Inc., Natick, MA). Values are presented as means 
± SEM. P < 0.05 was considered significant. 
4.3 RESULTS 
After three months of vehicle infusion average sleep duration during the day was 242.95 ± 29.57 
minutes and the mean number of daytime sleep bouts was 11.48 ± 0.95 bouts/day, which was not 
significantly different from the post-MPTP values for the vehicle-treated group (daytime sleep 
duration: 245.76 ± 34.11 minutes; daytime sleep bouts: 11.21 ± 1.28 bouts/day). There was also 
no change in the daytime sleepiness after three months of NTF treatment compared to post-
MPTP for the groups receiving 450 µg CDNF (Sleep duration: 145.72 ± 19.63 to 121.46 ± 39.18 
minutes, p=0.17; daytime sleep bouts: 8.42 ± 1.25 to 6.96 ± 1.94 bouts/day, p=0.13), or 150 µg 
CDNF (Daytime sleep duration: 186.96 ± 38.57 to 199.93 ± 39.98 minutes, p=0.16; daytime 
sleep bouts: 9.87 ± 1.77 to 10.18 ± 1.88 bouts/day, p=0.32).  For the N2 treatment group again 
there was a trend for reduction in daytime sleep bouts, but not for daytime sleep duration, from 
post-MPTP to post-infusions (daytime sleep duration: 197.28 ± 41.81 to 170.89 ± 50.66 minutes, 
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p=0.25; daytime sleep bouts: 9.61 ± 1.59 to 7.75 ± 1.52 bouts/day, p=0.08). However, the mean 
latency to wake up in the morning significantly decreased from 13.50 ± 4.80 minutes after lights 
on to 2.50 ± 5.20 minutes before lights on for the N2 treatment group, p=0.05. Daytime sleep 
duration decreased significantly after three months of N4 infusion from 272.60 ± 51.10 minutes 
to 229.81 ± 52.94 minutes (p=0.02 Figure 18A). And, daytime sleep bouts showed a trend 
towards reduction after three months of N4 infusion from 272.60 ± 51.10 minutes to 229.81 ± 
52.94 minutes (p=0.06; Figure 18B). The mean latency to wake up in the morning also 
significantly decreased from 16.27 ± 2.26 minutes after lights on to 5.77 ± 6.21 minutes before 
lights on for the N4 treatment group (p=0.02; Figure 18C). For all monkeys, the mean time to 
wake up in the morning post-infusion three was significantly predictive of the number of 
dopamine cells present in post-mortem brain tissue (r=-0.479, p=0.005; Figure 19).   
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Figure 18. A. Mean daytime sleep duration, B. mean daytime sleep bouts, and C. mean 
latency to wake during the pre-MPTP period (open bars) ,post-MPTP (black bars) and 
post-infusion with N4 (grey bars). Asterisks indicate a significant difference between two 
time periods, as indicated by horizontal lines (p<0.05). A plus sign indicates significant 
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Figure 19. Correlation between, cell counts and latency to wake in the morning.  
Vehicle (open diamond), 450 µg GDNF (open square), 450 µg CDNF (open circle), 
150 µg CDNF  (closed circle), 337.5 µg N2 (closed square), 280 µg N4 (closed 
diamond) 
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4.4 DISCUSSION 
Monkeys that received a single low-dose unilateral MPTP injection had a significant increase in 
daytime sleepiness (see Chapter 3). After treatment with neurotrophic factor infusions for three 
months, the daytime sleep duration in monkeys receiving three infusions of N4 decreased 
significantly. With both N2 and N4 there was a trend for a decrease in number of daytime sleep 
bouts after 3 months of treatment, and the latency to wake up in the morning decreased 
significantly with both N2 and N4 treatment after three monthly infusions. Thus, this study 
shows for the first time in an animal model of PD that NTF’s can improve daytime sleep 
dysfunction. 
  The improvement in sleep seen after N2 and N4 infusions, but not CDNF and GDNF 
could reflect the fact that N2 and N4 have the widest distribution within the brain of the trophic 
factors we tested [Runeberg, Saarma and Penn, unpublished data]. In this study, all of the NTF 
infusions were given in the putamen, that lies in close proximity to the nucleus accumbens, a 
structure implicated in arousal mechanisms [Murillo-Rodríguez et al., 2007]. Increased release of 
dopamine in the nucleus accumbens has been shown to improve wakefulness and arousal levels 
in rodents [Robbins et al., 1997; Murillo-Rodríguez et al., 2007; Monti et al., 2007].  Planned 
analyses with the post-mortem brains from this study will look at both the tissue distribution of 
N2 and N4, as well as measure tissue levels of DA, TH, HVA, and DOPAC in the accumbens. A 
higher level of DA and DA metabolism, coupled with increased N2 and N4 staining in 
accumbens compared to other NTF’s, would support the hypothesis that NRTN variants reached 
the accumbens in higher concentration than the other NTFs tested in this dissertation and that 
dopamine release was increased after N2 and N4 treatment. 
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The loss of DA-containing neurons from midbrain SNpc to the striatum is well 
documented after MPTP administration (see Chapter 1.4). These DA neurons receive direct 
projections from serotonin neurons originating in the dorsal raphe nucleus. SNpc neurons also 
project back to the dorsal raphe nucleus [Forno, 1996; Fornai et al., 2007; Monti et al., 2007]. 
The loss of projections from SNpc neurons to the raphe nucleus after MPTP could potentially 
lead to changes in the activity of serotonin neurons post-MPTP. Several studies have also shown 
neuronal loss and Lewy body formation in the serotonergic neurons in the dorsal raphe nucleus 
in PD [Ohama et al., 1976; Huot et al., 2011,2013]. According to the Braak staging of PD, 
changes to the raphe nucleus occur before DA loss in midbrain and could possibly play a role in 
the development of sleep problems that precede the presentation of motor symptoms in PD 
[Braak et al., 2003, 2006; Hawkes et al., 2010]. Serotonin levels in the striatum, and other 
regions of the brain, are indeed significantly reduced in PD [Kish et al., 2008, Huot et al., 2013]. 
Similarly, reduced serotonin levels in the striatum of MPTP-treated primates have been reported 
[Perez-Otano et al., 1991; Russ et al., 1991]. After N2 and N4 infusions, there could be 
restoration and recovery of function in DA neurons in SNpc that project to and receive 
projections from serotonergic raphe neurons. This, in turn, could restore the homeostasis of 
serotonin neurons that are implicated in sleep. Alternatively, N2 and N4 may have diffused far 
enough to directly provide trophic support to serotonin neurons [Ducray et al., 2006]. Planned 
analyses of the post-mortem brain tissue collected in this study will measure tissue levels of 
serotonin and its metabolites, as well as other neurotransmitters including norepinephrine. 
Improved levels of serotonin correlates strongly with better response to levodopa therapy in PD 
patients [Huot et al., 2011, 2013]; a similar change observed in these monkeys could provide 
evidence for improvement of sleep problems through non-dopaminergic pathways. 
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  There is a clear loss of locus coeruleus neurons in PD patients and the loss is nearly as 
severe as that is seen with DA neurons [Braak et al., 2000, 2003, 2004, 2006; Fornai et al., 
2007]. This loss is again thought to precede the DA loss according to the Braak staging of PD. In 
a recent study, a significant reduction in noradrenaline (NA) within motor thalamic regions in 
PD patients was reported [Pifl et al., 2012]. These decreased levels of NA in PD patients could 
play a key role in the origin of sleep and arousal problems in PD. NA plays a role in the 
regulation of rapid eye movement sleep through central adrenergic receptors and inhibition of 
NA release is thought to play a role in narcolepsy, a disorder characterized by excessive daytime 
sleepiness [Brown et al., 2002]. Also, in PD animal models, loss of NA neurons enhanced the 
parkinsonian symptoms and increased the loss of DA neurons in animal models [Fornai et al., 
2007]. Pifl et al., [2012, 2013] also has reported that in monkeys after MPTP treatment only the 
monkeys that had significant reductions in NA in thalamic regions had parkinsonian symptoms, 
while the asymptomatic monkeys after MPTP did not have any changes in NA levels in 
thalamus. Although the reduction of NA levels and the loss of NA neurons in the locus coeruleus 
has been reported in PD patients, the consequences of this loss has received little attention 
[reviewed in, Forno, 1996; Fornai et al., 2007]. There are reports that loss of locus coeruleus 
neurons containing NA can exacerbate the symptoms and motor dysfunction in PD 
[Rommelfanger et al., 2007; Fornai et al., 2007]. Planned analyses of post-mortem brain tissue 
will also examine NA levels in the locus coeruleus of the monkeys in the present study. 
Some studies have reported loss of hypocretin neurons, that are involved in sleep 
regulation, in PD patients [Thannical et al., 2007]. Moreover, a combination of orexin/hypocretin 
system, the NA system and the histamine system might act though a common pathway to excite 
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serotonin neurons leading to arousal [Brown et al., 2002]. Impairment of this combined 
neuromodulatory system in PD could lead to an increase in daytime sleepiness.  
N4 was generated from NRTN by adding the tail region of PSPN to the NRTN molecule 
[Runeberg, Saarma and Penn, unpublished data]. PSPN is another trophic factor that does not 
bind to heparin. N2 and N4 are mutant molecules about which very little is known with respect 
to the receptors through which they might act or the signaling cascades they might activate. 
Power analyses after completion of this study indicate that both CDNF and the two variants of 
the NRTN molecule are likely to have similar effect sizes. Thus, it is possible that N2 and N4, 
with slightly greater capacity to diffuse to brain regions outside the putamen, were effective in 
reversing daytime sleep abnormalities that developed post-MPTP, but that CDNF would be 
effective also if it reached the critical brain regions impacting sleep. 
In summary, this is the first report of neurotrophic factor treatment leading to 
improvement of sleep in an animal model of PD. NTF’s present a promising alternative to 
current treatments, like L-Dopa, to treat both PD-associated motor and non-motor symptoms, 
like sleep dysfunction. The mechanism through which NTF’s act to restore sleep function in 
neural circuits should be investigated in future experiments in both animal studies and in 
patients. Moreover, future studies with NTF’s should consider their impact on both motor and 
non-motor symptoms of the disease. 
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5.0  GENERAL DISCUSSION 
 
5.1 DISTRIBUTION OF NTFS IN BRAIN TISSUE 
There has been tremendous progress in the utilization of neurotrophic factors to test their 
effectiveness for treating PD since the discovery of GDNF and its DA neuron survival-
promoting effects [Lin et al., 1993]. The experiments using GDNF fuelled a huge number of 
investigations into neurotrophic factors, their mechanism of action for neuronal survival, and 
their role in counteracting age-related deficits that develop in the central nervous system. Other 
members of the GDNF family of NTFs were later discovered, including neurturin (NTRN) 
[Kotzbauer et al., 1996]. The degeneration of DA neurons is a hallmark of PD (see Section 1.1). 
Most GDNF family ligands have the property of promoting DA neuron survival and led to its 
testing as a treatment for PD [Saarma et al., 2003]. GDNF has been shown to improve PD-like 
symptoms in animal models of the disease both in rodents [Hoffer et al., 1994; Tomac et al., 
1995; Beck et al., 1995; Bowenkamp et al., 1995; Bjorklund et al., 1997] and in primates [Gash 
et al., 1996; Zhang et al., 1997; Connor et al., 1998]. The beneficial effects of GDNF in animals 
was found to depend on a number of factors, including the dose used and tissue distribution 
[Zhang et al., 1997; Grondin et al., 1998]. New techniques for delivery of NTFs to facilitate 
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distribution of bioactive molecules began to be explored early [Grondin et al., 1998, 2002, 
2003].  
  The issue of poor tissue diffusion of NTF’s became more apparent with the first 
experiments using GDNF in humans [Kordower et al., 1999]. The distribution of GDNF within 
the brain has been a major roadblock for converting the therapeutic use of NTF’s for treating PD 
from laboratory animals to humans in the clinic because NTF’s have much further to diffuse in 
larger human brains. A number of phase I and phase II clinical trials have since been conducted 
using GDNF [Nutt et al., 2003; Gill et al., 2003; Patel et al., 2005; Slevin et al., 2005; Lang et 
al., 2006]. In all these clinical trials, GDNF was not as efficient as when it was used in 
parkinsonian animal models [Hoffer et al., 1994; Beck et al., 1995; Bowenkamp et al., 1995; 
Opacka-Juffry et al., 1995; Tomac et al., 1995; Gash et al., 1995,1996; Hou et al., 1996; Martin 
et al., 1996; Schults et al., 1996; Bjorklund et al., 1997]. One of the main reasons for the poor 
effectiveness of GDNF in clinical trials was attributed to the poor distribution in the brain 
parenchyma [Gash et al., 2005; Barker, 2006, 2009; Evans et al., 2008; Deierborg et al., 2008]. 
Many members of the GDNF family of ligands, including GDNF and NRTN, have been shown 
to bind with  high affinity to heparin and heparan sulphate [Rickard et al., 2003; Rider, 2006]. 
Heparan sulfate is a ubiquitous acidic polysaccharide that is present in the extracellular matrix 
and on cell surfaces. It acts as a receptor and regulates a number of biological actions of GDNF 
and NRTN, including during neuronal development [Saarma et al., 2003]. There is a need for 
highly localized concentrations of many of these NTF’s during development and binding to 
heparan sulfate could provide a mechanism that ensures a high concentration of NTF’s at the site 
of developing neurons [Rider, 2006]. It has also been shown that the binding of GDNF to 
heparan sulfate prevents its proteolytic degradation and thus can prolong its action [Piltonen et 
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al., 2009]. Moreover, the heparin binding property of GDNF has been shown to be important in 
mediating the optimal neuroprotective effect of GDNF; truncated GDNF that does not bind to 
heparan sulfate and diffuses widely in brain parenchyma, does not have improved efficacy 
[Piltonen et al., 2009].  
Meanwhile, a search also began for a novel trophic factor that does not bind to heparan 
sulphate and is neurotrophic to DA neurons. CDNF was discovered using a bioinformatics 
approach [Lindholm et al., 2007]. CDNF was found to be both neuroprotective and 
neurorestorative in a 6-OHDA rat model of PD [Lindholm et al. 2007]. CDNF distributes to a 
larger area than GDNF [Voutilainen et al. 2011]. CDNF also was shown to protect the 
nigrostriatal DA system in a MPTP mouse model [Airavaara et al., 2012]. In this dissertation, 
CDNF was tested for effectiveness of NTF support to DA neurons in a primate MPTP model of 
PD [Langston et al., 1984; Bankiewicz et al., 1986; Bergman et al., 1990; Smith et al., 1993; 
Benazzouz et al., 1993; Ovadia et al., 1995; Gash et al., 1996; Bezard et al., 2001; Emborg, 
2007; Bove et al., 2012]. Shown in this dissertation for the first time, CDNF is effective in 
rescuing DA neurons and motor deficits a primate model of PD. The work undertaken here used 
two doses of CDNF, based on the previous effective dose of GDNF tested in primates [Zhang et 
al. 1997; Grondin et al. 1998] and the rodent data that suggested that CDNF was more effective 
than GDNF [Lindholm et al. 2007; Voutilainen et al. 2011; Airavaara et al., 2012]. The low dose 
of CDNF (150 µg) was effective in improving the motor symptoms of PD, but not the higher 
dose of CDNF (450 µg) that was tested. Thus, CDNF appears to follow the classic “inverted u-
shape curve” for dose effectiveness (discussed in detail in Section 5.3, ‘Optimal dose and dosing 
regimen’). The low-dose CDNF treatment led to significant improvements in the monkey 
Parkinson’s rating scale score after each infusion. Also, the low-dose CDNF treatment was able 
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to rescue fine motor function measured using mMAP, such that monkeys that had stopped 
working using the left hand after MPTP started working again after the low-dose CDNF 
infusions. With the ability of CDNF to rescue both gross motor and fine motor functions, CDNF 
has significant potential as a treatment option for PD patients.  
 More recently, the same group that discovered CDNF developed NRTN variants with 
point mutations in the site of the molecule that putatively binds to heparin and heparan sulphate, 
to test the importance of its heparin and heparan sulphate binding motifs in neuroprotection and 
diffusion within the brain [Runeberg, Saarma and Penn, unpublished data]. Two such NRTN 
mutants (N2 and N4) were found to be bioactive after mutations and also spread widely in rodent 
and monkey brain [Runeberg, Saarma and Penn, unpublished data]. N2 and N4 also showed 
successful protection of DA neurons, and were more potent than GDNF in rescuing dopamine 
neurons in a 6-OHDA rat model [Runeberg, Saarma and Penn, unpublished data]. Similarly, N2 
and N4 also displayed significant improvement of motor performance in the monkey Parkinson’s 
rating scale score. Both N2 and N4 were effective immediately after the first monthly infusion. 
The monkeys in both these groups continued to remain significantly improved until the end of 
the study. As shown in rodents [Runeberg, Saarma and Penn, unpublished data], it appears that 
N4 was more widely distributed in the brain that N2 in primates in a preliminary study 
[Runeberg, Saarma and Penn, unpublished data]. N4-treated monkeys displayed significant 
improvement in not just motor function, but also in non-motor functions of sleep and motivation. 
The improved efficacy of N4 in restoring non-motor functions could be due to the greater tissue 
distribution resulting from the small point mutations to the NRTN molecule that did not alter the 
neuroprotective properties of NRTN, whereas in Piltonen et al. [2009] a greater portion of the 
GDNF molecule was deleted, with the GDNF being truncated near this binding motif.  
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5.2 DELIVERY OF NTF’S TO THE BRAIN 
At the same time that GDNF was beginning to be tested as a therapy for PD, new methods of 
delivery that were less invasive were beginning to be investigated, as there was concern that 
patients shouldn’t have to undergo multiple surgeries to receive injections of NTF’s [Barker, 
2006, 2009]. Several novel delivery methods emerged and were tested for the delivery of 
bioactive compounds to the brain, including the use of catheters to pump NTF’s continuously 
into brain tissue [Grondin et al., 1998, 2002, 2003], and the use of viral-mediated gene transfer 
to provide a continuous supply of NTF [Bilang-Bleuel et al., 1997; Lapchak et al., 1997; 
Bensadoun et al., 2000; Rosenblad et al., 2000; Connor et al., 2001; Kordower et al., 2003]. 
However, development of an effective catheter system has eluded scientists so far, as all 
catheters tried to date form glial scars at the port of entry and thereby reduce the tissue 
distribution of NTF’s [Deierborg et al., 2008; Bjorklund et al., 2009].  
Retroviral-mediated gene transfer as a method of delivery was developed in the late 
1980’s and early 1990’s and progressed from lab animals to treatment in clinics within a short 
span of time for use in human gene therapy trials for a number of neurological diseases [Mann et 
al., 1983; Anderson, 1992] and was safely used in vivo for delivery of NTFs [Bilang-Bleuel et 
al., 1997; Lapchak et al., 1997; Bensadoun et al., 2000; Rosenblad et al., 2000; Connor et al., 
2001; Kordower et al., 2003]. An Adeno-associated virus type-2 (AAV2) vector that carries a 
gene encoding a modified form of human NRTN, called CERE-120, was successfully developed 
by Ceregene Inc. and used in both rat and monkey models of PD to successfully preserve nigral 
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dopamine neuron loss in these animal models [Kordower et al., 2006; Gasmi et al., 2007; Herzog 
et al., 2007; Herzog et al., 2008; Herzog et al., 2009]. Following the path of GDNF, CERE-120 
was tested successfully in a small Phase I clinical trial [Marks et al., 2008]. Then in larger Phase 
II clinical trial testing PD patients treated with CERE-120 failed to show significant 
improvement in parkinsonian symptoms [Marks et al., 2008, 2010]. Post-mortem data from 
patients who died of other complications during the trial showed poor diffusion of the trophic 
factor in the brain parenchyma [Marks et al., 2010; Vastag, 2010; Ceregene press release 2013; 
MJFF press release, 2013].  
Thus, even using a viral vector method of delivery does not guarantee the successful 
diffusion of the trophic factor into the target region, as was expected. The reason for this poor 
diffusion using viral vector-mediated delivery could be because of the binding of AAV type-2 
virus, itself, to heparan sulphate on cell surface, as it is also a viral receptor site [Summerford et 
al., 1998]. Hybrid recombinant AAV (rAAV) is one of the many viruses that are currently 
available as vectors for gene transfer. Many other enveloped viruses (retrovirus, Lentivirus, 
herpes simplex virus: HSV-1) and non-enveloped viruses (Adenoviruses) are also used for 
treatment using gene therapy [Thomas et al., 2003]. The binding of these viruses to extracellular 
matrix and their ability to safely infect and replicate only in the neurons of interest, without 
leading to oncogensis, in a wide array of tissues should be investigated further. There are a lot of 
challenges associated with using gene therapy including humoral immunity in the host that 
develops antibodies against the virus particles; safety issues also need to be addressed along with 
ethical and social implications of gene therapy [Thomas et al., 2003; Masat et al., 2013]. 
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5.3 OPTIMAL NTF DOSE AND DOSING REGIMEN 
 
Another important factor that needs to be taken into account to optimize efficacy of NTF’s is the 
dose of the NTF used. In a unilateral MPTP-treated monkey model, GDNF was shown to have a  
“inverted U-shaped” response curve, with maximum effectiveness in the middle of the dosing 
range (~300 µg) [Zhang et al., 1997]. Similarly, it was shown for GDNF that increasing the dose 
did not increase the efficacy of the NTF after a critical threshold for being effective was achieved 
[Gash et al., 2005]. In this dissertation, again using the same animal model, CDNF was found to 
be less effective at the higher dose tested (450 µg) compared to the lower dose (150 µg). For this 
dissertation, the GDNF dose that was chosen had been found to be optimally effective in the 
unilateral MPTP-treated monkeys in a number of previous studies from the Gash lab [Gash et al., 
1995, 1996, 2005; Zhang et al., 1997; Grondin et al., 1998, 2002, 2003]. In order to compare the 
efficacy of CDNF, a trophic factor that had not been previously tested in primates, we used the 
same dose that was optimal for GDNF (450 µg). However, in a number of studies using a rodent 
PD model it had been shown that CDNF was more effective than GDNF at the same dose 
[Lindholm et al., 2007, 2010; Voutilainen et al., 2011; Airavaara et al., 2012]. Taking this 
finding from rodents into account, and worrying that there may also be an “inverted U-shaped 
dose response curve” for CDNF, we also tested a lower dose of CDNF (150 µg) in monkeys. The 
studies in this dissertation show that the lower dose of CDNF (150 µg) significantly improved 
parkinsonian motor symptoms, while the high dose (450 µg) did not cause a significant 
improvement of motor symptoms.  
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Treatment with the 150 µg dose of CDNF, at monthly intervals, led to continued 
improvement in motor function measured by the monkey Parkinson’s rating scale with each 
monthly dose of CDNF. It is possible that the time-course of improvement using low-dose 
CDNF may last for a longer duration than one month [Cohen et al., 2011]. Hence, subsequent 
infusions at monthly intervals might have had additive effects so that the effectiveness of CDNF 
was greater after the second and third monthly CDNF infusions because a higher dose of CDNF 
was available in the brain. A detailed dose response curve for the effectiveness of CDNF to 
recover PD symptoms in rodent models of PD would be useful before further studies in 
nonhuman primates or humans are undertaken. A time-course analysis of the benefits after a 
single CDNF infusion by following the progression of improvement in a PD model would 
provide insight into the duration of effectiveness and the mechanisms behind the improvement 
seen with this NTF [Cohen et al., 2011].  
The planned dose for the two NRTN mutants tested (i.e., N2 and N4) was 337.5 µg. This 
dose was calculated for N2 as the molar equivalent of 450 µg of GDNF, and because N2 is less 
soluble than GDNF it was diluted in 1 µg/µl for a total of 337.5 µl infusate. N4 was even less 
soluble and it required 406.6 µl to dilute 337.5 µg. However, concern over infusing a 
significantly higher volume into the putamen led to a choice of a lower dose of N4 (280 µg) that 
could be prepared to be the volumetric equivalent of the N2 infusions. Surprisingly, the N4 dose 
(280 µg) was more effective in recovering the non-motor symptoms of PD that occurred in the 
MPTP model than the higher dose of N2 (337.5 µg). In contrast to CDNF, the N2- and N4-
treated monkeys significantly improved motor function after the first infusion but did not show 
continued improvements in motor function with subsequent infusions. The N2- and N4-treated 
animals appeared to have reached a ceiling effect for motor improvement immediately after the 
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first infusion.  However, this was not the case for some non-motor measures, where N4 infusions 
showed a progressive improvement in the latency to wake measurements after each infusion. On 
the other hand, for daytime sleep duration and number of daytime sleep bouts, the effects of 
monthly N4 infusions were variable. It would be useful for future studies in rodents using N4 to 
delineate a detailed dose response curve for both the motor and non-motor symptoms. It may be 
that the effects of N4 on latency to wake and daytime sleep might take a longer time to become 
apparent and stable, in contrast to the effects of N4 on motor function. 
 
5.4 STRATEGIES FOR DEVELOPING THE MOST EFFECTIVE NTF THERAPIES 
 
The intracellular mechanisms through which the NTF’s improve function and restore the 
health of DA neurons is still a work in progress [Grondin et al., 1998; Airaksinen et al., 1999, 
2002; Saarma et al., 1999, 2000; Sariola et al., 1999, 2003; Takahashi et al., 2001]. This is 
especially true for more recently discovered neurotrophic factors like CDNF, as even the 
receptors through which they might act are not clearly understood at this time [Lindholm et al., 
2007, 2008, 2010]. During the process of development, NTF’s play various specific and critical 
roles in supporting growth, sustenance, axon guidance to targets, pruning of synapses and other 
functions [Saarma et al., 1999, 2000; Takahashi et al., 2001]. GDNF has been found to play an 
important role in the migration, proliferation and outgrowth of neurites from neurons in the 
central and peripheral nervous system. NRTN is another member of the GDNF family of 
neurotrophic factors and it plays an important role in target innervation, branching and terminal 
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formation, following axon guidance paths, and increasing cell size (trophic to the cells). CDNF is 
a specifically trophic to DA neurons and has been shown to be both neuroprotective and 
neurorestorative in a rodent PD model [Lindholm et al., 2007, 2008, 2010]. CDNF is thought to 
play a role in protecting DA neurons against ER stress-induced cell death and facilitating protein 
folding in the ER. A simple combination of these trophic factors could be used to test the joint 
efficacy of these trophic factors in restoring function in PD.  An advantage of using this 
combination approach is to target different aspects of this disease to produce the most beneficial 
outcome. A combination of NTF’s could increase the benefit by rescuing neurons that are in 
advanced stage of degeneration by preventing or reversing the ER stress response [Palgi et al., 
2009, 2012; Lindholm et al., 2007, 2010], while also inducing sprouting and providing trophic 
support to the DA terminals that are still healthy [Zigmond et al., 1990, 1997, 2003; Sariola et 
al., 1999, 2003].   
The GDNF family of NTF’s mediate signaling through a common receptor tyrosine 
kinase RET (rearranged during transformation). The four main members of the GDNF family: 
GDNF, NRTN, Artemin (ARTN) and Persephin (PSPN) also bind with functional specificity to 
four identified GDNF family receptors (GFRα 1-4) [Sariola et al., 1999,2003]. Both ligand-
dependent and ligand-independent RET signaling pathways have been identified. RET induces a 
pro-apoptotic signal dependent on caspase activation, and this is blocked when a ligand binds to 
RET or there is a complex formed between GFR and RET in the absence of ligands [Saarma et 
al., 1999, 2000, Takahashi, 2001]. There has been a lot of work done in vitro to understand the 
signaling cascades through which GDNF family members mediate trophic action. In contrast, 
there is very little that is known about the intracellular mechanism of action for CDNF except 
that its binding affinity is at least an order of magnitude higher than that of GDNF binding to its 
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receptor [Voutilainen et al., 2011].  Recently, the structure of CDNF was solved [Parkash et al., 
2009] and this provided insight into the possible mechanisms through which it could be 
signaling. At the amino terminal end of CDNF a saposin-like domain is present and saposins are 
trophic to cultured neurons [Parkash et al., 2009; Voutilainen et al., 2011].   At the carboxy-
terminal end it is similar to MANF that is protective again ER-stress induced cell death. Thus, 
CDNF might be acting through functional domains providing protection through two distinct 
activities. A combination strategy, combining NTFs such as CDNF and N4, would be similar to 
the strategies that are now being  commonly used to treat other diseases, such as cancer, where 
multiple drugs are used to target different aspects of the same disease to produce the most 
effective treatment regimen [Thompson et al., 1995]. This concept of combining therapies that 
work on different intracellular mechanisms has received little attention in the field of 
neurodegenerative disorders, but deserves more attention in the future. 
  Another strategy that may be useful for improving effectiveness of NTF 
treatment would be to follow the treatment regimen for growth factor infusions that mimic their 
endogenous pattern of secretion during development [Saarma et al., 1999, 2000; Sariola et al., 
1999, 2003]. During normal development there is initially an increase in concentration of GDNF 
signaling leading to sprouting and new neurites being formed during the embryonic stage of 
development [Airaksinen et al., 1999, 2002]. This is followed by a sequential increase in NRTN 
signaling during the perinatal period that plays a crucial role in target innervation through axon 
guidance and terminal formation [Grondin et al., 1998; Takahashi, 2001; Airaksinen et al., 1999, 
2002]. This shift in pattern of signaling is also present in the enteric nervous system suggesting a 
common evolutionary conservation of this developmental mechanism. Thus, in order to restore 
the health of degenerating neurons in PD it may be necessary to use a sequential combination of 
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trophic factors Future experiments in animal models should consider taking into account this 
multifactor approach to restore function.  
 
5.5 THE EFFECTIVENESS OF TREATING NON-MOTOR SYMPTOMS OF PD 
WITH NTF’S 
 
Non-motor symptoms in PD have been described from the very beginning of the description of 
the disease (see review in Chapter 1) [Parkinson, 1817]. However, considerably less attention has 
been paid to understanding more fully the non-motor symptoms and only recently has it begun to 
be accepted that other non-motor systems could also be a part of this multi-factorial disease 
[Braak et al., 2000, 2003, 2006; Hawkes et al., 2010].  
 This dissertation reports for the first time that a low dose unilateral MPTP 
monkey model of PD has the non-motor symptom of daytime sleep dysfunction that can be 
recovered using the NTF, N4 (see Chapters 3, 4). Thus, this dissertation shows that using an 
unilateral low dose of MPTP that leads to a moderate lesion of dopamine neurons in the 
nigrostriatal pathway is sufficient to cause an imbalance in DA concentration that leads to non-
motor problems like sleep. It has been known for a long time that growth factors including 
GHRH, NGF, BDNF and GDNF are involved in sleep regulation [Sassin et al., 1969; Obal et al., 
1988; Kerkhofs et al., 1993; Kapas et al., 1996; Faraguna et al., 2008; Kreuger et al., 1999; 
Kushikata et al., 2000].  However, there has been a paucity of research to test the benefits of 
these factors in treating sleep disorders, such as those that occur with PD. The successful use of 
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NTFs to treat the sleep problems associated with PD would open a wide array of treatment 
possibilities for sleep disorders, that would not be just limited to the sleep problems seen in PD. 
 
5.6 FINAL CONCLUSIONS 
This dissertation explored the therapeutic effectiveness of CDNF, a novel recently discovered 
neurotrophic factor, and two variants of the NRTN molecule (i.e., N2 and N4), to rescue 
nigrostriatal DA neurons and treat PD-like motor and non-motor symptoms in a low-dose MPTP 
unilateral non-human primate model. All three trophic factors were successful in rescuing 
nigrostriatal DA neurons (Chapter 2), as well as the PD-like motor symptoms measured using a 
monkey version of the Parkinson’s rating scale (Chapter 2). We also found that there was strong 
dose dependence in the effects of treatment using CDNF. The lower dose of CDNF that was 
tested (150 µg) was effective in improving parkinsonian symptoms, but not the higher dose (450 
µg) that was the molar equivalent of a known effective dose of GDNF in this same model [Zhang 
et al., 1997; Gash et al., 2005]. This suggests that there is ‘an inverted U-shaped dose response 
curve’ for the neurorestorative effects of CDNF. Gross motor functions measured by the rating 
scale, accelerometers and Ethovision assessment of whole body movement were all significantly 
correlated with the post-mortem DA cell counts (p<0.001, p=0.05, p=0.009, respectively). Fine 
motor function measured using mMAP and scoring of naturally-occurring fine motor movement 
in the homepen also correlated with DA cell counts (p=0.002 and p=0.06, respectively). 
However, with group sizes of 4-6 animals/group, CDNF, N2 and N4 did not lead to significant 
improvement in specific measures of gross and fine motor movement. Power analyses predict 
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that for the low-dose CDNF group the differences would become significant with a sample size 
of 8-10 monkeys. 
This dissertation also presents evidence that increased daytime sleep is rapidly evident in 
a low-dose unilateral MPTP non-human primate model of PD (Chapter 3). As increased daytime 
sleepiness is a symptom that becomes apparent early in the preclinical stage of PD [Hawkes et 
al., 2010], and is in fact a predictor of later onset of PD [Abbott et al., 2005; Gao et al., 2011], 
this finding suggests that the low-dose MPTP non-human primate model will be useful for 
understanding early aspects of PD. Some aspects of increased daytime sleepiness (i.e., longer 
latency to wake in the morning) were recovered after treatment with the NRTN variants, N2 and 
N4 (Chapter 4). Further evidence of a therapeutic effect of N2 and N4 on daytime sleepiness is 
offered by the finding that there were significant correlations between DA cell count and daytime 
sleep duration, number of daytime sleep bouts and latency to wake. Moreover, the N2 and N4 
treatments led to a significant shortening in latency to wake. These findings offer strong support 
for the conclusion that N2 and N4 have significant potential to serve as new tools for the 
treatment of increased daytime sleepiness in PD. 
In conclusion, the research presented in this dissertation shows that these novel  
neurotrophic factors have significant potential for treating PD early in the disease process by 
either halting or slowing the progression of DA neuronal loss, motor and sleep problems inherent 
in this disease. This is the first report of daytime sleep dysfunctions occurring early in the 
process of DA neuronal degeneration and improvement of PD-associated sleep problems after 
NTF therapy. Future experiments should address both the mechanisms of action of these novel 
NTFs, as well as modes of NTF treatment that optimally recover functions in both the motor and 
non-motor domains of this complex disease that affects multiple systems. 
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APPENDIX A 
EFFECTS OF UNILATERAL MPTP INJETCIONS ON MOTIVATION AND THE 
EFFECTS OF MONTHLY TROPHIC FACTOR INJECTION OF CDNF, N2 AND N4 
A.1 INTRODUCTION 
Parkinson’s disease (PD) is a debilitating neurodegenerative disorder characterized by the 
progressive loss of dopamine (DA) neurons in the substantia nigra (SN) and their projections to 
the striatum.  PD is clinically characterized by the presence of resting tremor, bradykinesia, 
rigidity, and postural imbalance (for details see Section 1.3).  Despite the clinical diagnosis of 
these motor symptoms, many non-motor symptoms (NMS), including sleep disturbances, 
cognitive decline, greater apathy or loss of motivation, depressive symptoms, and loss of smell, 
among others, co-occur or even precede the onset of the motor symptoms [Pfeiffer, 2007; 
Bayulkem et al., 2010; Korczyn et al., 2010; Ferrer et al., 2012].  PD patients most regularly cite 
the NMS, especially reduced motivation, sleep and other depressive symptoms, as most 
disruptive to quality of life [McDowell et al., 2012; Videnovic et al., 2012] and yet, animal 
models of PD routinely only focus on the motor symptoms of the disease. 
The nonhuman primate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of 
PD has been studied as a reliable model of the motor symptoms of  PD for more than two 
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decades [Bankiewicz et al., 1986;  Przedborski et al., 2001].  Although the monkey MPTP model 
of PD does have its limitations it remains the “gold standard for preclinical testing” of PD 
therapies [Tieu et al., 2011; Porras et al., 2012].  The monkey MPTP model reliably produces a 
stable lesion of striatal DA neurons and concomitant motor deficits observed in PD [Bankiewicz 
et al., 1986; Ding et al., 2008; Gash et al., 1996]. Like PD patients, monkeys given MPTP 
respond to typical anti-parkinsonism drugs and exhibit the same motor complications that result 
from their long-term use [Ding et al., 2008].  Thus, the monkey MPTP model of PD best suited 
to answer the question of NMS and the treatments for the same using trophic factors.  
Despite the ubiquity of the monkey MPTP model of PD for studying the motor symptoms 
and associated pathologies, only a few studies have examined the NMS in this model.  These 
studies have focused on cognitive decline [Taylor et al., 1990; Schneider et al., 1993; Vezoli et 
al., 2011] or sleep [Barraud et al., 2009; Verhave et al.,  2011; Vezoli et al., 2011], but only one 
study [Brown et al., 2012] to date has focused on reduced motivation in the monkey model of 
PD.   
We use a reliable model [Bankiewicz et al., 1986; Ding et al., 2008] of objectively 
measured motivation in the rhesus monkey model of PD. The Progressive Ratio (PR) task that is 
a  “gold standard” for assessing motivation was used to objectively measure motivation [Arnold 
et al., 1997; Paterson et al., 2003; Roane, 2008; Zhang et al., 2003].  This is a task used to assess 
motivation to seek a drug in a number of addiction as well as other studies. The objective 
measures of motivation that were tested in this study are, namely, the number of times a freely 
behaving monkey refuses to participate (i.e., number of balks) in both motor tasks and non-motor 
tasks.  
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Reduced motivation was assessed in monkeys treated with a single, unilateral right 
intracarotid dose of MPTP. The monkeys were then tested for the recovery of this loss of 
motivation after three monthly trophic factor infusions.  
A.2 MATERIALS AND METHODS 
A.2.1 Animals 
Twenty-six female rhesus monkeys (15-20yrs, 5-8 kg) living in social pens (4m x 4m x 4.7m) 
that had perches, toys, and a thick layer of sawdust bedding were used in this study.  Monkeys 
were pair housed, and could see and hear other monkeys in several other pens. Monkeys were 
fed Purina Monkey Chow (#5038; Ralston Purina Co., St. Louis, MO) once daily and given 
fruit/vegetables, seeds, and nuts daily to encourage foraging.  Monkeys had ad libitum access to 
drinking water.  Monkeys were observed multiple times daily for health and menstrual status.  
All procedures were performed in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals and were approved by the University of Pittsburgh Institutional Animal 
Care and Use Committee. 
 
A.2.2 MPTP administration 
Monkeys had baseline assessments for motor function and motivation made for 6 weeks before 
they received MPTP, as described below.  All monkeys then underwent a surgery to expose the 
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right carotid artery and each received a right intracarotid injection of MPTP-HCl (Sigma 
Chemical Co., St. Louis MO), at a dose of 0.14-0.16 mg/kg (average dose = 0.15±0.001 mg/kg), 
delivered at 1 mL/min, using previously published techniques (Ding et al., 2008). Monkeys were 
then allowed to recover in quarantine for 3 days to allow for excretion of MPTP and they were 
subsequently moved back into the pen living environment. Starting 10.7±0.7 days and 
20.04±1.41 days after MPTP administration, assessments of motor function and motivation, 
respectively, were continued for an additional four weeks.  
 
A.2.3 Experimental design 
Group Size: Monkeys were assigned into six groups (n=6/group). At six weeks post-
MPTP, when stable symptoms of PD are established, monkeys were assigned in each group such 
that the distribution of PD-like symptoms was uniform and had homogeneity across these six 
groups. Each monkey received four intraputamenal infusions of trophic factor/vehicle at monthly 
intervals (see, Figure 2). Groups were treated as follows: Group 1: MPTP + vehicle; Group 2: 
MPTP + CDNF (450µg); Group 3: MPTP + CDNF (150 µg); Group 4: MPTP + GDNF (450 
µg)); Group 5: MPTP + N2 (280  µg)); Group 6: MPTP + N4 (280 µg)  
Neurotrophic Factor Dosing: Many trophic factors and pharmacological agents have 
“inverted U” dose response curves with lower efficacy at both lower and higher concentration 
levels [Gash et al., 1995, 1996; Zhang et al., 1997], which was taken into consideration when 
considering doses of NTFs to test in this study. The CDNF doses that were utilized for the 
current study were chosen based on previous work demonstrating that a 450 µg dose of GDNF, 
delivered intraputamenally, was effective in improving DA function in MPTP-treated monkeys 
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[Ovadia et al., 1995; Gash et al., 1996; Grondin et al., 2002]. We chose to test this same dose of 
CDNF in monkeys in one group. However, CDNF had been shown to be more effective than 
GDNF in a rodent model of PD [Lindholm et al. 2007], so there was concern that if the same was 
true for monkeys as we may be on the diminishing slope in an “inverted U” dose response curve. 
Thus, a lower dose of CDNF was also tested (150 µg). A molar equivalent dose of N2 (337.5  
µg), of the 450 µg dose of GDNF, was tested. N4 was less soluble than N2 and hence a 280 µg 
that corresponds to the same volume as that of the N2 dose that was administered was used. 
A.2.4 Motivation assessments 
Motivation was assessed in three ways: 1) by performance on a Progressive Ratio (PR) task, 2) 
by performance on a cognitive task of object recognition, and 3) during performance on a motor 
assessment task (the mMAP test).  
Progressive Ratio (PR) task: The PR and object recognition tasks were performed using 
the Wisconsin General Testing Appartus [WGTA; Meunier et al., 1996] and previously 
published techniques [Rhyu et al., 2010]. Monkeys were transferred to a testing room and placed 
in a cage to which the WGTA was attached, with a solid sliding access door separating the 
monkey from the WGTA test tray.  Monkeys were allowed to adapt to the testing cage for at 
least 1 week prior to the onset of testing.  Monkeys were trained to move aside a toy that 
completely covered a treat in a well on a tray in front of them each time the sliding door was 
raised.  
After training, monkeys then received PR testing. The PR test is commonly used to assess 
motivation in animal models of drug addition [Arnold et al., 1997; Paterson et al., 2003; Roane, 
2008; Zhang et al., 2003].  We based our PR task on previously published procedures in 
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monkeys [Cilia et al., 2001], modifying it for use with the WGTA. During PR testing monkeys 
were required to move a toy aside to retrieve a treat and in each trial they had to move the toy 
progressively more times to retrieve the reward.  For example, on the first trial, the monkey had 
to move the toy aside once after the screen was raised, and a treat was present under the toy.  On 
the second trial, the monkey had to move aside the toy the first time the screen was raised (but no 
reward was present under the toy), the screen was briefly lowered and the toy was replaced with 
a treat under it, and the screen was raised a second time allowing the monkey to push aside the 
toy a second time to retrieve the treat.  On the third trial, the treat was given the third time the 
screen was raised, and this pattern progressed with each trial.  Monkeys were given 60 seconds 
to respond to each toy presentation.  If a monkey did not respond within 60 seconds at any time, 
PR testing ceased for the day.  The PR task was given for 3 days, and the number of trials a 
monkey completed each day was recorded. For each monkey a break point (BP), i.e, the total 
number of completed trials before the monkey refused to work, was calculated for each of the 3 
days, and was averaged across the 3 days to yield a mean BP [Cilia et al., 2001].  This 3-day test 
was given at 29.81±2.42 days pre-MPTP and at 20.04±1.41 days post-MPTP. 
Object discrimination Task: Object discrimination testing was started the day after PR 
testing was completed using previously described methods [Rhyu et al., 2010]. Briefly, two 
easily discernable objects were placed over the lateral wells of the testing tray and the position of 
the objects varied from trial to trial according to a random sequence. The monkey’s access door 
was lowered, and the experimenter placed a treat under the designated object. The access door 
was raised and the monkey could retrieve the treat by displacing the designated object. Monkeys 
were tested until they reached 90% criterion (18/20 trials correct object displacement in a single 
testing session) with the designated object. Assessments of motivation during the object 
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discrimination task were made by recording each animal’s balk rate for each day of testing: that 
is, the percentage of trials in a day that the monkey refused to work (monkeys were allowed 60 
sec to move the toy in each trial). Testing ended for the day if a monkey balked for 5 trials in a 
row. A mean balk rate was calculated across all testing days in each phase of the experiment 
(i.e., pre-MPTP, post-MPTP and post-Infusions). 
Assessment of motivation during a motor function task: To confirm previously reported 
findings that a single, low-dose intracarotid injection of MPTP results in stable mild motor 
dysfunction [Ding et al., 2008], we assessed monkeys on the primate version of the Unified 
Parkinson’s Disease Rating Scale [Ovadia et al., 1995] once a week for 4 weeks pre-MPTP and 6 
weeks post-MPTP. Monkeys were rated on bradykinesia, rigidity, tremor, balance, and posture 
during a 5-min, videotaped session in which seeds, nuts, raisins and other small treats were 
thrown into the sawdust bedding of their home pen.  Two independent raters scored each 
videotaped session and assigned ratings. If variability was greater than 15%, a third rater scored 
the session. Inter-rater reliability of greater than 90% agreement was achieved. 
Fine motor function of hands was measured throughout the study using the monkey 
Motor Assessment Panel (mMAP), an apparatus that has been shown to accurately assess motor 
function in both human and non-human primates [Gash et al., 1999; Maswood et al., 2002] as 
well as age-related motor decline in non-human primates [Zhang et al., 2000].  mMAP testing 
was performed from two to six weeks pre-MPTP (Mean=3.0±0.2 weeks pre-MPTP)  and for 5 
weeks post-MPTP (starting 10.7+0.7 days post-MPTP).  Monkeys were transferred from their 
home pen to a testing room and placed in a testing cage with the mMAP apparatus attached to 
the front.  Monkeys had been acclimated to the testing cage for at least 1 week prior to the onset 
of testing.  Each day of mMAP testing consisted of 12 trials total, 6 trials for each hand. This 
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allowed us to compare motor function between the left hand (i.e., the side that would be affected 
by right intracarotid MPTP) and the right hand (i.e., the unaffected side).  During mMAP testing, 
monkeys were required to reach through two openings to retrieve a small food reward on an 
elevated platform [Gash et al., 1999].  The openings were each equipped with photodiodes to 
monitor arm/hand movements of the subject, thereby recording with millisecond accuracy the 
latency to retrieve the food reward [Gash et al., 1999].  Monkeys were given 5 minutes to 
respond per trial before the trial ended. At each trial the latency to retrieve the treat was 
recorded. If the monkey did not retrieve a treat at the end of 5 minutes the trial was scored as a 
balk. The trials alternated between the right and left hands. The testing was stopped if the 
monkey did not retrieve the treat for three consecutive trials. The assessment of motivation in 
this task was by calculating the balk rate in the mMAP task. For these calculations mean balk 
rate across all sessions of mMAP testing was calculated pre-MPTP, post-MPTP and post-
Infusions for each monkey. 
Statistical Analysis: Prior to analyses, all dependent variables (monkey Parkinson’s rating 
scale, mean BP, mean balks during object discrimination testing, and mean balks during mMAP 
testing both pre- and post-MPTP) were examined for normality and homoscedacity.  As no 
monkeys showed impairments in the monkey Parkinson’s rating scale during the baseline (pre-
MPTP) period, all monkeys received a score of 0 (lowest possible score) for the baseline value, 
as has been reported in previous studies with monkeys using this experimental model [Brown et 
al., 2012].  Rating Scale data collected pre-MPTP was not used in the analyses in this study. The 
post-MPTP rating scale data were normally distributed. Pre- and post-MPTP BP values were 
normalized using a reciprocal root transformation (-1/√Y).  Pre- and post-WGTA balk rate 
values were normalized using a square root transformation (√Y).  Paired-samples t-tests were 
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then used to analyze the changes in BP and WGTA balk rate from pre- to post-MPTP. The pre- 
and post-MPTP mMAP balk data could not be normalized using standard methods, so the 
nonparametric Wilcoxon signed rank test was used to analyze these data from pre- to post-
MPTP.  Spearman correlations were employed to examine the relationship between post-MPTP 
BP and balks during object discrimination and mMAP testing, as well as the relationship 
between these measures of motivation and loss of motor function as assessed by post-MPTP 
monkey Parkinson’s rating scale scores. Data are reported as mean+SEM. SPSS v21.0 was used 
for all analyses, and p <0.05 was considered significant. 
 
A.3 RESULTS 
A.3.1 MPTP reduces both motor function and motivation 
Compared to baseline, monkeys showed a significant decline in motor function across the 
6 weeks post-MPTP as evidenced by poorer scores on the monkey Parkinson’s rating scale 
(t(25)=-13.30, p<0.001). Monkeys also exhibited impairment in their left hand during mMAP 
testing post-MPTP, as evidenced by a significant increase in balk rate with this hand (pre-MPTP: 
2.08±0.66%, post-MPTP: 69.81±6.92%, =4.23, p<0.001). Balking with the left hand was 
significantly increased compared to balking with the right hand post-MPTP (t(25)=7.44, 
p<0.001). However, monkeys also exhibited a significant increase in balks post-MPTP during 
mMAP testing in the right hand (Z=3.01, p=0.003; Figure 20). 
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Monkeys showed a significant decrease in motivation as assessed by BP from pre- to 
post-MPTP (t(25)=3.055, p=0.005), averaging 3.22+0.39 trials pre-MPTP and 2.60+0.39 trials 
post-MPTP (Figure 20).  However, balk rate during object discrimination testing was not 
significantly increased post-MPTP (t(24)=0.109, p=0.914). Nevertheless, measures of motivation 
were consistent across tasks (Table 1), such that monkeys exhibiting a lower post-MPTP BP (i.e., 
less motivation) also exhibited more balks during object discrimination testing (i.e., less 
motivation; r(s)=-0.681, p<0.001) as well as more balks with the right hand during mMAP 
testing (i.e., less motivation; r(s)=-0.599, p=0.001).  Additionally, monkeys who balked more 
during post-MPTP object discrimination testing also balked more with their right hands during 
post-MPTP mMAP testing (r(s)=0.693, p<0.001).   
A.3.2 Decline in motivation predicts motor dysfunction after MPTP 
Balk rate during post-MPTP mMAP testing positively predicted the post-MPTP score on the 
rating scale (r(s)=0.559, p=0.003; Figure 21; Table 1), such that monkeys exhibiting reduced 
motivation after MPTP during mMAP testing (higher balk rate) also had higher scores (more 
impairment) on the monkey Parkinson’s rating scale.  BP during the post-MPTP testing period 
negatively predicted the post-MPTP score on the monkey Parkinson’s rating scale (r(s)=-0.442, 
p=0.024; Figure 21; Table 1) such that monkeys exhibiting reduced motivation after MPTP 
during PR testing (lower BP) also had higher scores (more impairment) on the rating scale.  
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A.3.3 Effect of CDNF, N2 and N4 on motivation after MPTP administration  
In the 150 µg CDNF group there was significant improvement in motivation to work with the 
left affected hand as assessed by balk rate from post-MPTP to post-Infusions from 79.2±14.0 to 
29.0±18.0 percent (p=0.02). Similarly the right hand balk rate which is a direct measurement of 
the monkey’s motivation in the MPTP unaffected right hand was significantly reduced from 
7.2±3.0 to 0.5±0.5 percent balking rate from post-MPTP to after three months of 150 µg CDNF 
trophic factor infusions (p=0.04). There was no significant change in any of the other treatment 
groups in these measures.  
Compared to post-MPTP values in the BP during progressive ratio testing there was an 
increase in motivation indicated by increased BP values at the end of three monthly infusions in 
the treatment groups: monkeys in the 450 µg CDNF changed their BP from 1.7±0.3 post-MPTP 
to 3.1±0.4 post-infusions (p=0.02), 150 µg CDNF changed from 2.5±0.6 post-MPTP to 4.1±0.7 
post-infusions (p=0.10), N4 changed from 1.8±0.5 post-MPTP to 4.5±1.1 post-infusions 
(p=0.04). There were no changes in the other treatment groups in this measure and no other 
measures of motivation had any significant changes in their values after infusions with trophic 
factors. 
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Figure 20.  Monkeys showed reduced motivation after MPTP as evidenced by (a) 
increased balk rate with the right hand during mMAP testing, and (b) reduced Break 
Point in the progressive ratio task. **p<0.01 
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Figure 21.  Reduced motivation was associated with impaired motor function after 
MPTP.  (a) Monkeys with a higher balk rate with the right hand during mMAP testing 
(r(s) =  0.559, p<0.01, and (b) lower Break Point in progressive ratio testing (r(s)= -
0.442, p<0.01) had higher scores on the UPDRS post-MPTP. 
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Table 1.  Correlations between measures of motivation and motor function after 
MPTP. 
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A.4 DISCUSSION 
A.4.1 Effect of unilateral low-dose MPTP administration on motivation 
We found that the unilateral MPTP-lesioned monkey can be used as a reliable model for 
motivational decline accompanying the motor symptoms after MPTP.  Similar to previously 
published reports, the monkeys in our study exhibited motor impairments as evidenced by poor 
scores on the UPDRS and poor performance on mMAP on the affected (left) hand, indicating 
stable lesions to the nigrostriatal pathway after a single unilateral dose of MPTP [Ovadia et al., 
1995; Ding et al., 2008; Brown et al., 2012]. 
To our knowledge, this is the first comprehensive, objective study of motivation in a 
nonhuman primate model of PD.  Other studies have examined “apathy,” defined as a lack of 
motivation [Brown et al., 2012], and “no-response errors,” or errors of omission [Roeltgen et al., 
1994] in MPTP-treated rhesus monkeys, but these assessments have limitations as reliable 
measures of motivation.  In the Brown et al. study (2012), the measures of “apathy” were 
subjective measures of the monkeys’ willingness to attempt tasks (i.e., walking and turning in 
circles using the common pole-and-collar method, and reaching tasks while restrained in a 
primate chair).  These tasks were given while the monkeys were under physical restraint (pole-
and-collar and primate chair), which may not accurately reflect their willingness to attempt 
particular behaviors as physical restraint has been shown to affect behavior in primates 
[Reinhardt et al., 1995].  Roeltgen et al., study (1994) used a more objective measurement 
(errors of omission, which reflect lack of persistence and thus are a proxy of attentiveness or 
motivation), but many of their subjects were also tested in a primate chair, thus confounding the 
reliability of the monkeys’ willingness to perform.  In contrast, we tested monkeys in a single 
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cage, which did not limit their movement, and monkeys were free to choose to participate in the 
task or not.  In addition to recording the number of balks in the cognitive and mMAP tasks, 
which is similar to recording errors of omission or lack of persistence, we also used the well-
established and reliable PR task to quantify motivation in our monkeys.  The reliability of these 
methods is evidenced by the fact that each of the measures of motivation was strongly correlated 
with each other (Table 1), confirming the comprehensive nature of motivational decline in 
unilaterally MPTP-treated monkeys. 
We further found that these monkeys’ loss of motor function after MPTP may in part be 
governed by their loss of motivation, as evidenced by the strong correlations between measures 
of motivation and motor function.  These findings corroborate similar reports in humans [Shiner 
et al., 2012], and further validate the unilateral MPTP nonhuman primate model as a reliable 
model for both motor and non-motor symptoms in PD.  The performance on the PR task was 
completed before the UPDRS measurements were done. However, PR performance negatively 
predicted UPDRS score. This further suggests that decreases in motivation after MPTP may 
precede motor dysfunction.  Recent models on the development of PD have now begun to 
consider the development of other non-motor symptoms before the clinical diagnosis of motor 
symptoms  (See Section 1.3.2 and Section 1.1.2). 
That monkeys did not show an increase in balk rate during WGTA testing on a cognitive 
task after MPTP suggests that reduction in motivation may be specific to tasks which require the 
use of a particular hand (i.e., the affected side).  This is supported by the fact that most monkeys 
failed to use their left hand during mMAP testing after MPTP, but worked better with their right 
hand.  Although they did balk significantly more with the right hand after MPTP compared to 
pre-MPTP. The monkey’s balk rate with the left hand was significantly higher than that with the 
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right hand. This suggests to us that the monkey’s motivation to work for the reward on the 
affected side was reduced.  As monkeys were not required to use one hand or the other in WGTA 
testing, it is likely that they relied more on using their right hands after MPTP and as such 
motivation on this task, as indicated by balk rates, was not significantly affected.  Thus it appears 
that while decreased motivation and decreased motor function may go hand in hand, decreased 
motivation is not necessarily co morbid with decreased cognitive function in PD.  Future studies 
should focus on a levodopa challenge test to determine if dopamine replacement therapy can 
improve motor function as well as motivation. 
A possible mechanism for the concurrent loss of motor function and motivation in these 
monkeys is that dopaminergic neurons in the substantia nigra-ventral tegmental area (SN-VTA) 
complex were also possibly mildly affected after a unilateral MPTP injection.  Whereas the SN 
sends dopaminergic projections to the striatum and is implicated in motor control, dopaminergic 
neurons in the VTA ascend to the limbic system via the nucleus accumbens (NAcc) and are 
associated with reward and motivation [Cardinal et al., 2002].  In fact, the NAcc has long been 
proposed as a functional interface between the limbic system and the motor system [Mogenson et 
al., 1980; Salamone, 1992].  It is likely that the unilateral intracarotid MPTP administration was 
not selective solely to neurons in the SN (i.e., the nigrostriatal pathway).  Although the VTA has 
been shown to be less susceptible to the ameliorative effects of MPTP [Hung et al., 1996; 1998], 
it is not immune, as studies have shown a loss of up to 20-40% of dopaminergic neurons in the 
VTA after MPTP [Schneider et al., 1987].  This loss is likely accountable, in part, to the loss of 
motivation observed in our monkeys, owing to a reduction of dopaminergic function in the other 
dopaminergic pathway. 
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Taken together, our findings represent a comprehensive study of motivational decline 
after MPTP in the rhesus monkey, and suggest that there is a loss of motivation after MPTP 
injection.  These findings highlight the utility of the nonhuman primate MPTP model for 
studying both motor and non-motor symptoms of PD.  Future studies will be able to take 
advantage of this model for analyzing the effectiveness of treatments targeted toward the 
different symptoms seen in PD. This model has the potential to positively impact and find 
treatments for motivational decline and the reduced quality of life that PD patients face as a 
result of it. 
A.4.2 Effect of neurotrophic factors infusion on motivation 
a. Decreased Motivation in PD patients 
The lack of motivation or apathy is not attributable to cognitive impairment or emotional distress 
or depression in PD [Levy et al., 1998]. However, apathy is defined as lack of motivation that 
manifests itself as diminished goal-directed behavior [Pederson et al., 2009]. Apathy is 
associated with reduced social [Brown et al., 2002], and functional impairment [Gerritsen et al., 
2005], reduced quality of life in patients and caregivers [Aarsland et al., 2007], poor illness 
outcome and response to treatment [Starkstein et al., 2006]. In terms of the pathophysiology, the 
cause of apathy is dysfunction in the frontal lobes following lesion of the frontal cortex or 
damage to regions tightly connected to its function like basal ganglia [Dujardin et al., 2007].  
This frontal-sub-cortical circuit is often involved in pathological cases of apathy [Levy et al., 
2006]. Thus apathy is commonly seen in PD where there is reduction of DA that disrupts the 
normal functioning of the frontal-sub-cortical circuits. Although apathy and depression may have 
 155 
overlapping symptoms in PD such as, lack of interest or pleasure many studies indicate that they 
are discrete syndromes in patients [Starkstein et al., 1992; Levy et al., 1998; Aarsland et al., 
1999; Isella et al., 2002; Kirsch-Darrow et al., 2006].   
b. Changes to measures of motivation after neurotrophic factors infusions 
We found that the 150 µg CDNF group, 450 µg CDNF group and the 280 µg N4 neurotrophic 
factor treatment groups were all effective in significantly changing measures of motivation after 
MPTP administration. The balk rate which is a measure of the monkey’s motivation to work in a 
task was significantly reduced in the 150 µg CDNF group from post-MPTP to post-infusions in 
both the left and right hands. The break point (BP) which measures the motivation of the monkey 
to retrieve a treat, is a standard test used in drug addiction studies was shown to increase 
significantly after treatment with three months of CDNF and N4 infusions. Thus the increase in 
BP which is a measure of increased motivation in monkeys was significantly different from post-
MPTP measurements in the 450 µg CDNF group and the 280 µg N4 group and showed a trend 
towards significance in the 150 µg CDNF group.  
 This is the first time any changes to direct measurements of motivation was shown to 
improve in the monkey MPTP model of PD. There has been an increased recognition of the role 
of non-motor symptoms in PD and the adverse impacts on the quality of life that it leads to 
[Chaudhuri et al., 2010].  Hence recent advances in treatment options for PD patients are 
increasingly focused on improving their quality of life. There has been a lot of progress in using 
neurotrophic factors for the treatment of PD [Nutt et al., 2003; Gill et al., 2003; Patel et al., 
2005; Slevin et al., 2005; Marks et al., 2008; Marks et al., 2010]. However these trophic factor 
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treatments have so far only focused on the improvement of motor symptoms. It is not known if 
the patients had improvements to their non-motors symptoms after being treated with trophic 
factors. Thus using these novel trophic factors could provide benefit to patients in both the 
domains of motor and non-motor symptoms. 
 The distribution of N4 trophic factor in the brain parenchyma was found to be the largest 
compared to CDNF and GDNF [Runeberg, Saarma and Penn, unpublished data]. The 
improvements in motivation as measured by BP are the highest for this group compared to any 
other trophic factor treatment. All our injections were directed only to the putamen that is 
involved in aspects of motor functions in basal ganglia. However the nucleus accumbens that is 
implicated in motivation lies just below the putamen and the larger distribution within the brain 
that is characteristic of N4 trophic factor could mean that improvements to motivation in this 
treatment group could be directly attributed to changes in the ventral striatum [Ikemoto et al., 
1999]. Future analysis will consider the spread of the N4 trophic factor and other neural and 
biochemical changes in the ventral striatum of the post-mortem monkey brains.  
The effective concentration of drugs that could lead to improvement in a particular aspect 
of behavioral function might work effectively in specific neural sub-circuit and structure. But, 
the same concentration of drug might be ineffective in a neighboring neural structure that has a 
different function. This could be due to the inherent properties of the different neurons present in 
these different circuits, the physiological and anatomical organization of the inputs and outputs 
of this circuit. The 450 µg CDNF group significantly improved the aspects of motivation, as it 
could be within the range of effectiveness at this concentration in the motivational circuits that 
govern the progressive ratio task, but could be ineffective in improving motor behaviors. Some 
evidence for this is also supported by the trend in improvement (p=0.10) in motivation seen the 
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measurements of BP with the 150 µg CDNF group which was tested at a lower concentration. A 
more detailed dose response analysis of CDNF to improving the different aspects of symptoms 
of PD in animal models needs to be carried out.  
Thus we show for the first time significant improvements in direct measures of objective 
motivation in a monkey model of PD. These trophic factors, i.e. the N4 and CDNF neurotrophic 
factors could be used for treatment of both motor and non-motor functions in this primate model. 
Future experiments should also explore infusions of these factors directly into other non-motor 
circuits of the basal ganglia that are also affected in PD patients. An appropriate dose, location 
and method of infusion that best improves both motor and non-motor functions should be 
considered before translation of neurotrophic factors to the clinic. Finally, clinical trials with 
these novel trophic factors should also comprehensively record the changes to all aspects of non-
motor function including motivation along with the improvements to motor functions. 
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